{
  "responseHeader":{
    "status":0,
    "QTime":5,
    "params":{
      "q":"(Background: colorectal cancer OR Colorectal Carcinoma OR CRC OR bowel cancer OR colon cancer OR Doc_title:colorectal cancer OR Colorectal Carcinoma OR CRC OR bowel cancer OR colon cancer) AND (Background: NRAS OR NS6 OR CMNS OR NCMS OR ALPS4 OR NRAS1 OR Doc_title: NRAS OR NS6 OR CMNS OR NCMS OR ALPS4 OR NRAS1)"}},
  "response":{"numFound":472,"start":0,"docs":[
      {
        "Meeting_name":" Colorectal cancer in the setting of inflammatory bowel disease",
        "Background":"[\"Colorectal carcinoma (CRC) is a serious complication of inflammatory bowel disease (IBD) and accounts for approximately 15% of all IBD-associated deaths. The likelihood of IBD-related carcinoma is greater than that of sporadic CRC. Over one half are diagnosed at stage III or IV. During the last few years we have worked on mining colon mucosal and submucosal layers for discovery of biomarkers that differentiate ulcerative colitis (UC) from Crohn's colitis (CC). Using LC-MS/MS, we examined signals found to be significantly different between CC and UC samples. We found a signal at m/z 5045 which was more intense in UC samples. The MALDI spectrum did not identify an intact protein entity but did identify hemoglobin chains. Macrophages are highly versatile phagocytes active in multiple roles in the immune system and key players in the inflammatory response. The microenvironment of most inflammation is filled with a large population of macrophages. In IBD, studies have found that macrophages can count for more than 50% of the exudative mass. Their presence within the inflammatory microenvironment, in some cases, has been proven to increase transformation, angiogenesis, and immunosuppression. In hemorrhagic situations (as in UC) macrophages engulf erythrocytes and as a result release free heme iron (heFe). Earlier studies observed that heFe has cellular proliferation effects on colon cancer cells. Recently, the potential carcinogenic effects of heFe were documented when it was shown that heFe increases the number of aberrant crypt foci in colon mucosa. In the colon, iron is expected to increase the production of reactive oxygen (O2) species (ROS) from peroxides via the Fenton reaction, which may be the cause of cellular toxicity and even pro-mutagenic lesions. Intracellular reactions with active O2 can result in the initiation and progression of carcinogenesis by induction of gene mutations, chromosomal damage and cytotoxic effects. We hypothesize that elevated expression of mucosal free heFe would be associated with an increased risk of UC-associated CRC. To validate this will require investigating whether hemoglobin could be classified as a proliferative or transforming agent for colon cancer cells by causing reactive oxygen species release. For this purpose, we plan to study the cellular viability of differentiated colon cell line (cancer\", ' CCL 224, CCL 227 and normal', ' NCM 356 and NCM 460) after administration of hemoglobin at different concentrations. ROS production will be investigated in each step. Additionally, we intend to examine the potential cytotoxicity of hemoglobin. Supported', ' MMC-VICC Cancer Partnership Grant # 3U54CA091408-09S 1 (SEA & HLM); MeTRC grant # 5U54RR026140-03 (SEA), and Vanderbilt SPORE in GI Cancer Grant # P50CA095103']",
        "Doc_id":"AACR_2012-2058",
        "Doc_title":" Colorectal cancer in the setting of inflammatory bowel disease",
        "_version_":1606189019501166592},
      {
        "Meeting_name":" Cystathionine--synthase overexpression increases cell proliferation, migration, bioenergetics and tumorigenesis in a non-tumorigenic colorectal cancer (CRC) cell line",
        "Background":"['Introduction', ' We recently described overexpression of the enzyme, cystathionine--synthase (CBS) in human CRC (but not normal colonic mucosa) produces endogenous hydrogen sulfide (H2S) increasing tumor bioenergetics, cell proliferation, invasion, migration and promotes tumor angiogenesis. Its role in the progression of a colorectal adenoma to carcinoma remains elusive. The purpose of this study was to determine whether CBS overexpression in a non-tumorigenic human CRC cell line (NCM356) is sufficient to increase cell proliferation, migration, tumorigenesis, and metastasis. Methods', ' NCM356-p (parental) are non-tumorigenic when xenografted into athymic nude mice and express low levels of endogenous CBS, similar to normal colonic mucosa. RNASeq analysis determined mutation status. NCM-p were transduced with a lentiviral vector containing a CBS cDNA (NCM-C) or vector (NCM-v). H2S production was visualized with a fluorescent probe, 7-azido-4-methylcoumarine (AzMC). Cell proliferation rates where determined with a Coulter Counter. Cell migration and invasion assay were performed in Boyden chambers with NIH3T3 conditioned media (CM) as a chemoattractant. Anchorage-independent growth was assessed by soft-agar assay. Cellular bioenergetics was assessed using Oxygraph-O2K respirometer chamber. Tumorigenesis and metastasis were assessed injecting cells subcutaneously and orthotopically into nude mice, respectively. Aminooxyacetic acid (AOAA) was used to inhibit CBS activity. Statistical significance (p0.05) set using ANOVA or non-parametric Student t-test. Results', ' CBS overepression and H2S production was verified by Western blot and AzMC fluorescence in the NCM-C cells. CBS overexpression demonstrated significantly increased proliferation rate (p<0.03 NCM-C vs. NCM-v or NCM-p) over 4 days in culture, invasion through matrigel (p<0.01), migration (p<0.001) toward NIH3T3 CM and increased colony formation in soft agar (p<0.01). CBS inhibition with AOAA (1mM) decreased invasion and migration (p<0.01) in the NCM-C cells compared to NCM-v. In high-resolution respirometry, respiratory rate was significantly higher in the NCM-C compared to -p and -v. (141.8  1.5 vs. 33.7  0.8 vs. 72.2  1.77  pmols1mg1, -p v -C p < 0.0001, -v v -C p < 0.0005, -p v -v p < 0.001). Exome-wide sequence analyses of the NCM-p identified inactivating mutations in the APC and TP53 tumor suppressor genes, and an activating mutation in KRAS. Although the NCM-C cells produced significantly larger tumors in mice compared with NCM-v or NCM-p (p<0.001 2-w ANOVA), none of the cell lines caused liver metastasis in vivo. Conclusion', ' A non-tumorigenic cell line with some known mutations can progress to a tumorigenic, but not metastatic, phenotype with CBS overexpression and H2S production. Our data supports the importance of CBS/H2S axis in the adenoma to carcinoma sequence.']",
        "Doc_id":"AACR_2016-4276",
        "Doc_title":" Cystathionine--synthase overexpression increases cell proliferation, migration, bioenergetics and tumorigenesis in a non-tumorigenic colorectal cancer (CRC) cell line",
        "_version_":1606188993259503616},
      {
        "Meeting_name":" Distribution of ETV6-NTRK3 translocations across neoplasms identified from the Mitelman Database.",
        "Background":"['Background', ' Discovered as a novel aberration in congenital fibrosarcoma (CF), the ETV6-NTRK3 translocation (EN) confers oncogenic potential and is inhibited by crizotinib. The present study aims to survey the scope of neoplasms that harbor EN across tumor types. Methods', ' Utilizing the National Cancer Institutes Mitelman Database (MD) of Chromosome Aberrations and Gene Fusions patients (pts) were identified with EN and categorized based on tumor type, subtype and incidence. Cancer pts who received tumor profiling with Caris were also surveyed for EN. Results', ' 47 pts with EN across 12 cancer types were extracted from the MD and had median age of 0.17 years (7 unreported); 38% male; 51% acquired malignancies, 49% congenital; 62% cases were pediatric, 23% adult and 15% unknown. 0/204 pts with Caris tumor profiling were found to have an EN. Cancers with the highest number of EN were', ' 15 (31.9% EN data set) congenital mesoblastic nephromas (CMN), 10 (21.3%) CF, 7 (14.9%) breast carcinoma (BC; 6 secretory ductal carcinoma (SD) and 1 invasive adenocarcinoma (IA)) and 3 (6.4%) colorectal carcinoma (CRC). EN were found in 8 other malignancies (Table 1). Cancer types with the highest incidence of EN+ cases in the MD were gastrointestinal stromal tumor (GIST; 100%), CMN (75%) and CF (23.3%). Conclusions', \" These results further our understanding of the distribution of ETV6-NTRK3 translocations in multiple tumor types across the age spectrum and suggest that pts with CMN, CF, BC and CRC requiring high order therapy should be considered for NTRK3-based treatment. Incidence of ETV6-NTRK3 translocations curated from the MD.Cancer TypeSubtype (N)N(%) of EN data set% of total cases within MD (N)CMN15 (31.9%)75.0% (20)CF10 (21.3%)23.3% (43)BCSD (6), IA (1)7 (14.9%)0.2% (4014)CRC3 (6.4%)0.9% (338)Salivary GlandMammillary analogue secretory (2)2 (4.3%)2.0% (102)Acute Myeloid LeukemiaM0 (1), M2 (1)2 (4.3%)0.0% (17227)AstrocytomaPilocytic (1), Grade III/IV (1)2 (4.3%)0.00% (66871)ThyroidPapillary (1), Unspecified (1)2 (4.3%)1.5% (134)GIST1 (2.1%)100% (1)Chronic Myeloid LeukemiaChronic Eosinophilic Leukemia (1)1 (2.1%)1.5% (65)Melanoma1 (2.1%)0.3% (377)Ewing's Sarcoma1 (2.1%)0.2% (475)\"]",
        "Doc_id":"ASCO_188391-199",
        "Doc_title":" Distribution of ETV6-NTRK3 translocations across neoplasms identified from the Mitelman Database.",
        "_version_":1606189039632777216},
      {
        "Meeting_name":" The tissue microenvironment (TME) of colorectal cancer (CRC)",
        "Background":"['Background', ' Tumor resident myeloid cells (MCs) are instrumental to cancer progression. Consequently, MCs are an emerging therapeutic target in many cancers. However, the mechanisms by which tumours regulate MCs remain poorly defined.Our aim was to investigate how the colorectal TME impacts on MCs recruitment and function. Methods', ' We analyzed the phenotype of tumor infiltrating MCs compared to those resident in uninvolved tissue employing multi-colour flow cytometry (n = 21, patients with Stage II/III CRC). We generated tumor (TCM) and normal (NCM) conditioned media from (n = 40) freshly cultured colorectal tumors and assessed levels of 16 cytokines using a multiplex assay. Finally, we designed a MC', 'Cell line co-culture model to investigate the molecular mechanisms that control MC function. Results', ' We found that two distinct MC subsets HLA-DRhiCD11chi and CD11bhiCD15hi, unique to the tumor tissue (n = 19), dominated the CD45+ compartment. Further analysis showed that the HLA-DRhiCD11chi and the CD11bhiCD15hi were of monocyte (CD14&CD64) and neutrophil (CD66b&CD16) origin, respectively. In support of their potential inhibitory and proangiogenic function, we showed that the HLA-DRhiCD11chi subset expressed ILT4, PDL1 and Tie-2. The CD11bhiCD15hi subset exhibited high levels of arginase, an enzyme involved in T cell suppression. Interestingly, both cell subsets displayed an altered chemokine receptor profile compared to their blood counterparts. Accordingly, we were able to confirm the upregulated expression of inflammatory mediators, CXCL1 (p < 0.0001), CXCL5 (p < 0.0198), CCL5 (p < 0.0001), CCL4 (p < 0.0074), IL-8 (p < 0.0127), and IL-1 (p < 0.0001) in TCM compared to NCM. Finally, using both the RT2 profiler PCR array and a kinome array we identified a number of key protumor genes and mTOR signaling as potential regulators of tumor associated MCs. Conclusions', ' This study identifies two MC subsets in patients with CRC. We demonstrate that the TME recruits these cells via a complex chemokine-chemokine receptor network subsequently transforming them into a highly activated but potentially suppressive cell that favors tumor growth.']",
        "Doc_id":"ASCO_168099-176",
        "Doc_title":" The tissue microenvironment (TME) of colorectal cancer (CRC)",
        "_version_":1606188979531546624},
      {
        "Meeting_name":" Molecular analysis of KRAS exon 2 wild type colorectal cancer patients enrolled in the CAPRI clinical trial reveals high degree of tumor heterogeneity",
        "Background":"['The CAPRI clinical trial (Optimal strategy in KRAS wild type metastatic colorectal cancer patients', ' cetuximab plus FOLFIRI followed by FOLFOX +/- cetuximab) enrolls metastatic colorectal carcinoma (mCRC) patients with no codon 12/13 (exon 2) KRAS mutations. Recent data showed that exon 3 and 4 KRAS mutations as well as NRAS exon 2, 3 and 4 mutations might confer resistance to EGFR monoclonal antibodies. In addition, somatic mutations in other genes such as BRAF, PIK3CA, PTEN, have been hypothesized to be prognostic and/or predictive in CRC. Therefore, molecular sub-classification of KRAS exon 2 wild type CRC might allow to identify subgroups of patients highly sensitive or resistant to anti-EGFR agents within the CAPRI trial. We analyzed 182 FFPE samples from mCRC patients enrolled in the CAPRI clinical trial by using a next generation sequencing (NGS) approach based on the Ion AmpliSeq technology. In particular, 10 ng of genomic DNA were analyzed with the Ion Ampliseq Colon and Lung cancer panel that targets over 500 hotspot mutations in 22 genes implicated in colon and lung cancers. Data analysis was performed using Ion Reporter Software. The analysis with the IonAmpliseq panel was successful in all the tested samples. Among the 182 analyzed cases, 58 (31.9%) showed no mutations in the investigated genes, whereas a total of 206 mutations in 14 genes were detected in 124 cases (68.1%). Surprisingly, 30 exon 2 KRAS mutations were identified in 29 patients (15.9%). Mutations at a frequency >4% were also found in', ' TP53 (39.5% of the cases mutant), KRAS exon 3 and 4 (7.5%), PIK3CA (13.2), BRAF (8.2%), NRAS (7.1%), FBXW7 (4.9%). A significant degree of tumor heterogeneity was observed', ' several tumors had multiple mutations in different genes, with some cases showing up to 5 mutations. In particular, 30/45 KRAS, 5/13 NRAS, 12/15 BRAF and 19/24 PIK3CA mutant cases showed variants in additional genes. The frequency of mutant alleles also differed significantly among tumors. For example, among the KRAS exon 2 mutant cases, the frequency of KRAS mutant alleles, after normalization for the neoplastic cell content, ranged between 6% and 130%, suggesting that some KRAS mutant cases were polyclonal and that in some other cases gain of mutant or loss of wild type KRAS alleles might have occurred. These data suggest that molecular classification of KRAS exon 2 wild type CRC with the Ion Ampliseq Colon and Lung cancer panel is feasible. This approach reveals mutations in several key genes involved in CRC tumor progression. The relatively high incidence of codon 12/13 KRAS mutations also suggests that an high rate of false negative results in KRAS testing occurs in clinical practice. Finally, the huge degree of tumor heterogeneity might have important implications for prognosis and response to therapy.']",
        "Doc_id":"AACR_2014-937",
        "Doc_title":" Molecular analysis of KRAS exon 2 wild type colorectal cancer patients enrolled in the CAPRI clinical trial reveals high degree of tumor heterogeneity",
        "_version_":1606189020275015680},
      {
        "Meeting_name":" A reversible DNA methylation signature precedes sporadic mutations in the colorectal adenoma-dysplasia-cancer development",
        "Background":"['Background and aims', ' New generation sequencing and array technologies now allow the systematic investigation and comparison of genetic or epigenetic alterations in AD-CRC. The colorectal adenoma-dysplasia-cancer (AD-CRC) development is characterised by sporadic (<45% frequency) mutations in a limited number of genes. Recent epigenetic investigations showed that methylation of selected genes occurs in high frequency (>95%) in early stages of cancers already.Aims', ' Evaluation of the role of epigenetic and genetic alterations in the AD-CRC development using new generation sequencing and DNA methylation arrays.Materials and methods', ' DNA was isolated from fresh frozen biopsy specimens (20 normal; 33 adenomas; 17 CRCs). First, a multiplex PCR panel was designed to amplify mutation hot spots of 12 selected genes (APC, BRAF, CTNNB1, EGFR, FBXW7, KRAS, MSH6, NRAS, PIK3CA, SMAD2, SMAD4, TP53). Further DNA methylation analysis of 94 genes was performed on Human Colon Cancer EpiTect Methyl II Signature PCR Array (Qiagen) from the same DNA specimen. After RNA isolation whole genome expression analysis was performed with HGU133plus2 microarrays (Affymetrix) from 49 normal, 49 adenoma and 49 CRC specimens and on HT-29 cells with and without 5-aza-deoxycytidin treatment. Immunohistochemistry confirmation of expression changes on protein level was performed using tissue microarrays.Results', ' Mutations were found in 76% of adenomas and 78% of the cancer cases. The average number of mutations found in mutated samples was 1; 1,8; 1,9 and 2,3 in low grade adenomas, high grade adenomas, carcinomas and serrated adenomas, respectively. The APC suppressor gene was mutated in adenomas more frequently than in carcinomas (36% vs. 24%). The most frequently mutated genes were APC, TP53 and KRAS with 36%, 18% and 26% frequencies in adenomas and 24%, 47% and 45% frequencies in carcinomas.DNA methylation was found in 100% of the investigated colorectal adenoma and cancer specimens. Eight genes were found to be methylated in all of the cases. This gen set included SFRP1, MAL, SLIT2, SST, VIM; another set of genes (DKK1, SLI3, TMEFF2) was found to be hypermethylated in adenomas and cancers in >75% of the cases. In adenomas 56 genes, in dysplasias 40 in cancer 37 genes were methylated (>50% of the cases). The effect of methylation could be confirmed by decreased mRNA and protein expression. Demethylation treatment successfully restored the expression profile of the top methylated genes.Conclusion', ' Methylation of gene sets occurred in early premalignant stages followed by somatic mutations in increasing number through the AD-CRC development. Demethylation treatment could reverse the systematic, robust methylation alterations. Epigenetic alterations precede the somatic mutations of the AD-CRC and show higher significance in CRC development than genetic.']",
        "Doc_id":"AACR_2015-3826",
        "Doc_title":" A reversible DNA methylation signature precedes sporadic mutations in the colorectal adenoma-dysplasia-cancer development",
        "_version_":1606189027733536768},
      {
        "Meeting_name":" Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer",
        "Background":"['Background', '  Colorectal cancer (CRC) is the third most common cancer worldwide, with metastatic disease accounting for 40 to 50% of newly diagnosed patients. EGFR monoclonal antibodies (Mab), cetuximab and panitumumab, are effective treatment for KRAS wild type CRC. Although mutations in KRAS predict resistance to EGFR Mab therapy, only 80% of CRC patients with KRAS wild-type (WT) status respond to treatment. This study is a retrospective evaluation of genomic alterations in the EGFR pathway such as  alterations in KRAS, BRAF, NRAS, PIK3CA and PTEN that may predict lack of response to EGFR Mab therapy in CRC patients.  Methods', '  A large database of 5,900 consecutive CRC patients was analyzed from 2011 onwards for demographics (sex, age, geography, site of tumor) and biomarkers that might correlate with response to EGFR Mab therapy. Comprehensive testing included gene sequencing for KRAS, BRAF, NRAS, PTEN, and PIK3CA (next-generation sequencing, Sanger, pyrosequencing) and immunohistochemistry for PTEN protein expression.  Results', '  Analysis revealed the incidence of KRAS mutation of 42% which is consistent with published literature. Analysis of the KRAS WT cohort revealed a mutation rate of 13.8 % for BRAF, 6.8% for NRAS, and 40% for patients with either PTEN loss of expression/mutation or a PIK3CA mutation. Earlier studies support that mutations in NRAS, BRAF and activation of the PI3K pathway by PTEN/PIK3CA analysis result in lower response rates to EGFR Mab therapy in CRC. Furthermore, multiplex biomarker testing revealed the rare occurrence of concurrent mutations', ' 1/5,900 subject harboring a BRAF and NRAS mutations, 7/5,900 others with BRAF and PIK3CA mutations, and 8/5,900 subjects with NRAS and PIK3CA mutations.  Conclusions', '  This is a comprehensive analysis of a large international cohort evaluating the prevalence of predictive molecular aberrations suspected of lack of response to EGFR Mab therapy in patients with WT KRAS. Prospective controlled studies are in progress to validate the role of BRAF, NRAS, PIK3CA, and PTEN in clinical management of CRC. It is imperative to further explore the molecular pathology of CRC beyond KRAS in patient selection for EGFR Mab therapy.']",
        "Doc_id":"ASCO_123000-143",
        "Doc_title":" Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer",
        "_version_":1606189005042352128},
      {
        "Meeting_name":" HER2 activating mutations are potential targets for colorectal cancer treatment",
        "Background":"['Background', 'Cancer genome sequencing is identifying new genetic alterations and new driver events in human cancers. The Cancer Genome Atlas (TCGA) colorectal cancer project found that 7% of colorectal cancer (CRC) patients have HER2 somatic mutations or HER2 gene amplification. HER2 gene amplification in CRC is known to produce resistance to the EGFR monoclonal antibodies, cetuximab and panitumumab. However, the impact of HER2 somatic mutations in CRC has not been studied and it is open question as to whether HER2 mutations are clinically important in CRC.Results', \"Introduction of the HER2 mutations, S310F, L755S, V777L, and V842I, into immortalized colon epithelial cells increased cell signaling pathways and anchorage-independent cell growth, indicating that they are activating mutations. Introduction of HER2 V842I mutation into colorectal cancer cell lines produced resistance to the EGFR antibodies, cetuximab and panitumumab. HER2 mutations are potently inhibited by low nanomolar doses of the second generation, irreversible tyrosine kinase inhibitors neratinib and afatinib. HER2 gene sequencing of 48 cetuximab resistant, quadruple WT (KRAS, NRAS, BRAF, and PIK3CA WT) colorectal cancer patient derived xenografts (PDXs) identified 4 PDX's with HER2 mutations (4/48 = 8.3%). Treatment of these PDX's with a single HER2 targeted drug (trastuzumab, neratinib, or lapatinib) delayed tumor growth, but dual HER2 targeted therapy with trastuzumab plus a tyrosine kinase inhibitor produced durable shrinkage of the tumors in mice. After the final timepoint in each PDX experiment, the mice were sacrificed and the tumors excised. The tumor histology demonstrated that dual HER2 targeted therapy caused reduction in tumor cellularity and acquisition of more differentiated features.Conclusions\", 'These data demonstrate that HER2 activating mutations are a new drug resistance mechanism to EGFR monoclonal antibodies. More importantly, these data suggest that HER2 activating mutations may themselves be a drug target for the treatment of colorectal cancer. These data form a strong pre-clinical rationale for clinical trials targeting HER2 activating mutations in metastatic CRC patients. The NSABP Foundation is in the design stage for such a clinical trial and will use its living patient biorepository (MPR-1 trial) that contains 1350 colorectal cancer patients to identify subjects for this trial.']",
        "Doc_id":"AACR_2015-132",
        "Doc_title":" HER2 activating mutations are potential targets for colorectal cancer treatment",
        "_version_":1606189037871169536},
      {
        "Meeting_name":" Genomic profiling of young adults with colorectal cancer",
        "Background":"['Background', ' 2-8% of all colorectal cancer (CRC) cases are in younger adults (YAs), patients (pts) less than age 50. However, current understanding of CRC in YAs is inadequate, especially that of sporadic onset. We conducted a study to describe the landscape of genomic alterations in YA CRC pts presenting to a large academic practice. Methods', ' Adult pts with CRC presenting to The Ohio State University Comprehensive Cancer Center oncology clinics were offered next generation sequencing (NGS) through a customized 22-gene Ion AmpliSeq Mutation Panel as part of clinical care. Commonly mutated areas of select genes (including AKT1, ALK, BRAF, EGFR, ERBB2/4, FBXW7, FGFR1/2/3, KRAS/NRAS, MET, NOTCH1, PIK3CA, PTEN, TP53) were sequenced from tumor sections. Institutional review board approval was obtained to retrospectively analyze this NGS testing between 1/2013-3/2016. Results', ' 258 CRC pts underwent genomic profiling. 57 pts (22.1%) were YAs at diagnosis (range 22-49 years); 20 pts (7.8%) were 40 years old or younger. 31 YA pts (54.4%) had metastatic disease. Of the YAs with CRC, 18 pts (31.6%) were diagnosed with R-sided colon, 16 pts (28.1%) with L-sided colon, and 22 pts (38.6%) with rectal cancer. 110 genomic alterations were found in YA pts, with a mean of 1.9 mutations per tumor (range 0-6); 35 (31.8%) of these in 32 (56.1%) YA pts were actionable. Of these 110 alterations, 41.8% were in TP53, 28.2% in KRAS/NRAS, 10.0% in PIK3CA, 3.6% in BRAF, 3.6% in FBXW7, and 2.73% in PTEN. 6 YA pts (10.5%) had microsatellite instability (MSI-H). Only 1 pt had concomitant MSI-H and a BRAF mutation; 4 pts with BRAF mutations were microsatellite stable. Comparing our YA pts to a separate cohort of pts age > 50 who had testing done, no significant difference was seen in mutation incidence in KRAS/NRAS (p = 1.0), TP53 (p = 0.3), PIK3CA (p = 0.128), or BRAF (p = 1.0). Conclusions', ' Genomic profiling through a targeted NGS panel is feasible as part of routine clinical practice. There is disagreement in the literature on genetic mutations in YA compared to older age CRC pts. Knowledge of the genomic landscape in YAs with CRC will lead to improved understanding of the underlying biology of CRC in YAs as it differs from CRC in older pts, and could impact future care of this cohort.']",
        "Doc_id":"ASCO_190873-199",
        "Doc_title":" Genomic profiling of young adults with colorectal cancer",
        "_version_":1606189023443812352},
      {
        "Meeting_name":" Genomic overview of right-sided and left-sided colorectal cancer using comprehensive genomic sequencing.",
        "Background":"['Background', ' Although the difference in right vs. left sidedness of colorectal cancer (CRC) in response to targeted therapy has been reported, we hypothesized that right-sided colorectal cancer (RCC) is more likely to have genetic alterations associated with resistance of anti-EGFR therapy. We tested this hypothesis using comprehensive genomic sequencing (CGS) on a set of samples from well-characterized CRC patients. Methods', ' Two-hundred-one primary colon cancer patients with either RCC or left-sided colorectal cancer (LCC) were analyzed. We investigated gene alterations using 415 gene panel, which includes the gene alterations associated with resistance of anti-EGFR therapy', ' TK receptors (ERBB2, MET, EGFR, FGFR1, and PDGFRA), RAS pathway (KRAS, NRAS, HRAS, BRAF, and MAPK2K1), and PI3K pathway (PTEN and PIK3CA). We defined the patients who had no alterations in any of the genes as all wild-type, who are theoretically considered as responders of anti-EGFR therapy. Other patients with genetic alterations in resistance pathways were defined as mutant-type. Results', ' Fifty-six patients (28%) and 145 patients (72%) had RCC and LCC, respectively. Mutation of PIK3CA, BRAF, ACVR2A, MSH6, and CTNNB1 were significantly associated with RCC. Conversely, mutation of APC and TP53 were significantly associated with LCC. Regarding the gene alterations associated with anti-EGFR therapy, only 6 of 56 patients (11%) of RCC were all wild-type; in contrast to 41 of 145 patients (28%) of LCC that were all wild-type (P = 0.009). In 45 Stage IV patients treated with anti-EGFR therapy, RCC showed significantly worse progression-free survival (PFS) than LCC (P = 0.019), and mutant-type RCC showed worse PFS compared to the others (P = 0.018). Conclusions', ' RCC is more likely to have the genetic alterations associated with resistance of anti-EGFR therapy compared to LCC. Primary tumor sidedness is a surrogate for the non-random distribution of molecular subtypes in CRC.']",
        "Doc_id":"ASCO_187862-199",
        "Doc_title":" Genomic overview of right-sided and left-sided colorectal cancer using comprehensive genomic sequencing.",
        "_version_":1606189002048667648},
      {
        "Meeting_name":" Aflibercept is highly active in clinically relevant, patient derived xenografts of colorectal cancer",
        "Background":"['Aflibercept (ziv-aflibercept in USA), a new fusion protein, targets vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF). Aflibercept + FOLFIRI is approved for treating metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin containing regimen. We investigated the pharmacological activity of aflibercept in CRC patient derived xenografts (PDX), most metastases-derived, and characterized PDX molecular and phenotypic properties. In 48 CRC PDX, Whole Exome Sequencing revealed', ' 85% APC, 79% TP53, 51% KRAS, 3% NRAS, 25% PIK3CA, 11% PTEN and 8% BRAF mutants. There was no significant association between angiogenic factors, tumor mutation profiles, and response to aflibercept.In tumors, protein levels of human (h) VEGF-A were significantly higher than mouse (m) VEGF-A, hPlGF, and mPlGF (Chiron et al, ESMO, 2013). Affymetrix probes detected VEGF-A and PIGF but not VEGF-B mRNA in most PDX. There was no significant association between expression of angiogenic factors and response to aflibercept. Histological sections of CRC tumors from PDX, xenografts created from cell lines, and patients tumor specimens indicated that stromal involvement in human tumors was recapitulated in PDX but not in tumors from cell lines. PlGF expression was analyzed by immunohistochemistry on colon cancer tissue arrays. A significant number of colon cancer specimens were positive for PlGF, expressed in tumor cells and stroma. Aflibercept resulted in anti-tumor activity in 47/48 CRC PDX models and complete tumor stasis in 31/48 models. Efficacy data from 5 PDX models responsive to aflibercept and CRC standard of care (SOC) drugs, all administered as monotherapies, are below. The robust activity of aflibercept in CRC PDX models that are sensitive to SOC drugs suggest that CRC patients would benefit from aflibercept treatment, independently of mutational status or expression of angiogenic factors.']",
        "Doc_id":"AACR_2014-4808",
        "Doc_title":" Aflibercept is highly active in clinically relevant, patient derived xenografts of colorectal cancer",
        "_version_":1606188994261942272},
      {
        "Meeting_name":" Prevalence of critical malnutrition (CMN) in patients enrolling on phase I/II (P1/2) clinical trials.",
        "Background":"['Background', ' Cancer therapies undergo evaluation in P1/2 trials, frequently in patients (pts) with disrupted caloric intake, weight loss, and other adverse effects of cancer on physical and psychological functioning. CMN and sarcopenia may increase treatment related toxicity (TRT) due to acquired pharmacokinetic variability and altered drug metabolism. Little is known about the prevalence of CMN among pts enrolling on P1/2 trials, its association with abnormal physical and psychological functioning, and its role in mediating TRT. Methods', ' Pts initiating a P1/2 trial were recruited. Study acceptance rate was > 95%. Pts had a comprehensive nutritional assessment using the validated PG-SGA, a short, 3-5 minute tool that evaluates multiple nutritional domains [symptom burden, functional status, metabolic stress and physical exam (muscle/fat status)]. CMN is defined as a PG-SGA score of  9. Distress, anxiety, depression and physical activity were also measured. BMI and albumin were extracted from the chart. Statistical significance was determined by Fishers exact test. Results', ' 54 pts (85% P1) were enrolled. CMN was identified in 39%. Pts with gastrointestinal (GI) cancers were more likely to have CMN than non-GI cancers (75% vs 24%, p = 0.001); otherwise, CMN rates were not different by age ( < 60 vs 60+), gender, race, or trial phase (1 vs 2). CMN was also associated with number of lines of therapy, but was surprisingly less common among patients with > 2 therapies compared to those with 0-2 (29% vs 57%, p = 0.051). Strong associations of CMN to distress (p = 0.028), depression (p = 0.020) and sedentary lifestyle (p = 0.012) were also seen. Clinical red flags of MN such as low BMI ( < 25) and low albumin ( < 3.5) had poor sensitivity (66.7% and 33.3%) and specificity (57.6% and 78.8%) for CMN. Correlation of CMN to TRT is underway. Conclusions', ' CMN is prevalent among P1/2 trial pts, notably in those with GI cancers and with fewer lines of therapy, and is associated with physical inactivity, distress and depression. BMI and albumin are poorly predictive of CMN. Undiagnosed CMN may, through multiple pathways, increase the vulnerability of pts on P1/2 studies to TRT. Comprehensive nutritional assessment of P1/2 pts should be considered.']",
        "Doc_id":"ASCO_185242-199",
        "Doc_title":" Prevalence of critical malnutrition (CMN) in patients enrolling on phase I/II (P1/2) clinical trials.",
        "_version_":1606189031767408640},
      {
        "Meeting_name":" The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer.",
        "Background":"['Background', ' KRAS mutations (MUT) negatively affect outcome after cetuximab (CTX) in metastatic colorectal cancer (mCRC). As only 40% of KRAS wild-type (WT) respond it is possible that other MUT, constitutively activating the Ras/Erk or PI3K/Akt pathways, are present in the non-responding KRAS WT. We analyzed the KRAS, BRAF, NRAS & PIK3CA MUT status in 276 chemorefractory CRC treated with CTX +- irinotecan and correlated the MUT status with outcome. Methods', \" KRAS codon 12,13, 61&146, BRAF V600E, NRAS codon 12&13, PIK3CA E542K, E545K, A, G, V (exon 9), H1047Y, R, L (exon 20), N345K, R88Q and Q546K MUT were evaluated on FFPE primary CRC using the Sequenom MALDI TOF MassArray system. A two- sided Fisher's exact test was used to evaluate the association between PIK3CA, KRAS, BRAF & NRAS MUT and objective response (OR). Progression-free (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Results\", ' 116/276 (42%) CRC had a KRAS MUT, 96% of which occurred in codon 12 or 13. KRAS WT was associated with OR (p<.0001), longer median PFS (p<.0001) and OS (p<.0001). 15/153 (9.8%) KRAS WT had a BRAF MUT. BRAF WT was associated with OR (p=.01), longer PFS (p<.0001) and OS (p=.007). 5/98 (5%) KRAS WT had an NRAS MUT and none of these showed OR. KRAS, BRAF and NRAS MUT were mutually exclusive. The combined KRAS/BRAF/NRAS WT state was associated with OR (p<.0001), longer PFS (p<.0001) and OS (p<.0001). 23/200 (12%) CRC carried a PIK3CA mutation', ' 5/39 (13%) of responders and 18/160 (11%) of non-responders (p=.781). Median PFS and OS were not associated with PIK3CA MUT state (p=.760 & p=.698) overall, nor in the KRAS/BRAF/NRAS WT subgroup (p=.946 & p=.509). 5/13 (38.5%) PIK3CA MUT KRAS/BRAF/NRAS WT CRC showed an OR. 13/107 (12%) of KRAS/BRAF/NRAS WT and 10/93 (11%) of KRAS/BRAF/NRAS MUT tumors harbored a PIK3CA MUT (p=.826). Conclusions', ' KRAS, BRAF & NRAS MUT are mutually exclusive and occur in at least 47% of CRC. Like KRAS WT, BRAF WT state of the primary is significantly associated with outcome in mCRC treated with CTX. The combined KRAS/BRAF/NRAS WT state is significantly associated with outcome. PIK3CA MUT occur independently of the KRAS/BRAF/NRAS MUT status. We cannot provide any evidence for a strong role of PIK3CA MUT as a marker in determining outcome to CTX.']",
        "Doc_id":"ASCO_34187-65",
        "Doc_title":" The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer.",
        "_version_":1606188976051322880},
      {
        "Meeting_name":" Molecular profiling of patients (pts) with advanced colorectal cancer (CRC)",
        "Background":"['Background', '  In routine clinical practice the prevalence of somatic mutations other than KRAS G12/13, PIK3CA, and BRAF in colorectal cancer (CRC) has not been well described. This study reports molecular profiling of pts with advanced CRC in clinical setting.  Methods', '  Patients (pts) with advanced CRC are enrolled in an ongoing institution-wide screening program. Molecular profiling is performed on formalin-fixed and paraffin-embedded (FFPE) archival tissues using a customized Sequenom panel (23 genes, 279 mutations) or the Illumina MiSeq TruSeq Cancer Panel (48 genes, 212 amplicons, 500x coverage) in our Clinical Laboratory Improvement Amendments-certified laboratory. PTEN is determined by immunohistochemistry (IHC), with H score <1 defined as negative. Statistical analysis was performed with chi-square tests.  Results', '  From March 2012 to October 2013, 190 pts were enrolled. At least one mutation was found in 55% (82/153) and 89% (33/37) of pts using Sequenom or MiSeq platforms respectively (p<0.01). Of all 190 pts, KRAS G12/13 mutation was identified in 35%, and non-G12/13 KRAS, BRAF, or NRAS mutations were present in 5% , 6%, and 4% respectively. Other mutations found included PIK3CA (13%, 24/190), CTNNB1, ERBB2, FGFR3, and EGFR (1% each). MiSeq detected additional mutations including KRAS A146 or L19F (4/37), SMAD4 (4/37), FRXW7 (3/37), APC (15/37), TP53 (26/37), ERBB4 (1/37), PTEN (1/37), and IDH1 (1/37). Co-mutation with KRAS was found in 63% of pts with PIK3CA mutation and 80% of pts with APC mutation. Of 85 pts with known PTEN IHC status, 19% were negative. A higher average number of mutations was observed in right- versus left-sided CRC (p<0.01).  Mutations with known clinical significance (RAS and BRAF) were collectively more prevalent in right colon (p<0.01).  Conclusions', '  Targeted next-generation DNA sequencing identifies more genomic alterations than SNP genotyping. Current strategy of anti-epidermal growth factor receptor therapy in KRAS G12/13 wild type pts might not benefit >15% of pts due to presence of other RAS/BRAF mutations. Clinically relevant genomic alterations are more likely to be detected in right colon.']",
        "Doc_id":"ASCO_129859-144",
        "Doc_title":" Molecular profiling of patients (pts) with advanced colorectal cancer (CRC)",
        "_version_":1606188971872747520},
      {
        "Meeting_name":" Molecular and clinical prognostic factors in metastatic colorectal cancer (CRC) patients (pts)",
        "Background":"['Background', '  Strong evidence is emerging about the usefulness of mutational profiling for CRC pts. This study aimed to evaluate the overall survival in three molecular groups, taking as reference the all-wild type category', ' (1) BRAF mutated; (2) KRAS mutated codons 12-13 only; (3) any of KRAS codons 61-146, PIK3CA exon 9-20 or NRAS cod 12-13-61 mutations. Also clinical variables were investigated as potential prognostic factors.  Methods', '  Data of 194 consecutive pts treated for metastatic colorectal cancer (mCRC) at our University Hospital in Udine, Italy, between Jan 2004 and Jan 2013 were reviewed. Point mutations were detected by pyrosequencing platform PyroMark Q96 ID instrument for KRAS/NRAS codons 12, 13, 61, and 146, BRAF exon 15, and PIK3CA exons 9 and 20.  Clinical and molecular prognostic factors were identified using the Cox proportional hazards model.  Results', '  The all wild-type population consisted of 76 pts (39%). 62 cases (32%) harboured mutations in KRAS codons 12-13. BRAF V600E mutation was found in 10 (5.2%) samples. Mutations in KRAS 61-146, PIK3CA and NRAS codons were detected in 9 (4.6%), 32 (16.5%) and 6 (3.1%) pts, respectively. All factors significant in univariate analysis were subjected to multivariate analysis (see Table). The all-wild type category had the longest survival (27.7 months). Patients carrying BRAF mutations reported an overall survival of 7.6 months and those with KRAS 12-13 mutation 16.7 months.  Conclusions', '  This study reinforces the prognostic value of a full mutational molecular profile and points out some prognostic clinical factors in CRC. The influence of clinical variables such as right colon cancer, primary tumour not resected, exposure to bevacizumab and lines of chemotherapy need further investigation.']",
        "Doc_id":"ASCO_123338-143",
        "Doc_title":" Molecular and clinical prognostic factors in metastatic colorectal cancer (CRC) patients (pts)",
        "_version_":1606189031161331712},
      {
        "Meeting_name":" Primary and acquired resistance to HERs inhibition in colorectal cancer cells",
        "Background":"[\"The monoclonal antibodies cetuximab and panitumumab are approved for the treatment of metastatic colorectal cancers (mCRC). When used as monotherapy, the anti-EGFR antibodies are effective in approximately 15% of patients. It is now well established that colorectal tumors carrying KRAS and BRAF mutations (40%) are refractory to EGFR targeted therapies (primary resistance). Virtually all-responsive patients eventually become insensitive to anti-EGFR antibodies (secondary resistance) within 3 to 12 months of initiating therapy. Primary and acquired resistance therefore limits the clinical benefit of EGFR blockade in CRC patients.We postulated that concomitant inhibition of multiple members of the HER (ErbB) receptors family might suppress the growth of CRC cells more effectively than selectively targeting only the EGFR with cetuximab or panitumumab.Accordingly, we assessed the pharmacological activity of momelotinib and afatinib- two pan-HER tyrosine kinase inhibitors- in a collection of 40 CRC cell lines, which recapitulate the genetic profiles commonly detected in CRC patients. We report that primary resistance to pan-HER inhibition is associated with KRAS and BRAF mutations thus suggesting that this patients' population will unlikely benefit from momelotinib and afatinib treatments. Notably, however, pan-HER blockade was effective in a subset of KRAS/BRAF wild type CRC cell lines refractory to cetuximab and panitumumab indicating that a subgroup of patients, which do not benefit from EGFR blockade, may profit from pan-HER inhibition.To define the molecular mechanisms of acquired resistance to ErbB inhibitors, three KRAS/BRAF/NRAS wild type CRC cell models were continuously treated with cetuximab, momelotinib and afatinib, until resistant derivatives emerged. Genetic characterization of such derivatives unveiled that, regardless of the drug used, the resistant populations were a mixture of clones carrying distinctive mutations in KRAS or NRAS. Detailed biochemical analyses of the ErbB signalling pathway revealed that resistant variants displayed high levels of MEK and ERK activation, which persisted upon ErbBs inhibition.Collectively, these results identify KRAS, BRAF and NRAS mutations as major drivers of primary and/or acquired resistance to HERs inhibition in colorectal cancer cells and suggest that a molecularly defined subset of CRC patients might benefit from pan-HER blockade.\"]",
        "Doc_id":"AACR_2014-1843",
        "Doc_title":" Primary and acquired resistance to HERs inhibition in colorectal cancer cells",
        "_version_":1606189036357025793},
      {
        "Meeting_name":" Targeted cancer gene sequencing identifies potential causative novel candidate mutations among Caucasian colon carcinogenesis",
        "Background":"[\"Much of the sporadic colorectal cancer's (CRC) underlying genetic cancer driver mutations are unknown in patients from specific ethnic groups. Here, we report the identification of distinct novel variants from adenoma and CRC patients in mismatch repair (MMR) genes MHS3 and MSH6, and in PIK3CA and APC.We developed a panel of 20 frequently altered colon cancer genes comprised of ACVR2A, APC, ARID1A, BRAF, FAM123B, FBXW7, KRAS, MSH2, MSH3, MSH6, NRAS, PIK3CA, POLE, PTEN, SMAD2, SMAD4, SOX9, TCF7L2, TGFBR2, and TP53 for targeted sequencing in 65 colon tissues, comprised of 1 normal tissue sample, 2 adenomas, and 63 tumors. Multiplex PCR and Ion Torrent sequencing was used to examine 98.8% of the targeted exons and splice junctions at a depth of sequencing that allowed for high confidence variant calling (most bases were covered by  500 reads). After alignment and variant calling, we annotated the variants with information from the 1000 Genomes Project, COSMIC, Polyphen2, and PFAM domain and transcription factor motifs. Excluding synonymous SNVs, 3 variants in adenoma, and 692 variants in tumors were detected. Two were known pathogenic variants (MSH6 p.R965H and APC p.R1432X). Novel variants (286, 244, and 115) were found in MMR genes (MSH6 and MSH3), APC, and PIK3CA, respectively. Most of the MMR (n = 98), APC (n = 128), and PIK3CA (n = 43) variants are deleterious. Notably, among the 63 CRC cases, [(29/61 = 46%) 46%) for MSH3, MSH6] [(19/63 = 30%) (30%) for PIK3CA] [31/63 = 49%) (49%) for APC)] carried likely deleterious MMR, PIK3CA and APC mutations, respectively, suggesting the value of a broad cancer gene panel. These finding further highlight the relevance of APC, PIK3CA genes in CRC onset but also the potential underestimation of the MSI-H in sporadic CRC as many of the novel mutations in MMR gens detected here were of a deleterious nature.\"]",
        "Doc_id":"AACR_2015-3930",
        "Doc_title":" Targeted cancer gene sequencing identifies potential causative novel candidate mutations among Caucasian colon carcinogenesis",
        "_version_":1606188984656986112},
      {
        "Meeting_name":" Impact of patient age on molecular alterations in left-sided colorectal tumors.",
        "Background":"['Background', ' The incidence of colorectal cancer (CRC) in younger patients (pts) is rising. This increase is most pronounced in tumors arising from the distal colon and rectum. Since tumor sidedness has emerged as an important prognostic and predictive biomarker in CRC, we aim to explore the impact of age on the tumor biology of left-sided colon cancer (LCC). Herein, we compare profiles of LCC from younger ( 45 years) and older pts ( 65 years). Methods', ' LCCs (splenic flexure to rectum; n = 1,602) were examined by NextGen sequencing, protein expression, gene amplification, and microsatellite instability fragment analyses. Tumor mutational load (TML) was calculated using only somatic nonsynonymous missense mutations. Chi-square tests were used for comparisons. Results', ' LCCs from younger (median age 40, range 22-45 years, n = 229) and older (median age 71, range 65-89, n = 503) pts were studied. The most frequently mutated genes included APC, TP53, KRAS, PIK3CA, ARID1A, FBXW7, SMAD4, ATM, BRAF, and NRAS. Comparing younger v. older pts, there were no significant differences in the rates of APC (75.3% v. 82.9%, P = 0.139), TP53 (79.5% v. 73.1%, P = 0.261), KRAS (37.6% v. 43.0%, P = 0.403), PIK3CA (9.4% v. 14.6%, P = 0.234), ARID1A (14.3% v. 13.2%, P = 0.884), FBXW7 (11.4% v. 10.5%, P = 0.830), SMAD4 (13.1% v. 7.4%, P = 0.129), BRAF (4.8% v. 5.7%, P = 0.762), or NRAS (3.5% v. 2.6%, P = 0.680) mutations. Additionally there were no significant differences in protein overexpression. However, there was a trend towards increased HER2 amplification in younger pts (5.7% v. 2.1%, P = 0.05). MSH6 (4.8% v. 0.5%, P = 0.015), MSH2 (2.4% v. 0%, P = 0.032), POLE (2.4% v. 0%, P = 0.032), and NF1 (7.9% v. 0%, P < 0.001) mutations were observed at higher rates in younger pts. High TML ( 17 mutations per megabase) was seen more frequently in younger pts (8.2% v. 2.6%, P = 0.02). Conclusions', ' The molecular differences between LCC in younger and older pts are mostly due to mutations in mismatch repair genes. Higher TML may predict a higher response rate to checkpoint inhibitors in younger pts with LCC. The differences in tumor biology observed here warrant further study and may eventually be used to tailor therapy.']",
        "Doc_id":"ASCO_192404-199",
        "Doc_title":" Impact of patient age on molecular alterations in left-sided colorectal tumors.",
        "_version_":1606189042113708032},
      {
        "Meeting_name":" Novel, sensitive simplex and multiplex assays for KRAS and NRAS mutation detection.",
        "Background":"['Background', ' Activating KRAS/NRAS mutations in colorectal cancer (CRC) predict resistance to anti Epidermal Growth Factor Receptor targeted therapies. To improve the molecular characterization of CRC, we developed novel simplex and multiplex real-time PCR based assays (SensiScreen) for KRAS/NRAS analysis, and compared them with Direct Sequencing (DS), Mutant-Enriched PCR (ME-PCR), TheraScreen and Cobas. Methods', ' SensiScreen assays (PentaBase) comprise SuPrimers (DNA primers with increased specificity), BaseBlockers (suppressing amplification of wild-type genes) and HydrolEasy probes (hydrolysis probe with increased S/N ratio and sensitivity). Sensitivity studies on plasmids and extracted cell line DNA were performed. Three cohorts were analyzed for KRAS exon 2 mutations', ' Cohort 1 (n = 100), SensiScreen was compared with DS and ME-PCR; Cohort 2 (n = 79), with DS and TheraScreen; and Cohort 3 (n = 307), with Cobas. KRAS exons 3/4 and NRAS exons 2/3/4 were tested by DS and SensiScreen on 156 patients. Results', ' Our sensitivity studies gave superimposable results for both simplex and multiplex assays. DS had a limit of detection of 10%, ME-PCR of 0.1% and SensiScreen of  0.1%. Patients with mutations found in KRAS exon 2 were', ' Cohort 1', ' 33 (33%) by DS, 43 (43%) by ME-PCR and 45 (45%) by SensiScreen. Cohort 2', ' 17 (21%) by DS, 19 (24%) by TheraScreen and 19 (24%) by SensiScreen. Cohort 3', ' 84 (27%) by Cobas and 88 (29%) by SensiScreen. In KRAS exons 3/4-NRAS exons 2/3, DS identified mutations in 6 (3.8%), 4 (2.6%), 1 (0.6%) and 2 (1.3%) cases respectively, whereas SensiScreen detected mutations in 8 (5.1%), 8 (5.1%), 4 (2.6) and 8 (5.1%) cases respectively. No NRAS exon 4 mutations were detected. Simplex and multiplex assays identified the same mutations. Conclusions', ' SensiScreen simplex and multiplex assays are novel, rapid, easy-to-use and highly sensitive methodologies enabling better identification of KRAS/NRAS mutations in CRC than currently used methodologies. The multiplex version analyzes 44 mutations of 6 exons with only 11 reactions.']",
        "Doc_id":"ASCO_166036-176",
        "Doc_title":" Novel, sensitive simplex and multiplex assays for KRAS and NRAS mutation detection.",
        "_version_":1606189002298228737},
      {
        "Meeting_name":" The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).",
        "Background":"['Background', '  EpHA2 is a 130 kD transmembrane glycoprotein belonging to ephrin receptor subfamily and involved in angiogenesis/tumour neovascularisation. High EpHA2 mRNA level has recently been implicated in cetuximab resistance. Previously, we found high EpHA2 levels in a panel of invasive colorectal cancer (CRC) cells, which was associated with high levels of stem-cell marker CD44. Our aim was to investigate the prognostic value of EpHA2 and subsequently correlate expression levels to known clinico-pathological variables in early stage CRC. Methods', '  Tissue samples from 509 CRC patients were analysed. EpHA2 expression was measured using IHC. Kaplan-Meier graphs were used. Univariate and multivariate analyses employed Cox Proportional Hazards Ratio (HR) method. A backward selection method (Akaikes information criterion) was used to determine a refined multivariate model.  Results', '  EpHA2 was highly expressed in CRC adenocarcinoma compared to matched normal colon tissue. In support of our preclinical invasive models, strong correlation was found between EpHA2 expression and CD44 and Lgr5 staining (p<0.001). In addition, high EpHA2 expression significantly correlated with vascular invasion (p=0.03).HR for OS for stage II/III patients with high EpHA2 expression was 1.69 (95%CI', ' 1.164-2.439; p=0.003). When stage II/III was broken down into individual stages, there was significant correlation between high EpHA2 expression and poor 5-years OS in stage II patients (HR', ' 2.18; 95%CI', ' 1.28-3.71; p=0.005).HR in the stage III group showed a trend to statistical significance (HR', ' 1.48; 95%CI=0.87-2.51; p=0.05). In both univariate and multivariate analyses of stage II patients, high EpHA2 expression was the only significant factor and was retained in the final multivariate model. Higher levels of EpHA2 were noted in our RAS and BRAF mutant CRC cells, and silencing EpHA2 resulted in significant decreases in migration/invasion in parental and invasive CRC sublines. Correlation between KRAS/NRAS/BRAFmutational status and EpHA2 expression in clinical samples is ongoing.  Conclusions', '  Taken together, our study is the first to indicate that EpHA2 expression is a predictor of poor clinical outcome and a potential novel target in early stage CRC.']",
        "Doc_id":"ASCO_130612-144",
        "Doc_title":" The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).",
        "_version_":1606189002281451520},
      {
        "Meeting_name":" Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.",
        "Background":"['Background', ' A challenge in delivering personalized cancer care to the clinic is identifying tumor genotypes that predict response to targeted therapeutics. Methods', ' In 2008, we established a Personalized Cancer Medicine Registry (PCMR) and began consenting patients for the following', ' 1) prospective genotyping of their cancer; 2) storing their tumor material for future research; and 3) permission to re-contact them if their tumor genotype fits the profile for a new therapeutic. As of the end of 2009, more than 800 patients were enrolled in the PCMR, including cases of colorectal carcinoma (CRC, n = 199), endometrioid carcinoma (EC, n = 95), thyroid carcinoma (TC, n = 276), bladder carcinoma (n = 80), and malignant melanoma (MM, n = 163 ). Tumor DNA from archival tissue was genotyped using a Sequenom MassArray system. Each sample was analyzed using a panel (320 assays) that detects known mutations in 29 genes. Clinical and genotyping data are stored in a web-interfaced, customized SQL database. Results', ' 95% of approached patients consented to registry enrollment. Archival tumor suitable for analysis was obtained in 95% of cases. Mutations in EC include PIK3CA (21%), CTNNB1 (13%), KRAS (11%), FBXW7 (5%), TP53 (5%), AKT1 (4%), FGFR2 (3%), NRAS (1%) and PDGFRA (1%); 14 cases harbor 2 or more mutations. Among cutaneous MM we found mutations in BRAF (47%; 10.8% other than V600E), NRAS (13%), CTNNB1 (3%), PIK3CA (2%), AKT1 (1%) and MEK2 (1%). In CRC we found mutations in KRAS (30%), TP53 (16%), PIK3CA (12%), NRAS / BRAF / FBXW7 (3% each), CTNNB1 (2%), and MEK1 / AKT1 / AKT2 / RET (1% each). Remarkably, 10 of 14 CRC tumors (71%) with a PIK3CA mutation also have a KRAS mutation. In TC, we found mutations of BRAF (63%), RET-PTC (7%), and PIK3CA/KRAS/NRAS/HRAS (1.5% each). Conclusions', ' Prospective tumor genotyping for PCMR patients reveals a remarkable diversity of potentially druggable mutations, knowledge of which will help in clinical trial enrollment. While rare in the examined tumors, mutations in FGFR2, MEK1/2, AKT1/2, PDGFRA and RET could be targeted as part of individualized cancer treatments. In CRC, the common overlap of PIK3CA mutations with KRAS mutations may negatively impact response to inhibitors of the PI3 kinase pathway.']",
        "Doc_id":"ASCO_43173-74",
        "Doc_title":" Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.",
        "_version_":1606189038180499456},
      {
        "Meeting_name":" Phase II study of panitumumab in KRAS wild-type metastatic adenocarcinoma of the small bowel or ampulla of vater.",
        "Background":"['Background', ' Given the benefit noted with epidermal growth factor receptor (EGFR) antibodies in KRAS wild-type colorectal cancer, we conducted a phase II trial to evaluate the efficacy of panitumumab in metastatic small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC). Methods', ' This is a single-center open-label single arm two-stage phase II study. The primary objective was response rate (RR). Secondary objectives included overall progression-free survival (PFS), overall survival (OS) and toxicity. Eligibility included', ' KRAS exon 2 wild-type, ECOG PS 0-1, metastatic disease, adequate organ function and prior progression or intolerance to fluoropyrimidine with oxaliplatin. Panitumumab was administered at a dose of 6mg/kg IV every 14 days. Next generation sequencing panels were used for genomic analysis. Results', ' 9 patients [M/F 7/2, median age', ' 61 yrs (range', ' 40-74), ECOG PS 0/1', ' 2/7] were enrolled from September 2013 to October 2015. 1 pt had AAC (pancreaticobiliary subtype) and 8 pts had SBA (duodenal in 3, jejunal/ileal in 5). The most common toxicity was grade 1 acneiform rash in all patients. The most common grade 2/3 toxicities were anemia (33%), fatigue (22%), hypomagnesemia (22%) and skin infection (22%). None of the patients had a response, 2 patients had SD while the remaining 7 patients had PD. At a median follow-up time of 16.6 months, the median PFS and median OS were 2.4 months and 5.6 months, respectively. Extended RAS mutational testing identified 0/9 patients with mutations in extended KRAS or NRAS. Further genomic analysis of genes relevant to anti-EGFR activity (BRAF, PIK3CA and ERBB2) identified 2/9 patients with BRAF G469A mutation, 1/9 patients with PIK3CA H1047R mutation, and 0/9 patients with ERRB2 mutations. Conclusions', ' Although well tolerated, panitumumab had minimal clinical activity in patients with metastatic SBA and AAC. Given recent findings suggesting that right-sided colon cancers (hindgut derivation) benefit less from anti-EGFR therapy compared to left-sided colon cancers (midgut derivation), we propose that our findings may relate to the primarily foregut (proximal duodenum) and midgut (distal duodenum to ileum) derivation of the small bowel. Clinical trial information', ' NCT01202409']",
        "Doc_id":"ASCO_184739-199",
        "Doc_title":" Phase II study of panitumumab in KRAS wild-type metastatic adenocarcinoma of the small bowel or ampulla of vater.",
        "_version_":1606188975270133760},
      {
        "Meeting_name":" Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients",
        "Background":"['The molecular landscape of colorectal cancers (CRC) is presently assessed by genotyping neoplastic tissue obtained through surgical or bioptic procedures. We evaluated whether blood-based molecular profiles could be used to perform diagnostic determinations and monitor resistance to therapy in colorectal cancer patients. We find that RAS pathway mutations, which are commonly evaluated prior to administration of anti-EGFR antibodies, can be ascertained directly in the blood. Sequencing of circulating DNA identified genomic alterations in KRAS, NRAS, MET, ERBB2, FLT3, and MEK1 in patients with primary or acquired resistance to cetuximab or panitumumab. Secondary resistance to EGFR blockade is frequently accompanied by emergence of mutant RAS clones, which can be tracked in blood. We find that upon withdrawal of anti-EGFR antibodies, KRAS alleles decline in circulating DNA indicating that clonal evolution continues beyond clinical progression. Functional analysis of CRC cell populations, which had acquired resistance to cetuximab, revealed that KRAS mutant clones can decay when EGFR blockade is suspended. These results establish proof of principle that genotyping colorectal cancers using circulating DNA can inform therapeutic decisions, identify mechanisms of drug resistance and provide insights for further lines of therapy.']",
        "Doc_id":"AACR_2015-616",
        "Doc_title":" Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients",
        "_version_":1606189018776600576},
      {
        "Meeting_name":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "Background":"['Background', '  In the management of metastatic colorectal cancer (mCRC), all RAS (KRAS, NRAS) and BRAF V600E mutation status guides therapeutic options and identify a unique cohort of patients (pts) with a more aggressive clinical course. We hypothesizedthat relapsed/refractory CRC pts develop unique mutational signatures that guide standard and targeted therapy but also predict for therapeutic response, identify novel driver mutations and highlight key signaling pathways for clinical decision making.  Methods', ' Relapsed/refractory mCRC pts (N=31) were molecularly profiled by NGS Caris Molecular Intelligence (IHC, FISH/CISH, NGS) and/or Foundation One (NGS, copy number). Samples were annotated by histology, primary and/or metastatic site, biopsy location, gene mutation, domain, topology, and mutation count. Web-based bioinformatics tools (Enrichr/IntAct) were utilized to analyze mutational profiles, identifying pathway-networks.    Results', '  Pts included progressed on fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, cetuximab or panitumumab. Most common histology was adenocarcinoma followed by squamous cell carcinoma (colon N=28; rectal N=3). TP53 was the most common mutation followed by APC, KRAS, PIK3CA, BRAF, SMAD4, SPTA1, FAT1, PDGFRA, ATM, ROS1, ALK, CDKN2A, FBXW7, TGFBR2, NOTCH1 and HER3. Pts had on average >5 unique gene mutations. High mutational burden was not predictive for PD-1 (5 pts) or PD-L1 (1 pt) positivity. The most common activated signaling pathways were', ' ERRB2/HER2, FGFR, p38 activation through BRAF-MEK cascade via RIT and RIN, ARMS-mediatedactivation of MAPK cascade, and VEGFR2.     Conclusions', ' Dominant oncogene mutations do not always equate with oncogenic dependence, therefore understanding the pathologic interactome in each patient is important to both identification of clinically relevant targets and choosing the next best therapy. Mutational signatures derived from corresponding pathway-networks represent a meaningful tool to 1). Evaluate functional investigation in the laboratory, 2). Predict response to drug therapy, and 3). Guide rational drug combinations in relapsed/refractory mCRC pts entering targeted and immune checkpoint trials.']",
        "Doc_id":"ASCO_157504-173",
        "Doc_title":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "_version_":1606189028578689024},
      {
        "Meeting_name":" Efficacy of photoactivated generation of a meditope-enabled anti-EGFR antibody drug conjugate in RAS/RAF mutant colorectal carcinoma.",
        "Background":"['Background', ' EGFR is a clinically validated target for advanced colorectal carcinoma, but EGFR targeted therapies are useless against EGFR expressing tumors with K/NRAS mutations. We hypothesized that an anti-EGFR antibody drug conjugate (ADC) that used EGFR to target the tumor and deliver a cytotoxic payload rather than blocking EGFR pathways may be useful for K/NRAS mutant EGFR expressing cancers. To this end, an anti-EGFR ADC was designed using a meditope-directed site-specific conjugation strategy. This strategy uses proprietary peptides that bind an antibody Fab fragment noncovalently in a unique site outside the paratope. This novel binding is exploited for site-specific covalent conjugation of cytotoxic payloads to any meditope-enabled antibody. The meditope peptide can be designed with a photoactivatable side chain, allowing the peptide-antibody interaction to be covalent. Herein, we report the development of an anti-EGFR ADC, utilizing a technology which we call SnAP (site-specific novel antibody platform) which may be effective against KRAS/NRAS mutant forms of colorectal carcinoma. Methods', ' An ADC was designed and tested for cytotoxicity in wild type and KRAS mutant cancer cell lines. Highly efficient site-directed covalent attachment of a toxin to the antibody was facilitated by a novel photoactivatable meditope peptide. Non-GLP safety studies were performed, and conjugation stability was assessed. Efficacy studies were performed in KRAS wildtype as well as KRAS mutant EGFR expressing xenografts. Results', ' A stable ADC with precisely controlled drug-antibody ratio (DAR) and unaltered affinity for EGFR was created using a novel photoactivation strategy. The meditope-directed ADC showed selective cytotoxic activity in EGFR+ cell lines, irrespective of KRAS mutation status. The potency of the ADC against EGFR dependent tumors was demonstrated in an EGFR expressing colon carcinoma xenograft study. Conclusions', ' Meditope-directed photoactivation is a novel way to generate site-directed ADCs. Anti-EGFR ADCs created in this fashion may permit patients with KRAS mutated EGFR expressing tumors to receive EGFR targeted therapies.']",
        "Doc_id":"ASCO_171398-176",
        "Doc_title":" Efficacy of photoactivated generation of a meditope-enabled anti-EGFR antibody drug conjugate in RAS/RAF mutant colorectal carcinoma.",
        "_version_":1606189000560738305},
      {
        "Meeting_name":" Mutational analysis of clinically relevant cancer related genes in colorectal cancer.",
        "Background":"['Background', '    Whole genome sequencing of colorectal cancer (CRC) has identified common mutations that have been implicated in tumorigenesis. We investigated the association between genetic mutations in known cancer related signaling pathways, and clinicopathological variables in patients with CRC.  Methods', '    DNA samples of patients with CRC were genotyped for Single Nucleotide Polymorphisms (SNPs) including potentially clinically relevant mutations using the Sequenom platform.  Results', '    Tissue from 68 patients was genotyped. 163 mutations were identified in 21 cancer related genes. 45% of patients had stage III CRC & 10% had stage IV CRC at diagnosis. 17 patients developed metastatic CRC.  59 patients had at least 1 mutation. Mutations occurring in at least 5% of patients included KRAS(35%), PIK3R1(34%), TP53(32%), PHLPP2(32%), BRAF(16%), PIK3CA(13%), APC(13%), IDH1(12%), FBXW(7%) & MET(6%). Less frequent mutations (<5%) included GNAS, PTPN, NRAS, STK11, TBX3, and EGFR.  KRAS mutations were associated with mucinous histology (P=0.04). TP53 mutations were associated with nodal disease at diagnosis (p=0.03).  There was no statistically significant difference in overall survival in patients with KRAS, PIK3, TP53 or BRAF mutations as compared to their wild type (WT) counterparts.  No mutation was predictive of disease progression. In patients with mCRC and TP53 mutations, DFS was significantly shorter when mutations in APC, FBXW7, IDH1, MET and NRAS were present (10 months verses 15.5 months p=0.01). Mutations in APC, FBXW7, IDH1, MET and NRAS only occurred in the presence of other mutations. A trend towards reduced DFS was seen in KRAS WT patients with mCRC when mutations in APC, FBXW7, IDH1, MET and NRAS were present (9 months vs. 22 months, p=0.2). A trend towards reduced DFS was seen in patients with mCRC & 3 or more distinct mutations (10 months vs. 18 months p=0.2).  Conclusions', '  These results suggest that mutations in known cancer related signaling pathways occur frequently in patients with CRC. Mutations in APC, FBXW7, IDH1, MET and NRAS conferred a shorter DFS in patients with mCRC &, TP53 mutations, KRAS wild type patients and patients with multiple distinct mutations']",
        "Doc_id":"ASCO_140610-158",
        "Doc_title":" Mutational analysis of clinically relevant cancer related genes in colorectal cancer.",
        "_version_":1606189005572931584},
      {
        "Meeting_name":" Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay.",
        "Background":"['Background', '    The current mainstay of clinical molecular testing for advanced colorectal carcinoma (CRC) is mutation analysis for KRAS, NRAS, and BRAF to determine anti-EGFR therapy eligibility. However, the growing number and potential of targeted therapies  has led to the need for broader molecular panels to triage patients. Here, we report our experience with a next-generation sequencing (NGS) assay that enables the detection as well as molecular characterization of CRC with rare and potentially targetable receptor tyrosine kinase (RTK) alterations.  Methods', '  We use a hybrid capture-based NGS assay encompassing all exons of 341 cancer genes (MSK-IMPACT) to sequence tumor against matched normal to detect potentially actionable somatic alterations including point and indel mutations, copy number alterations, and selected structural rearrangements. CRC with hotspot mutations in KRAS/ NRAS exons 2-4 and BRAF exons 11 and 15 were excluded from further analysis as these downstream mutations often lead to primary resistance.  Results', '  Seventy four of 164 CRC had wild type RAS/RAF. Twelve cases (16%) of this subgroup harbored RTK alterations previously reported to be activating and potentially targetable. Hotspot mutations commonly seen in other tumor types were also identified, including one each of EGFR p. L858R in a patient also harboring an ERBB2 p. S310F, EGFR p. L861R, and ERBB2 p. V842I a patient with ERBB2 amplification. One each of in-frame fusions of RTKs were also detected', ' ERBB2-GRB7 in a patient with ERBB2 amplification, RET-NCOA4, and ETV6-NTRK3. Additional RTK amplifications were also observed in the absence of other oncogene alterations, including FGFR1 (n = 3), ERBB2 (n = 2), MET (n = 1) . No ALK or ROS1fusions were detected in any of the 164 CRC. Of these 12 patients with potentially targetable RTK alterations, 3 have already enrolled in matched targeted therapies.  Conclusions', '  Using a broad molecular assay to interrogate potentially actionable mutations, approximately 16% of RAS/ RAF wild type CRC harbor RTK alterations that are known to be activating and potentially responsive to inhibition.']",
        "Doc_id":"ASCO_150439-156",
        "Doc_title":" Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay.",
        "_version_":1606188999000457216},
      {
        "Meeting_name":" A new classification of dynamic CT images predictive of malignant characteristics of hepatocellular carcinoma.",
        "Background":"['Background', ' The aim of this study was to elucidate whether the histopathological characteristics of hepatocellular carcinoma (HCC) can be predicted from baseline dynamic-CT images. Methods', ' This retrospective study included 86 consecutive patients with HCC who underwent surgical resection between January 2000 and September 2008. The arterial and portal-phase dynamic-CT images obtained preoperatively were classified into four enhancement patterns', ' Type-1 and Type-2 are homogeneous enhancement patterns without or with increased arterial blood flow, respectively, Type-3; heterogeneous enhancement pattern with septum-like structure, and Type-4; irregularly-shaped ring structures with enhancement pattern. We also evaluated the predictive factors for poorly-differentiated HCC, specific macroscopic type of HCC (simple nodular type with extranodular growth [SNEG] and confluent multinodular [CMN]) by univariate and multivariate analyses. Results', ' The percentages of poorly-differentiated HCC according to the enhancement pattern were 3 of 51 nodules (6%) of Type-1 and 2, 3 of 24 (13%) of Type-3, and 8 of 11 (73%) of Type-4. The percentages of SNEG/CMN according to the enhancement pattern were 12 of 51 nodules (24%) of Type-1 and 2, 13 of 24 (54%) of Type-3, and 5 of 11 (45%) of Type-4. Multivariate analysis identified Type-4 pattern as a significant and independent predictor of poorly-differentiated HCC (p < 0.001) while Type-3 pattern was a significant predictor of SNEG/CMN (p = 0.017). Conclusions', ' Heterogeneity of dynamic-CT images correlates with malignant characteristics of HCC and can be potentially used to predict the malignant potential of HCC before treatment.']",
        "Doc_id":"ASCO_41652-74",
        "Doc_title":" A new classification of dynamic CT images predictive of malignant characteristics of hepatocellular carcinoma.",
        "_version_":1606189015175790592},
      {
        "Meeting_name":" Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer",
        "Background":"['Colorectal cancer (CRC) patients who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signalling axis on the acquisition of resistance to cetuximab in patients and cellular models.Mutational profiling was performed on both biopsies collected from 37 CRC patients who became refractory to cetuximab and on a collection of cetuximab-resistant derivatives obtained from CRC cells sensitive to EGFR blockade.The genetic profile of tumor specimens obtained after cetuximab treatment revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF and PIK3CA genes, including two novel EGFR ectodomain mutations. Mutational profiling of cetuximab resistant cells recapitulated the molecular landscape observed in clinical samples and revealed three additional EGFR ectodomain alleles.Structural modelling showed that these mutations are located in the cetuximab-binding region, except for one mutant. Functionally, EGFR ectodomain mutations prevent binding to cetuximab but a subset is permissive for interaction with panitumumab.In conclusion, we reported that colorectal tumors evade EGFR blockade by constitutive activation of downstream signalling effectors and through mutations affecting receptor-antibody binding. Both mechanisms of resistance may occur concomitantly. Our data have implications for designing additional lines of therapy for CRC patients who relapse upon treatment with anti-EGFR antibodies.']",
        "Doc_id":"AACR_2015-3588",
        "Doc_title":" Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer",
        "_version_":1606189028811472896},
      {
        "Meeting_name":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "Background":"['Background', ' In the management of metastatic colorectal cancer (mCRC), all RAS (KRAS, NRAS) and BRAF V600E mutation status guides therapeutic options and identify a unique cohort of patients (pts) with a more aggressive clinical course. We hypothesized that relapsed/refractory CRC pts develop unique mutational signatures that guide standard and targeted therapy but also predict for therapeutic response, identify novel driver mutations and highlight key signaling pathways for clinical decision making. Methods', ' Relapsed/refractory mCRC pts (N = 32) were molecularly profiled by NGS Caris Molecular Intelligence (IHC, FISH/CISH, NGS) and/or Foundation One (NGS, copy number). Samples were annotated by histology, primary and/or metastatic site, biopsy location, gene mutation, domain, topology, and mutation count. Web-based bioinformatics tools (Enrichr) were utilized to analyze mutational profiles, identifying pathway-networks. Results', ' Pts included progressed on fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, cetuximab and/or panitumumab.Most common histology was adenocarcinoma followed by squamous cell carcinoma (colon N = 29; rectal N = 3).TP53 was the most common mutation followed by APC, KRAS, PIK3CA, BRAF, SMAD4, SPTA1, FAT1, PDGFRA, ATM, ROS1, ALK, CDKN2A, FBXW7, TGFBR2, NOTCH1 and HER3. Pts had on average > 5 unique gene mutations. 5 pts were MSI-H. High mutational burden was not predictive for PD-1 (5 pts) or PD-L1 (1 pt) positivity.The most common activated signaling pathways were', ' ERRB2/HER2, FGFR, p38 activation through BRAF-MEK cascade via RIT and RIN, ARMS-mediated activation of MAPK cascade, and VEGFR2. Conclusions', ' Dominant oncogene mutations do not always equate with oncogenic dependence, therefore understanding the pathologic interactome in each patient is important to both identification of clinically relevant targets and choosing the next best therapy. Mutational signatures derived from corresponding pathway-networks represent a meaningful tool to 1). Evaluate functional investigation in the laboratory, 2). Predict response to drug therapy, and 3). Guide rational drug combinations in relapsed/refractory mCRC pts entering targeted and immune checkpoint trials.']",
        "Doc_id":"ASCO_171220-176",
        "Doc_title":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "_version_":1606188974590656512},
      {
        "Meeting_name":" Routine multiplexed mutational analysis of colorectal cancers (CRCs)",
        "Background":"['Background', '  Colorectal tumors harbor mutations in genes that play key roles in CRC carcinogenesis and that may enable prioritization of appropriate anti-cancer therapy.  KRAS testing is part of standard of care testing prior to initiation of anti-epidermal growth factor receptor antibodies.  Other mutations are emerging as significant drivers, but they are not yet part of routine screening.  Methods', '  As part of Vanderbilt-Ingram Cancer Centers Personalized Cancer Medicine Initiative, we developed a  clinical algorithm to genotype patients colorectal tumors using a SNaPshot-based assay (multiplexed PCR, primer extension, and capillary electrophoresis) designed to detect 65 somatic mutations in 7 genes (KRAS, BRAF, AKT1, PIK3CA, SMAD4, PTEN, and NRAS) important in CRC carcinogenesis.  Adult patients with metastatic CRC were consented for genotyping of tumor tissue.  Mutational profiling was performed in Vanderbilts CLIA-certified Molecular Diagnostics Laboratory.  Results were reported in the electronic medical record for clinical use.  Results', '  Study enrolled from May 2012 to February 2014.  SNaPshot results were available from 126 patients.  49 tumors (38.9%) were wildtype for all mutations tested.  58 (46.0%) tumors had a KRAS mutation, including one with two KRAS mutations; the most common was G12D (n=23), but two had a Q61H mutation and two had a K117N mutation, which are not included in some commercial KRAS tests.  Ten (8.9%) tumors carried the V600E BRAF mutation.  Nine (7.1%) tumors harbored a PIK3CA mutation.  Three (2.4%) tumors had mutations in SMAD4.  Four (3.2%) tumors had a NRAS mutation.  One (0.8%) tumor had a PTEN mutation.  Nine (7.1%) tumors harbored double mutations, the most common being KRAS and PIK3CA double mutations (N=6).  24 (19%) subjects subsequently were treated on clinical trial therapy, including 6 subjects on therapy based on the SNaPshot results.  Not surprisingly, RAS results impacted use of anti-EGFR therapy.  Conclusions', '  61% of the tumors carried at least one mutation in the seven genes tested, suggesting that trials of tumor genotyping-based treatment assignment are feasible.   Study was supported by Vanderbilt University Medical Center.']",
        "Doc_id":"ASCO_140647-158",
        "Doc_title":" Routine multiplexed mutational analysis of colorectal cancers (CRCs)",
        "_version_":1606189035847417856},
      {
        "Meeting_name":" Stratification of metastatic colorectal cancer patients using DNA and RNA sequencing and in-silico prediction of tumor antigens for consideration in immunotherapy",
        "Background":"[\"Colorectal cancer (CRC) is the third most common type of cancer in the United States. Although chemotherapy, radiation and targeted therapies can improve survival rates, recent studies have shown the potential benefit of immunotherapies to improve outcomes for patients with advanced CRC. Targeted therapies that use monoclonal antibodies (mAbs) to EGFR have been shown to benefit some CRC patients. Until recently, KRAS has been the only predictive biomarker for anti-EGFR therapy for metastatic CRC. However, 40% to 60% of patients with wild-type KRAS do not respond to anti-EGFR therapy. Therefore, to accurately predict patients response to treatments and improve clinical outcomes, additional prediction and treatment methods are imperative. One of the many efforts to improve prediction for CRC patient's response to the anti-EGFR therapy is the development of gene expression based RAS signature scores for identification of RAS activated tumors independent of mutations in the KRAS gene. Recently there have been major advances in immunotherapeutic approaches in a wide variety of cancers. In solid tumors such as melanoma and colon cancers, immune checkpoints have been shown to improve clinical outcomes. There is considerable effort being placed on combinations of targeted therapy and immunotherapies to improve responses for these cancers. Similarly, since no single treatment can apply to all CRC patients, we aim to stratify patients using a combination of three methods\", ' 1. RAS signature score based on the expression profile of 18 genes. This RAS signature score enables measurements of mitogen-activated protein/extracellular signal-regulated kinase (MEK) pathway functional output independent of tumor genotype. 2. Expression profile of immune checkpoint inhibitor target genes, such as PD1 and PDL1, and 3. In-silico prediction of neo-antigens and peptide binding affinity between tumor antigens derived from mutations and human HLA alleles.55 FFPE samples were selected from a cohort of 468 samples with matching FF samples. These 55 samples have about 1', '1', '1 ratio of high, medium and low RAS scores. Here we showed our ability to obtain RAS signature scores with concordant results using different platforms including RNA-seq, targeted RNA-seq, Nanostring and Affymetrix microarray. Samples that have RAS activating mutations such as KRAS and BRAF have significant higher RAS scores (p<0.001). Interestingly, expression of PD-L1 was significantly lower in tumor samples harboring mutations of genes such as MET, PTEN, NRAS, FBXW7, and GNAS. Kruskal-Wallis test showed that the expression of PD-L1 was significantly lower in samples with higher RAS signature scores (p<0.05). Combined with further prediction of tumor antigen derived from genes with missense mutations, we provide a combinatorial method for stratifying metastatic CRC patients.']",
        "Doc_id":"AACR_2016-3946",
        "Doc_title":" Stratification of metastatic colorectal cancer patients using DNA and RNA sequencing and in-silico prediction of tumor antigens for consideration in immunotherapy",
        "_version_":1606189027746119680},
      {
        "Meeting_name":" Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab",
        "Background":"['Introduction', ' The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has resulted in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). However, clinical benefit to EGFR blockade is observed in only a subgroup of CRC patients wild type for KRAS andNRAS. Genomic characterization of patient derived xenograft (PDX) models of mCRC have revealed additional resistance mechanisms to the EGFR MAb cetuximab including amplification of MET, HER2 and mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 (Bertotti et al. 2011, 2015). However, not all resistance is understood and the biochemical signaling correlates of sensitivity and resistance remain incompletely understood. Phosphoproteomics allows for comprehensive protein phosphorylation profiling, and thereby may shed new insights into the biology of CRC and the molecular basis of cetuximab response.Aim', ' To identify aberrant signaling pathways, predictive biomarkers, and alternative drug targets in genomically-annotated CRC PDX models by mass spectrometry-based phosphoproteomics.Methods', ' We performed LC-MS/MS based phosphoproteome profiling (van der Mijn et al. 2015; Piersma et al. 2015) on untreated CRC PDX models lacking KRAS, NRAS or BRAF mutation (n = 20). For comparison, KRAS, BRAF or NRAS-mutant and MET or HER2 amplified models (n = 21) were analyzed. Phosphopeptides were captured by phosphotyrosine antibodies and titanium dioxide. MS/MS data was searched using MaxQuant. Phosphoproteome data (ion intensities and spectral counts) were correlated with drug sensitivity. Dedicated bioinformatics was used to identify hyperactive kinases and signaling pathways in individual tumors.Results', ' The dataset contained 13.418 tyrosine-, serine- and threonine-phosphorylated peptides derived from 4588 proteins, including 237 phosphorylated kinases. Unsupervised hierarchical clustering of phosphopeptide intensities revealed subclusters enriched for sensitive and resistant models. Among cetuximab-resistant models, HER2 and MET were identified as hyperphosphorylated and hyperactive driver kinases, confirming the genomic annotation. Sensitivity to combination treatment of both EGFR and driver kinases was observed previously, providing proof-of-principle of the use of phosphoproteomics for the identification of driver kinases.Conclusion/Future', ' This project is uncovering the phosphoproteomic landscape of colorectal tumors and will yield a better understanding of signaling pathways involved, with an emphasis on identifying activated drug targets and predictive biomarkers in this disease, in relation to KRAS/NRAS/BRAF status and response to anti-EGFR therapy.']",
        "Doc_id":"AACR_2016-880",
        "Doc_title":" Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab",
        "_version_":1606189005409353728},
      {
        "Meeting_name":" Concordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor (PT) and metachronous metastases in patients (pts) with colorectal cancer (CRC).",
        "Background":"['Background', ' The concordance of KRAS mutation status between the PT of CRC and synchronous metastases is 95%. However, there were reports showing that KRAS mutation status in metastases may change during chemotherapy (CT). The aim of this study was to evaluate the concordance KRAS, NRAS, BRAF, PIK3CA mutation status between the PT and metachronous metastasesin pts with CRC. Methods', ' The inclusion criteria were', ' metachronous metastases (appearance  12 mo. from the date of surgery for the PT) and  2 metastasectomy. Only 19 from 1457 (1.3%) pts met the inclusion criteria. PT was located in the colon in 37% pts. The median time between the resection of the PT and metastasectomy was 19.7 mon. (12-63). Most of pts (74%) received CT before metastasectomy. None of the pts received anti-EGFR Mabs. We performed DNA melting analysis with TaqMan probes with following Sanger sequencing for detection of mutation hot-spots in exon 2 and 3 KRAS and NRAS, exon 15 BRAF, exon 9 and 20 PIK3CA. Statistical analyses were performed using SPSS v.22, Inc., Chicago, IL. Results', ' Mutations in KRAS, NRAS, PIK3CA and BRAF genes in PT were detected in 57.9%, 5.2%, 26.3% and 0%, respectively. Mutations in the tumor material obtained at the first metastasectomy were found in 68.4%, 0%, 21% and 0% pts, respectively. In tumor obtained in subsequent metastasectomy, mutations were detected in 52.6%, 5.2%, 10.5% and 0% pts, respectively. Discordance in any gene mutation status between PT and metastases were found in 42% pts', ' in KRAS status - 26.3%, NRAS - 5.2% and PIK3CA - 21% pts. The average time between the resection of the PT and metastasectomy did not differ between pts with or without changes in gene status', ' 18.2 mon. vs. 21.3 mon., p = 0.7. Nonsignificant prevalence in changes of mutation status revealed in pts with rectal cancer', ' 41.7% vs 14.2%, p = 0.3. CT between resection of the PT and metastasectomy was not associated with changes in gene mutation status (p = 1.0). Conclusions', ' We detected clinical significant differences in the mutational status of KRAS between the PT and metachronous metastases in pts with CRC. We recommend to re-test of KRAS mutation status in case of metachronous (  12 mon.) metastatic disease']",
        "Doc_id":"ASCO_166200-176",
        "Doc_title":" Concordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor (PT) and metachronous metastases in patients (pts) with colorectal cancer (CRC).",
        "_version_":1606189000386674688},
      {
        "Meeting_name":" Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.",
        "Background":"['Background', ' Molecular profiling for CRC commonly utilizes tissue, however, there are two major limitations. It is hard to overcome the complications of tumor heterogeneity and inconvenient to do multiple biopsies during the surveillance. While the alterations in KRAS have been shown to have a high degree of concordance between tissue and ctDNA testing, a detailed survey of other commonly mutated genes, and the influence of intervening treatment in CRC has not been conducted Methods', ' Tissue and blood samples underwent sequencing on a 50-gene hotspot AmpliSeq panel (IonTorrent) in a CLIA-compliant setting. The mutation rate and the concordance of gene mutations in tissue and in ctDNA were compared. Follow up blood draw was conducted in some patients Results', ' 161 patients with colorectal cancer underwent the test. 148 patients had tissue test, and 84 had ctDNA test, 63 had pairs of tissue and ctDNA. With the 50-gene hotspot tissue test, only 9.5% (14 in 148) of the patients did not have any mutation. The most common mutation gene was P53(72.3%, 107 in 148). The mutation rate of KRAS, NRAS, BRAF and PIK3CK in tissue was 45.1%, 4.6%, 5.1%, and 1.5% respectively. Whereas in blood, the mutation rate was 43.9%, 4.9%, 5.1% and 10.9% respectively. Both values are identical and in accord with the known prevalence of mutations observed in mCRC patient populations. In the paired 63 patients, the concordance for KRAS,NRAS, BRAF, PIK3CA and P53 was 96.6%, 100%, 96%, 97.9% and 90.9% respectively. In 25 patients who had more than twice ctDNA surveillance, the dynamic change of mutations in the blood was totally corresponding with the efficacy. 13 patients had no mutations detected after R0 resection, and 6 patients in 14 who received cetuximab treatment gain new mutations(RAS,EGFR,P53,SMARCB) before disease progression. 6 patients had dynamic gain and loss mutationS Conclusions', ' The common gene mutations rate in CRC detected in ctDNA is identical to that detected in tissue, is thus an appropriate surrogate testing in determining treatment options. And ctDNA reflects treatment efficacy, which warrants routine use in clinical practice']",
        "Doc_id":"ASCO_167419-176",
        "Doc_title":" Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.",
        "_version_":1606189039144140800},
      {
        "Meeting_name":" Relationship between oncogenic mutations (RAS, BRAF and PIK3CA) and tumor location and prognosis in colorectal cancer.",
        "Background":"['Background', ' Several studies have reported that right-sided colon cancers (RCC) and left-sided colorectal cancers (LCRC) differ in several factors including genetic features. We investigated the difference in clinicopathological characteristics and oncogenic mutation status between patients with RCC and LCRC in all stages and assessed outcome. Methods', ' This study was a prospective, observational study. Patients were recruited from November 2014 to February 2016. Formalin-fixed paraffin-embedded tissue blocks were collected and DNA wes extracted from tissue sections from 227 cases. There was no double cancer. Mutations in KRAS, NRAS, HRAS, BRAF and PIK3CA were detected by next-generation DNA sequencer. Tumors from cecum to transverse colon were defined as RCC, and tumors from descending colon to rectum were defined as LCRC. The median follow-up period was 521 days. Results', 'KRAS, NRAS, BRAF and PIK3CA mutations were present in 95 patient (41.9%), 7 patients (3.1%), 10 patients (4.4%) and 23 patients (10.1%) respectively, and there was no HRAS mutation in all patients. RCC was 68 patients and LCRC was 159 patients. Poorly differentiated adenocarcinoma and mutinous adenocarcinoma were significantly more frequent in RCC compared to LCRC (P = 0.031). KRAS mutations were detected in 37 patients with RCC (54.4%) and in 58 patients with LCRC (36.5%). BRAF mutations were detected in 7 patient with RCC (10.3%) and in 3 patients with LCRC (1.9%). KRAS and BRAF mutation in RCC were significantly more frequent than in LCRC (P = 0.012 and P = 0.005, respectively). The incidence of NRAS and PIK3CA mutation was no difference between two groups. In all patients, overall survival was evaluated. On univariate Cox regression analysis, BRAF mutation was associated with significantly poorer overall survival than BRAF wild type (HR = 4.831, P = 0.013). Other oncogenic mutation status and tumor location werent associated with overall survival. Conclusions', 'KRAS and BRAF mutation were more frequent in the patients with RCC compared to those with LCRC in all stages. This study suggested BRAF mutation correlated with poor outcomes in patients with colorectal cancer.']",
        "Doc_id":"ASCO_189036-199",
        "Doc_title":" Relationship between oncogenic mutations (RAS, BRAF and PIK3CA) and tumor location and prognosis in colorectal cancer.",
        "_version_":1606188996262625280},
      {
        "Meeting_name":" Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.",
        "Background":"['Background', ' PD-L1 expression as detected by immunohistochemistry (IHC) is significantly lower in colorectal cancers (CRC) when compared with lung cancer or other types of cancer. We explored if mutations in the RAS/RAF gene family, TP53 or PIK3CA can define a subgroup of CRC that express PD-L1. Methods', ' Tissue samples collected from 107 patients with CRC were studied for the expression of PD-L1 using clone SP142. The same samples were also tested for mutations in NRAS, KRAS, HRAS, BRAF, TP53, and PIK3CA using Next Generation Sequencing (NGS). Results', ' Of the 107 CRC samples only 15 (14%) showed PD-L1 positive tumor cells (1%) and 8 of the 15 (7.5% of total) had PD-L1 in 5% of tumor cells. Detected mutations in these samples were as follows', ' TP53 65%, KRAS 49.5%, PI3KCA 22.5%, NRAS 5%, HRAS 1%, and BRAF 17%. There was no correlation between PD-L1 expression and mutation status in any of the RAS/RAF genes. There was also no correlation between TP53 mutation and PD-L1 expression. This was true irrespective if PD-L1 expression is considered as a continuous variable or when cut-off points of 5%, 20%, or 50% were used. However, patients without any mutation in RAS or TP53 had significantly (P = 0.005) more expression of PD-L1 when cut-off point of 5% is used. This remained true if PD-L1 expression is considered as a continuous variable (P = 0.04). There was no correlation between PIK3CA and PD-L1 expression. Conclusions', ' PD-L1 expression is significantly more common in CRC that lack mutations in RAS or TP53. PD-L1 expression is detected in 31% of patients with wild-type RAS/TP53 as compared with 12% in patients with RAS/TP53 mutations (P = 0.04). If a cut-off point of 5% is used, 31% of RAS/TP53-wild-type CRC were positive for PD-L1, while only 6% of RAS/TP53- mutant CRC were positive for PD-L1 (P = 0.005). This suggests that in CRC without RAS/TP53 mutation, the PD-L1 may play a more important role in oncogenesis. Exploring immunotherapy in this group of CRC patients might be justified.']",
        "Doc_id":"ASCO_180398-199",
        "Doc_title":" Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.",
        "_version_":1606188990330830848},
      {
        "Meeting_name":" Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.",
        "Background":"['Background', ' Right-sided colon cancer (RC) is distinct from left-sided colorectal cancer (LC) in terms of embryology, pathology and genetics. Previous reports have shown that RC have more KRAS and BRAF mutations and poorer clinical outcomes than LC. We investigated whether primary tumor location affects cetuximab efficacy in patients with RAS wild-type (WT) metastatic colon cancer determined by extended RAS genotyping. Methods', ' Extended RAS analysis by SequenomMassARRAY technology platform (OncoMap) targeting KRAS (exon 2, 3, 4), NRAS (exon 2, 3, 4), PIK3CA and BRAF (exon 15) was performed in tumors from 307 patients treated with cetuximab as salvage treatment. Tumors with mutated RAS (n = 127) and synchronous primary tumors (n = 10) were excluded. The border of right-sided colon and left-sided colon was defined as splenic flexure. Results', ' A total of 170 patients were included (RC versus LC, 23 and 147). More mutant BRAF (39.1% vs. 5.4%), poorly differentiated (17.4% vs. 3.4%) and mutant PIK3CA (13% vs. 1.4%) tumor and peritoneal involvement (26.1% vs. 8.8%) were observed in RC. Progression-free survival (PFS) was significantly shorter in RC (2.0 vs 4.9 months, P = 0.004). Overall survival (OS) was 4.1 months in RC and 13.0 months in LC (P = 0.002). In multivariate analysis, BRAF mutations, RC, poorly differentiated histology and peritoneal involvement were associated with shorter overall survival (adjusted hazard ratios, 2.96, 1.63, 2.97 and 2.12, respectively). Conclusions', ' In RAS WT colon cancer treated with cetuximab as salvage treatment, right-sided colon cancer had a poor survival. Further investigation is required to verify the difference in cetuximab efficacy according to primary site of metastatic colorectal cancer.']",
        "Doc_id":"ASCO_170068-176",
        "Doc_title":" Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.",
        "_version_":1606188994192736256},
      {
        "Meeting_name":" Linking tumor evolution and therapy response using diagnostic targeted next generation sequencing in colorectal cancer",
        "Background":"['Complex sets of driver mutations critically control clinical course and treatment response in colorectal cancer (CRC). It is expected that multiple mutations in different signaling pathways interact to establish an individual cancer cell phenotype. Furthermore, mutational patterns can evolve under selective pressure, for instance during tumor metastasis or targeted therapy. Yet only few mutations, such as these in KRAS, NRAS and BRAF, are routinely assessed in the clinic today. With the introduction of next generation sequencing (NGS) many more genes can be simultaneously sequenced, allowing detailed analyses of mutational patterns.We have assembled the CRC5.2 NGS panel for application with Ion Torrent PGM covering 100 frequently mutated genes with 784 amplicons (covering 21,000 COSMIC mutations), going well beyond the scope of commercially available cancer panels. In particular, exon coverage was optimized to embrace all genomic information related to drug sensitivity, using several drug and signaling network databases.The German Consortium for Translational Cancer Research (DKTK) comprises the top cancer centers in Germany. As a part of this group, we employ our custom CRC5.2 panel for the analysis of mutational patterns in CRC. We address several key questions relevant for current diagnostics and treatment in colorectal cancer. In retrospective and prospective clinical studies, we assess mutational heterogeneity in primary tumors, synchronous and metachronous metastases of individual patients. In-depth NGS mutational analyses, transcriptome analysis and methylation studies will identify (epi-)genetic alterations occurring as a consequence of selective pressure during tumor evolution e.g. during metastasis, chemotherapy or targeted tumor therapy. Thus, we will uncover new links between cancer-specific mutations, clinical course and treatment response as well as novel mechanisms of secondary resistance. In addition we aim to identify novel predictive and prognostic mutational markers for the benefit of future CRC patients']",
        "Doc_id":"AACR_2014-5170",
        "Doc_title":" Linking tumor evolution and therapy response using diagnostic targeted next generation sequencing in colorectal cancer",
        "_version_":1606188970829414400},
      {
        "Meeting_name":" Comparative genomic analysis of primary versus metastasis in colorectal carcinomas.",
        "Background":"['Background', '  Activating mutations in exon 2 of KRAS are routinely used to exclude colorectal cancer (CRC) patients from treatment with  EGFR inhibitors. Retrospective studies have also shown a lack of response among patients with BRAF and NRAS mutations, whereas preliminary studies of PIK3CA have been conflicting. As most testing is done on primary tumor tissue, while metastatic disease is what is treated with anti-EGFR agents, we compared the mutational and copy number profiles of primary and metastatic CRCs.  Methods', '  736 fresh frozen tumors from 613 patients were analyzed for mutations in KRAS, NRAS, BRAF, PIK3CA and TP53 using a Sequenom MALDI-TOF mass spectrometry-based genotyping assay and Sanger sequencing.  The cohort included 84 matched primary and metastases and 30 matched metastases.  Formalin-fixed paraffin embedded tissue was also subjected to Sanger sequencing in cases showing discrepant results in their mutational profile. All tumors were checked for misidentification using a multiplexed PCR/MS-based genetic fingerprinting assay and a subset of matched pairs was analyzed by comparative genomic hybridization (Agilent, 1M array). Results', '  We identified 259 (42%) KRAS (219 in exon 2, 12 in exon 3 and 28 in exon 4), 18 (3%) NRAS, 40 (6%) BRAF, 72 (12 %) PIK3CA and 247 (40%) TP53 mutations in the 613 cases. BRAF mutations were significantly less frequent in metastatic CRC tumors, compared to primary tumors (3.8% vs. 7.3%, p=0.01), while TP53 mutations were significantly more frequent (55.6% vs. 30.2%, p<0.001). Mutational analysis of 84 matched pairs of primary and metastatic CRC revealed a concordance rate of 98%, 98% and 95% for RAS/BRAF, PIK3CA and TP53 mutations, respectively. Unsuperivised clustering of array CGH data from 22 matched pairs of primary and metastatic CRC showed that all pairs clustered together. Conclusions', '  In regards to RAS/BRAF/PIK3CA and TP53 mutational status, primary and metastatic CRC tumors show an extremely high degree of concordance. The results suggest that genomic characterization of the primary tumor for RAS/BRAF/PIK3CA and TP53 mutations can correctly characterize the mutational status of these genes in the patients with metastatic disease.']",
        "Doc_id":"ASCO_80181-102",
        "Doc_title":" Comparative genomic analysis of primary versus metastasis in colorectal carcinomas.",
        "_version_":1606189041499242496},
      {
        "Meeting_name":" Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.",
        "Background":"['Background', '     For patients presenting with advanced and metastatic colorectal carcinoma (CRC), standard cytotoxic therapy can provide significant benefit but patients eventually develop progressive disease. We queried whether comprehensive genomic profiling (CGP) could uncover clinically relevant genomic alterations (CRGA) that could lead to targeted therapy selection.  Methods', '    DNA was extracted from 40 microns of FFPE sections from 3,117 clinically advanced CRC. CGP was performed using a hybrid-capture, adaptor ligation based next generation sequencing assay to a mean coverage depth of > 600X. The results were evaluated from each sample for all classes of genomic alterations.  Results', '    There were 1746 male (56%) and 1371 female (44%) patients with all (100%) of cases either stage III or IV at the time of sequencing. The median frequency of GA per case was 5.7. The CRGA frequency was 2.1 CRGA per case. The most frequent GA were in APC (76%), TP53 (75%) and KRAS (53%), all were higher than in TCGA (61%, 44% and 34% respectively). There was 100% concordance with the KRAS status determined by the CGP assay and standard hot-spot sequencing assays performed on the same tumor. The combined KRAS and NRAS mutation frequency was 56% and BRAF was mutated in 7%. Only 1.4% of the cases with KRAS, NRAS, or BRAF mutations harbored combination of any 2 out of the 3 genes. Potential CRGA that could lead to targeted therapy-based clinical trials included', ' PIK3CA (18%), PTEN (8%), ERBB2 (5%), SRC (4%), SMAD2 (3%), NF1 (3%), EGFR (3%), ERBB3 (2%), MET (1%) and KIT (1%). Either WNT signaling, cell cycle/apoptosis, and/or RTK/RAS signaling pathways were the altered in 83% cases. Clinical outcome case examples demonstrating efficacy of therapies targeting BRAF, ERBB2, FGFR2, and MET in CRC patients will be presented.  Conclusions', '    When CRC is evaluated by CGP, a significant number of the patients harbored CRGA which have the potential to influence and personalize therapy selection. Given the limited treatment options and poor prognosis of patients with advanced chemo-refractory CRC deep genomic profiling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease.']",
        "Doc_id":"ASCO_146935-156",
        "Doc_title":" Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.",
        "_version_":1606188978467241985},
      {
        "Meeting_name":" A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.",
        "Background":"['Background', ' The Epidermal Growth Factor Receptor (EGFR) is a key driver of tumor growth in colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), and non-small cell lung cancer (NSCLC). Although EGFR inhibitors prolong overall survival in many patients, resistance inevitably develops. Resistance usually arises through alterations in the EGFR pathway itself or through upregulation of alternative signaling pathways. In CRC in particular, mutations in KRAS and NRAS are strong predictors of resistance to EGFR inhibitors. Such resistance may potentially be overcome by combining MM-151, a potent EGFR inhibitor, with trametinib, a MEK inhibitor. In KRAS/NRAS wild-type tumors, resistance may arise through activation of parallel signaling pathways. Emerging data suggest that heregulin (HRG)-driven signaling through ErbB3 and insulin-like growth factor-1 (IGF-1)-driven signaling through IGF-1R may confer resistance to EGFR inhibitors by activating pro-survival signaling through the PI3K/Akt pathway. If HRG-mediated signaling is active, resistance may potentially be overcome through the combined administration of MM-151 and the ErbB3-targeting antibody MM-121. Similarly, if IGF-1-mediated signaling is active, resistance may be overcome by combining MM-151 with the IGF-1R-targeting antibody MM-141. The rationale underlying this trial is that mechanisms of resistance may be identified through biomarker analyses, allowing patients to be prospectively assigned to an appropriate investigational regimen. Methods', ' This is a Phase 1, biomarker-directed open-label study evaluating the safety, pharmacology and preliminary activity of MM-151 in combination with trametinib, MM-121, or MM-141. Patients are evaluated for KRAS/NRAS status and tumoral expression of HRG and IGF-1 and are then assigned to the study arm matching their biomarker profile. A modified 3 + 3 design is used to establish a recommended Phase 2 dose. Expansion cohorts in CRC and SCCHN will then be opened to further evaluate safety and preliminary signs of efficacy. Key exploratory analyses include evaluations of PK, PD, and biomarkers of additional resistance pathways. Clinical trial information', ' NCT02538627']",
        "Doc_id":"ASCO_167954-176",
        "Doc_title":" A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.",
        "_version_":1606188988385722368},
      {
        "Meeting_name":" Colorectal cancer cell lines recapitulate molecular and pharmacological features of clinical samples",
        "Background":"['Colorectal Cancer (CRC) is characterized by wide genetic, biological and clinical heterogeneity. Oncogenic events, such as KRAS, NRAS and BRAF mutations, are known negative biomarker of response to EGFR targeted therapies. In addition to mutational analysis, transcriptional profiling has been recently exploited to identify distinct CRC molecular subtypes, associated with biological and clinical features such as cell of origin, microsatellite instability, prognosis and response to treatments. Detailed analysis of the relationships between the subtypes and clinical/biological features requires a large panel of preclinical models closely recapitulating the molecular heterogeneity of CRC. To this aim, we assembled a large collection of 151 CRC cell lines. For each line, we', ' (i) verified genetic identity by short tandem repeat (STR) analysis; (ii) assessed microsatellite instability (MSI) status; (iii) sequenced mutational hotspots in the KRAS, BRAF, NRAS and PIK3CA genes; (iv) performed microarray-based global mRNA expression profiling; (v) evaluated sensitivity to the EGFR-targeting drug cetuximab. STR analysis revealed that some cell lines previously thought to be unrelated are indeed derived from the same individual. This result was confirmed by cell line hierarchical clustering based on mRNA expression profiles. Overall, the mutational landscape of the compendium was concordant with what observed in patients (mutation rates', ' KRAS = 47%; BRAF = 17%; NRAS = 0.7%; PIK3CA = 18%). Similarly, sensitivity to cetuximab was confined to lines without RAS or BRAF mutations. Gene expression profiling was exploited to assign cell lines to molecular subtypes, according to five different published transcriptional classifiers. We found that all molecular subtypes previously identified in CRC patients were robustly maintained in the lines. Moreover, significant overlaps were detected between individual subtypes across distinct classifiers. Subtype-specific molecular and pharmacological associations previously defined in CRC samples were largely recapitulated in the compendium. In particular, MSI+ cells were significantly enriched in inflammatory and goblet subtypes and less prevalent in the Transit Amplifying (TA) and Stem groups. Cell lines carrying BRAF mutations clustered in the inflammatory subtype, while RAS mutations were equally distributed among all subtypes. Notably, in TA lines without RAS or BRAF mutations, the fraction of cetuximab-sensitive cells was strongly enriched (56%), confirming clinical data and indicating that addiction to the EGFR pathway is an intrinsic feature of this CRC subtype. In conclusion, our results describe a powerful preclinical resource reflecting the molecular and functional heterogeneity of CRC, which can be used to explore multidimensional information of potential clinical relevance.']",
        "Doc_id":"AACR_2015-583",
        "Doc_title":" Colorectal cancer cell lines recapitulate molecular and pharmacological features of clinical samples",
        "_version_":1606188977204756481},
      {
        "Meeting_name":" Intrinsic and acquired resistance to cetuximab in colorectal cancer patients.",
        "Background":"['Anti-EGFR antibodies, such as cetuximab, are effective therapies for many late-stage colorectal cancer (CRC) patients; unfortunately, many tumors are initially unresponsive while others show initial efficacy but eventually develop acquired resistance. Genomic studies of patient tumors, cell lines, and xenograft models have identified putative anti-EGFR resistance markers, including mutations in KRAS, NRAS, BRAF, PIK3CA, and the EGFR extracellular domain, as well as amplifications in ERBB2 and MET. In order to further confirm and identify new resistance mechanisms to anti-EGFR treatment in CRC, we performed retrospective genomic profiling of 25 CRC patients treated at Samsung Medical Center from 2006-2015. Patients received cetuximab containing chemo regimens with varying duration of responses, including acquired resistance cases. Our analysis identifies mutations in receptor tyrosine kinases, such as EGFR, NTRK1, and PDGFRA, as well as RAS/MAPK pathway genes that affect cetuximab response. We also uncover genomic alterations in ERBB2 and c-KIT as potential novel mechanisms regulating sensitivity to anti-EGFR antibodies. Additional genomic analyses of acquired resistance tumors and in vitro studies of a patient-derived cell line provide added insights into clonal selection and signaling pathways that bypass the EGFR blockade. Overall, our study elucidates important new facets in the landscape of anti-EGFR resistance mechanisms.']",
        "Doc_id":"AACR_2017-4104",
        "Doc_title":" Intrinsic and acquired resistance to cetuximab in colorectal cancer patients.",
        "_version_":1606189031797817344},
      {
        "Meeting_name":" Large panel genomic profiling using CancerPlex to reveal candidates for HER2 targeted therapies in colorectal cancer.",
        "Background":"['Background', ' Human epidermal growth receptor type 2 (HER2) overexpression/amplification is associated with the efficacy of HER2 targeted therapies in breast and gastric cancers, where candidates for its targeted therapies are selected by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) testing. However, the HER2 status in colorectal cancer (CRC) has not been fully investigated to date. CancerPlex is a comprehensive next-generation sequencing-based test that evaluates 400-plus genes for mutations and copy number changes, including HER2. In the present study, we aimed to clarify the association between HER2 status and HER2 gene alteration detected with CancerPlex in CRC. Methods', ' This retrospective study included 100 patients with Stage I-IV CRC, who were evaluated HER2 status and HER2 gene alteration. IHC for HER2 was classified as 4 grades according to the immunoreactivity. The patients with IHC2+ were further tested with FISH. IHC3+/IHC2+ and FISH positive patients were defined as HER2 positive. HER2 gene alteration was tested with CancerPlex, and the associations between HER2 status and HER2 gene alteration were analyzed using Fishers exact test. Results', ' HER2 positive cases were observed in 8% patients (IHC3+ in 6% and IHC2+ and FISH positive in 2% patients). CancerPlex results demonstrated that 6% had HER2 amplification, 15% had HER2 mutations, and 1% had both HER2 amplification and mutation. Additionally, CancerPlex detected the other mutations of MAPK pathway (KRAS, NRAS, HRAS, and BRAF). The Fishers exact test revealed a significant association between HER2 status and HER2 amplification detected with CancerPlex (P< 0.001), however, there was no significant association between HER2 status and HER2 mutation. Conclusions', ' We found 8 of 100 (8%) Japanese CRC cases are HER2 positive. There is a significant association between HER2 status and HER2 amplification detected with CancerPlex. CancerPlex is a comprehensive testing tool for detecting gene alterations including not only mutations of MAPK pathway (KRAS, NRAS, HRAS, and BRAF), but also HER2 amplification, which is a possible useful predictor of the candidates for HER2 targeted therapies in CRC.']",
        "Doc_id":"ASCO_163212-176",
        "Doc_title":" Large panel genomic profiling using CancerPlex to reveal candidates for HER2 targeted therapies in colorectal cancer.",
        "_version_":1606189041737269248},
      {
        "Meeting_name":" Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors.",
        "Background":"['REDX05358 has been identified as a novel, highly selective and potent next generation pan RAF inhibitor with improved therapeutic potential and predicted safety profile. Aberrant signalling via the MAPK pathway is commonly seen in cancer. RAF inhibitors such as Dabrafenib and Vemurafenib have been approved for the treatment of unresectable and metastatic BRAF mutant melanoma, but these agents lack efficacy in BRAF mutant colorectal cancer (CRC), partly because of EGFR-mediated feedback reactivation of the MAPK pathway via CRAF. Furthermore, RAF inhibitor treatment of RAS-mutant, BRAF wildtype melanomas has been associated with other skin cancers, such as cutaneous squamous cell carcinoma due to MAPK pathway paradoxical activation mediated by CRAF. There is therefore a clinical need for novel agents targeting the MAPK pathway that do not have these undesirable properties. Here we present, REDX05358 that demonstrates subnanomolar binding affinity for BRAF and CRAF with high selectivity profile against a panel of 468 kinases that exhibits negligible paradoxical activation due to inhibition of both RAF monomers and dimers. As a result, REDX05358 not only inhibits MAPK signalling in BRAF V600E mutant tumor cells, but also in those harbouring NRAS and KRAS mutations. Furthermore, REDX05358 does not induce feedback reactivation of the pathway through its ability to sustain inhibition of MAPK signalling in CRC cell lines. Correspondingly, profiling of REDX05358 in a panel of CRC, melanoma and NSCLC cell lines shows it has potent anti-proliferative activity in cell lines harbouring BRAF or RAS mutations. REDX05358 is an orally bioavailable, well tolerated small molecule that has demonstrated in vivo efficacy in BRAF V600E CRC xenograft model. In contrast, first generation inhibitors such as Vemarafenib and Dabrafanib have been reported to be ineffective in this genetic background in CRC cell lines and patients. Thus, we have developed a pan RAF inhibitor with unique pharmacological properties enabling it to have utility in treating BRAF and RAS mutant cancers']",
        "Doc_id":"AACR_2017-5160",
        "Doc_title":" Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors.",
        "_version_":1606188988557688832},
      {
        "Meeting_name":" Characterization of tumor mutation load (TML) in solid tumors.",
        "Background":"['Background', ' Rapid advances in immunotherapy have created a need for biomarkers to improve patient treatment selection. TML is proposed as a potential predictive biomarker due to its association with tumor immunogenicity. Methods', ' TML was assessed in 8020 tumors from 14 different cancers using somatic nonsynonymous missense mutations sequenced with a 592-gene panel. High TML was set at  17 mutations per megabase (mt/MB) based on an established concordance ( > 99%) with MSI-High in colorectal cancer (CRC). Results', ' Mean TML was highest in melanoma (Mel; 21 mt/MB), NSCLC (11 mt/MB), and bladder cancer (BLC; 11 mt/MB), whereas prostate cancer (PC), pancreas adenocarcinoma (PA), and renal cell carcinoma (RCC) had the lowest levels (all 6 mt/MB). High TML was seen most frequently in Mel (36%), NSCLC (15%), BLC (15%), and anal cancer (SCCA; 9%); and least frequently in PA (1.6%) and RCC (0.5%). Primary NSCLC carried lower TML than its brain metastases (11 vs. 16 mt/MB, p < 0.001). Older age was associated with higher TML in Mel (p = 0.001), CRC (p = 0.009), breast cancer (BC; p = 0.01), and NSCLC (p = 0.02). Higher TML was seen in males than in females for Mel (p = 0.002) and NSCLC (p < 0.001). Presence of mutations in oncogenic driver genes such as EGFR, ALK, ROS1 RET fusions, cMET exon 14 skipping correlated with lower TML in NSCLC (6.9 vs. 12 mt/MB, p < 0.001), as did BRAF and NRAS mutations in Mel (17 vs. 26, p = 0.003). Conversely, mutations in tumor suppressor genes such as ARID1A (CRC, NSCLC, and BLC) and NF1 (BC, CRC, Mel, BLC, and NSCLC) were associated with higher TML (p < 0.05). MSI-high was correlated with high TML in CRC and gastric cancers (p < 0.05). Conclusions', ' TML varied significantly among different cancers. High TML was associated with older age, absence of oncogenic mutations and presence of tumor suppressor gene mutations. Future studies will assess the impact of TML on clinical outcome and establish its role in selecting patients for immunotherapy. N = 8020Mean TMLHigh TML %PD-L1 %TML  17 & PD-L1 %Mel3992137239NSCLC21851115153BLC1731115243CRC176810631right390121062Left6119321SCLC9910553SBA9597112SCCA42910315Gastroesophageal Ca45485121HCC917260BC11437260TNBC40172110Non-TNBC7027460Biliary Tract Ca5127471PC2606210RCC19260.5160PA60761.691']",
        "Doc_id":"ASCO_184601-199",
        "Doc_title":" Characterization of tumor mutation load (TML) in solid tumors.",
        "_version_":1606189037735903232},
      {
        "Meeting_name":" Clinical correlation with codon-specific mutations in metastatic colorectal cancer.",
        "Background":"['Background', ' Mutational status in colorectal cancer (CRC) impacts response to EGFR inhibition, prognosis, and may affect response to chemoradiation. It is unclear if obesity or other clinical characteristics, including smoking and diabetes, increases the predilection for certain genotypes. The purpose of the following study was to explore the relationship between clinical factors, codon-specific mutations and overall survival (OS). Methods', ' Metastatic colorectal cancer patients were retrospectively analyzed; clinical characteristics including smoking, diabetes, and body mass index (BMI) were extracted from medical records. Genotyping was performed for > 150 mutations across 15 commonly mutated cancer genes including NRAS, KRAS, PIK3CA, BRAF, and PTEN as part of their clinical management and recorded. Logistic regression was used to establish associations between clinical characteristics and genotypes. Results', ' 394 metastatic CRC patients were identified. Median age was 58 (range 25-89). 219 (56%) were male. 202 (51%) were non-smokers. 61 had diabetes. 272 patients had a BMI  25. 136 patients had KRAS mutations, the most common of which was G12D (37%). Diabetes was associated with a higher incidence of KRAS (odds ratio [OR] 1.9 95% CI 1.1-1.3; p = 0.02) and PIK3CA mutations (OR 2.4 95% CI 1.1-5.0; p = 0.02), but not OS. KRAS mutations were not significantly associated with BMI  25 nor OS. BRAF mutations were significantly associated with poorer OS (hazard ratio [HR] 1.9 95% CI 1.3-2.7; p < 0.001). Current smokers were more likely to have CTNNB1 mutations (OR 11.3 95% CI 1.5-83.2; p = 0.02) and G12D KRAS mutations (OR 5.6 95% CI 1.0-30.3). Current smokers were less likely to have BMI  25 (OR 0.44; p = 0.02). Patients with BMI  18.5 have an association with poor OS (HR 2.6 95% CI 1.1-6.4; p = 0.03), although this needs to be corroborated with a larger sample size. Conclusions', ' A statistically significant association was found between diabetes and KRAS and PIK3CA mutations. The association of BRAF mutations and decreased overall survival was significant, concordant with previous reports. Smokers were more likely to harbor G12D KRAS mutations, and low BMI ( 18.5) trended toward poorer overall survival.']",
        "Doc_id":"ASCO_169054-176",
        "Doc_title":" Clinical correlation with codon-specific mutations in metastatic colorectal cancer.",
        "_version_":1606188981260648449},
      {
        "Meeting_name":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "Background":"['Targeted deep massive parallel sequencing (MPS) has been implemented in routine molecular diagnostics for high-throughput genetic profiling of formalin-fixed paraffin-embedded cancer samples. This approach is now widely used to interrogate simple somatic mutations but experience with the analysis of copy number variations (CNV) is still limited. Here, we retrospectively analyzed CNVs in 822 cancer cases (n = 135 melanoma, n = 468 non-small cell lung cancers (NSCLC), n = 219 colorectal cancers (CRC)) that were sent to our institution for routine molecular profiling using a semiconductor based sequencing platform. Amplifications and deletions inferred by MPS coverage data were independently validated by a qPCR assay. We observed a decreasing frequency of CNV in clinically actionable genes from melanoma to NSCLC to colorectal cancer.Of 56 melanomas with genetic aberrations in BRAF, 31 showed co-occurring CNV in other genes, mainly affecting CDKN2A. Some tumors (5 cases each) revealed clustered deletions affecting either ABL1, NOTCH1, and RET or STK11, GNA11, and JAK3. 8.1% of the cases had amplifications in clinically actionable genes. In the group of NRAS mutant tumors (n = 39), 26 showed co-occurring CNVs in other genes, such as CDKN2A and FGFR3, and 9 NRAS mutant cases were additionally mutated in BRAF. 19.1% had amplifications in clinically actionable genes. In contrast to BRAF mutant tumors, we did not see any specific CNV clusters. In the group of BRAF/NRASwt tumors (n = 11), we observed 5 cases with co-amplification of KDR, KIT, PDGFRA and another 6 cases with KIT mutations. While co-amplified cases had many gene deletions, KIT mutated tumors harbored only very few genetic aberrations in other genes.Across both NSCLC data sets, we identified 14 cases with amplified EGFR (10 of them harboring co-occurring EGFR mutations) and detected 8 NSCLC with KRAS amplifications (of which 7 had co-occurring mutations of KRAS). KRAS mutated tumors displayed frequent amplifications in MYC (n = 10) and MDM2 (n = 5). Of the 22 BRAF mutant tumors, two harbored mutated KRAS. In contrast to melanoma, we observed no clustering of CNVs in BRAFmut NSCLCs. Within the group of KRAS/EGFR/BRAFwt tumors, we identified 15 cases harboring genetic aberrations in MET (n = 8 mutations, n = 7 amplifications).Compared to melanoma and NSCLC, the number of CNV in CRC was rather low. IGF2 amplifications were most prevalent (n = 13) followed by MYC (n = 9). Two cases showed amplified wild-type alleles of KRAS. Two KRAS mutant tumors showed concomitant amplification of NRAS and three cases harbored amplified EGFR.In conclusion we demonstrate that i) detection of CNVs by targeted MPS data obtained from FFPE material is feasible and ii) could be validated independently, iii) this approach enables detection of known CNV patterns, and iv) uncovers new CNV patterns in clinically actionable targets across cancers.']",
        "Doc_id":"AACR_2016-3167",
        "Doc_title":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "_version_":1606188994698149888},
      {
        "Meeting_name":" Prognostic impact of cytomegalovirus (CMV) detection in colorectal cancer (CRC).",
        "Background":"['Background', ' CMV is a widespread herpesvirus that lies latent in the majority of immunocompetent hosts but may reactivate and infect colon epithelium. Prior studies have identified CMV proteins in CRC tumors, where CMV superinfection may play an oncomodulatory role. CMV constitutively activates virally encoded chemokine receptors that may act as oncogenes via promotion of angiogenesis, proliferation, and migration. However, the clinical significance of CMV superinfection in CRC has not been clearly demonstrated. Methods', ' We obtained clinical and tumor characteristics from 355 CRC patients in The Cancer Genome Atlas (TCGA). TCGA RNA-seq was aligned to curated viral genomes from GenBank after first filtering out the reads that mapped to the human genome. Reads that mapped to CMV were quantified. Consensus Molecular Subtypes (CMS) by gene expression were obtained from www.synapse.org. Results', ' Among 355 CRC patients, 60 (16.9%) had CMV detected by RNA-seq. CMV+ was significantly associated with older median age (69.5 vs. 64 years, p = 0.016) and rectal rather than colon primary (odds ratio 3.76, 95% CI 1.87-7.57). CMV status was not significantly associated with stage, sex, race, microsatellite stability, BRAF/KRAS/NRAS mutation, or CMS subtype. On Cox univariate analysis, CMV+ was associated with inferior survival (HR 1.91, 95% CI 1.10-3.34), as were age (HR 1.03, 95% CI 1.01-1.05), stage (HR 2.00, 95% CI 1.54-2.59), and CMS4 subtype (HR 2.12, 95% CI 1.29-3.48). CMV+ remained significantly associated with inferior survival on multivariate Cox analysis when adjusting for age, stage, and CMS4 subtype. Conclusions', ' CMV+ as detected on RNA-seq is significantly associated with older age at diagnosis and rectal primary tumor and independently confers inferior prognosis. These findings warrant further investigation of the potential oncomodulatory role and prognostic value of CMV reactivation in CRC.']",
        "Doc_id":"ASCO_191189-199",
        "Doc_title":" Prognostic impact of cytomegalovirus (CMV) detection in colorectal cancer (CRC).",
        "_version_":1606189000512503808},
      {
        "Meeting_name":" Association of primary (1) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (EGFR) therapy.",
        "Background":"['Background', ' CRCs originating in the right colon (RC) have features distinct from those in the rectum/left colon, including more frequent CpG island methylator phenotype (CIMP-High) and BRAF mutation (MT). Prognosis and response to therapies, including EGFR regimens, differ dramatically by 1 site in mCRC, but pathobiologic explanations remain unclear. Methods', ' 198 KRAS wild-type (WT) mCRC tumors were tested for CIMP status via bisulfite pyrosequencing and PCR amplification. BRAF and NRAS were sequenced. PFS on first EGFR regimen was retrospectively determined in 167 patients. Univariate and multivariate Cox regression analyses with multiple imputations were performed. Tumors from 179 independent CRC patients were tested for promoter methylation (Illumina HumanMethylation450) and gene expression. Results', \" Inferior PFS with EGFR therapy was associated with RC CRC (HR = 1.56, CI 1.01-2.41), CIMP-High (HR = 2.38, 1.47-3.85), BRAF MT (HR = 2.15, 1.26-3.65), and NRAS MT (HR = 2.11, 1.23-3.65). On multivariate analysis, CIMP status (p = 0.041), BRAF MT (p = 0.038), and NRAS MT (p = 0.012) remained significant, but 1 site did not (p = 0.27). Inferior OS was associated with RC CRC (HR = 1.45, 1.04-2.01), CIMP-High (HR = 1.53, 1.08-2.16), BRAF MT (HR = 2.46, 1.61-3.75), and NRAS MT (HR = 1.70, 1.03-2.81). RC 1 site was also associated with CIMP-High (OR = 2.35, 1.22-4.54) and BRAF MT (OR = 5.45, 2.47-12.03). Independent data from MDACC and TCGA showed RC 1 site and CIMP-High were both strongly associated with hypermethylation of promoters and suppression of expression of the EGFR ligands EREG and AREG. 1 site was also strongly associated with consensus molecular subtypes (CMS) 1 and 3 (p < 0.001, p = 0.03), which were previously shown in mCRC patients to have worse outcomes than the classic' CMS2 subtype. Conclusions\", ' CRC 1 site is associated with OS and PFS after EGFR therapy. Molecular analyses suggest that BRAF MT, NRAS MT, molecular subtypes, and tumor methylation account for the effect and may provide a biologic explanation for the association with anatomic location.']",
        "Doc_id":"ASCO_171167-176",
        "Doc_title":" Association of primary (1) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (EGFR) therapy.",
        "_version_":1606189021824811008},
      {
        "Meeting_name":" Colorectal cancer",
        "Background":"['Background', ' Recent data show that patients with left sided colon tumors (LT) have better survival and respond differently to biologics compared to patients with right-sided tumors (RT), likely due to molecular differences. We sought to examine these differences. Methods', ' Primary colorectal tumors (n = 1730) with origins clearly defined as RT (cecum to hepatic flexure; n = 273), LT (splenic flexure to sigmoid colon; n = 585), or rectal (RC; n = 872) were examined by NextGen sequencing, protein expression and gene amplification. Tumor mutational load (TML) was calculated in 1001 of these tumors using only somatic nonsynonymous missense mutations. Chi-square was used for comparison. Results', ' When compared to LT, RT carried a significantly higher rate of BRAF (25% vs 7%; p < 0.0001), PTEN (5.4% vs 1.3%; p = 0.008), and ATM (4% vs 1%; p = 0.04) mutations. RT were likely to have more MSI-high tumors (22% vs 5%; p < 0.0001) and PD-1 overexpression (58% vs 44%; p = 0.01). There were no differences in the rate of KRAS (50% vs 42%; p = 0.07) or NRAS mutations (2.2% vs 3.4%; p = 0.4). When compared to RC, RT had a higher rate of BRAF (25% vs 3%; p = 7E-07), PIK3CA (22% vs 11%; p = 0.001), CTNNB1 (3% vs 0.3%; p = 0.02); ATM (3% vs 1%; p = 0.04), PTEN (5% vs 1%; p = 0.004), and BRCA1 mutations (4% vs 0%; p = 0.02), and a lower rate of TP53 (56% vs 71%; p = 0.001) and APC (53% vs 66%; p = 0.003) mutations. When compared to RC, LT showed higher rates of BRAF (6.7% vs 3.2%; p = 0.04) and CTNNB1 (2.1% vs 0.3%; p = 0.04) mutations, and a higher rate of MSI-high tumors (4.6% vs 0.7%; p = 0.04), whereas RC had a higher rate of KRAS mutation (50% vs 42%; p = 0.04). There were no differences between RT, LT, and RC for the frequency of PD-L1 (2%, 2%, and 1%) or Her-2 (1%, 2%, and 3%) overexpression, although Her-2 amplification was significantly different (1%, 3%, and 5%, RT vs RC; p = 0.03). Mean TML was 12, 11, and 8 mutations/megabase for RT, LT, and RC, respectively (RT vs RC; p = 0.01). There was a correlation between TML and PD-L1 (p = 0.04) and PD-1 (p = 0.01). Conclusions', ' Tumors arising in the right colon carry genetic alterations that are different from LT as well as RC. However, it appears that CRCs carry a continuum of molecular alterations from the right to the left side, rather than displaying sharp, clear-cut differences.']",
        "Doc_id":"ASCO_190984-199",
        "Doc_title":" Colorectal cancer",
        "_version_":1606189040430743552},
      {
        "Meeting_name":" Comprehensive genomic profiling in colorectal cancer (CRC) to identify differing frequencies of clinically relevant genomic alterations (CRGA) in tumors of patients (pts) less than age 50 as compared to those of pts over age 65.",
        "Background":"['Background', '  CRC is increasing in young pts and are believed to have worse pathological features than older pts. Mutational profiles may differ in pts. The objective of this study was to compare and describe the genomic complexity of CRC in pts < 50 to > 65 in the FoundationOne database. Methods', '  DNA was extracted from 2,267 FFPE clinical specimens with colorectal cancer (CRC) (< 50 yo, n=1280; > 65 yo, n = 987). CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 603X for 3,769 exons of 236 cancer-related genes plus 47 introns from 19 genes frequently rearranged in cancer.  All classes of genomic alterations (GA) were identified.  Clinically relevant genomic alterations (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials. Results', '  Among the 50 genes analyzed, the > differences were noted in BRAF and FAM123B in pts > 65. KRAS mutations occurred in 50.5% vs 51.3%; NRAS, 2.6% vs 4.8%, BRAF, 5.5% vs 11.9% in younger pts vs older pts, respectively.  Few differences in genomic complexity were observed, although a trend toward increase frequency of BRAF mutations were observed in pts > 65. Conclusions', \"  While some differences in tumor genomic profiles and complexity were observed in CRC pts < 50 vs > 65, changes in BRAF and FAM123B were more frequent in the > 65.  Ongoing studies will assess differences in molecular and genomic features between younger and older CRC pts.  Most significant alterations between cohorts using Fisher's exact statistical analysis.GeneFrequency observed in Under 50 groupFrequency observed in Over 65 groupP-valueBRAF5.49%11.88%5.3234040577e-008DNMT3A0.71%3.05%2.58551923319e-005MLH12.43%0.51%0.0002471202FAM123B4.08%7.61%0.0003131498MYC10.82%7.01%0.0019676479AKT10.71%2.23%0.002881084\"]",
        "Doc_id":"ASCO_160255-173",
        "Doc_title":" Comprehensive genomic profiling in colorectal cancer (CRC) to identify differing frequencies of clinically relevant genomic alterations (CRGA) in tumors of patients (pts) less than age 50 as compared to those of pts over age 65.",
        "_version_":1606188987992506368},
      {
        "Meeting_name":" Overcoming resistance to BRAF inhibitors in colon cancer and melanoma cell lines.",
        "Background":"['Mutations in the B-raf oncogene constitutively activate the RAF-MEK-ERK signaling pathway, a key regulator of cell proliferation and survival. The most common BRAF mutation (V600E) occurs in approximately 70% of primary melanomas and 10% of colorectal cancers. Melanoma patients carrying the BRAF(V600) mutation respond with frequency of 80% to the BRAF inhibitor vemurafenib, while colon cancer patients respond at a rate of 5% only, indicative of intrinsic resistance. Moreover, clinical benefit is further limited by the rapid emergence of acquired resistance among vemurafenib responders. Combination therapy targeting both BRAF(V600E) and possible escape pathways appears to be a promising approach to reverse resistance to BRAF inhibitors. Here, we present the molecular characterization and in vitro chemosensitivity profiles of 20 melanoma and 20 human colorectal cancer cell lines. Four of the colon and 11 of the melanoma cell lines were established at Oncotest from patient-derived tumor xenografts (PDX). Molecular profiles include the mutation status of BRAF, PIK3CA, KRAS, and NRAS (exon sequencing) and protein levels for components of the MAPK, EGFR and PI3K/AKT pathways (Western blot analysis). Sensitivity profiles for inhibitors of BRAF, MEK, EGFR and PI3K were determined in vitro using a fluorescence-based survival and proliferation assay. Overcoming resistance to BRAF inhibitors was investigated by combination of vemurafenib with other inhibitors of the RAF-MEK-ERK pathway or inhibitors of potential escape pathways like EGFR, PI3K/AKT or c-MET and evaluated by combination index according to Chou-Talalay.In line with the clinical situation, the BRAF V600E substitution was found in 13/20 (65%) of the melanoma and only in 4/20 (20%) of the colon cancer cell lines. BRAF and NRAS mutations were mutually exclusive in melanoma cell lines and KRAS mutations did not occur at all. Among the colon cancer cell lines, in addition to the BRAF(v600E) mutation, alteration in KRAS (10/20 cell lines), PIK3CA (6/20) and NRAS (1/20) were detected. Chemosensitivity profiling revealed intrinsic resistance to BRAF inhibitors for 3/13 (23%) BRAF(V600E) melanoma cell lines and for 3/4 (75%) BRAF(V600E) colon cancer cell lines. Reversal of the resistance of BRAF inhibitor-insensitive melanoma cell lines was recorded as synergism between vemurafenib and inhibitors of vasious kinases (c-MET, AKT, PI3K, MEK, or EGFR. A particularly strong synergistic interaction was found for vemurafenib and the c-MET inhibitor SU11274, irrespective of BRAF status. For colon cancer cell lines, the strongest synergisms were detected for the combinations of vemurafenib with inhibitors of c-MET, EGFR, PI3K, AKT and MEK.Displaying similar mutation and chemosensitivity profiles as melanomas and colon cancers in the clinic, the present cell line panels represent valuable tools to investigate the reversal of resistance towards BRAF inhibitors.']",
        "Doc_id":"AACR_2013-3381",
        "Doc_title":" Overcoming resistance to BRAF inhibitors in colon cancer and melanoma cell lines.",
        "_version_":1606188985166594048},
      {
        "Meeting_name":" High intra- and inter-tumoral heterogeneity of RAS mutations in colorectal cancer.",
        "Background":"['Background', ' Anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs) are a standard treatment in metastatic colorectal cancer (mCRC) with wild-type (WT) RAS status. However, approximately 30% of patients with RAS WT mCRC are non-responders to anti-EGFR mAbs, possibly due to undetected tumoral subclones harboring RAS mutations. The aim of this study was to analyze the distribution of RAS mutations in different areas of the primary tumor, metastatic lymph nodes and distant metastasis. Methods', ' A retrospective cohort of 18 patients with a CRC was included in the study. All tumors were tested for KRAS, NRAS (codon 12, 13, 59, 61, 117 and 146) and BRAFV600E mutations using transparietal sections. Six were KRAS mutant, one NRAS mutant and one BRAF mutant. Multiregion analysis was performed in 60 spatially separated tumor areas according to the pTNM staging, including 49 in primary tumors (submucosa (pT1), musculosa (pT2) and/or subserosa (pT3)), 10 in metastatic lymph nodes and 1 in metastasis. KRAS, NRAS and BRAF mutations were tested using pyrosequencing. Intra-tumoral heterogeneity is defined by the presence of different tumoral subclones within the same tumor mass. Inter-tumoral heterogeneity consists in the presence of different tumor subclones in various tumor sites (i.e. primary tumor, metastatic lymph nodes or metastases). Results', ' Among the 60 tumor areas, 35 were KRAS mutated (in 11 tumors), 8 NRAS mutated (in 3 tumors) and one BRAF mutated(in 1 tumor). In primary tumors (n = 18), intra-tumoral heterogeneity for RAS mutation was found in 8 patients (44%). Inter-tumoral heterogeneity for RAS mutation between primary tumors and metastatic lymph nodes or distant metastasis (n = 11) was found in 6 patients (54%). Moreover, 5 tumors had multiple RAS mutated subclones in the same tumor (28%). Indeed, we observed the coexistence of different KRAS mutations (n = 3) as well as KRAS and NRAS mutations (n = 4). Conclusions', ' A high proportion of CRC presented intra- and/or inter-tumoral heterogeneity, which has relevant clinical implications for anti-EGFR mAbs prescription. These results suggest the need for multiple RAS testing in different part of the same tumor and/or more sensitive techniques.']",
        "Doc_id":"ASCO_164964-176",
        "Doc_title":" High intra- and inter-tumoral heterogeneity of RAS mutations in colorectal cancer.",
        "_version_":1606189013178253312},
      {
        "Meeting_name":" Molecular analysis of Kras and Nras mutations in a series of 720 patients for guiding the treatment of metastatic colorectal cancer in Turkey.",
        "Background":"['Background', ' Mutations in Kras and Nras genes in primary colorectal tumors are the reasons for nonresponse to anti-epidermal growth factor receptor (EGFR) antibodies in patients with metastatic colorectal cancer (mCRC). Results of the molecular analysis guides the treatment decision-making in mCRC. The aim of this study was to evaluate the Kras and Nras mutation data from 720 patients with mCRC between 01 January 2015 and 31 January 2016 using minisequencing method. Methods', ' We performed a two round nested PCR for the amplification of Exons 1, 2, 3 of Kras and Nras genes harbouring codons 12, 13, 59, 61, 117, and 146 followed by a multiplex minisequencing reaction for the detection of potential mutations. Results', ' A total of 720 patients were analysed for the mutations in codons 12, 13, 59, 61, 117, and 146 of Kras and Nras genes. Results were obtained from 718 out of 720 (99,72%) patients and no results were obtained from 2 (0,28%) of the cases. 400/718 (55,71%) patients were wild-type for Kras mutations while 318 of them carried a Kras mutation (44,29%). 8 of 318 (2,52%) patients carried two mutations which made totally 326 Kras mutations. Kras mutation rates were 192/326 (58,90%), 98/326 (30,06%), 3/326 (0,92%), 8/326 (2,45%), 3/326 (0,92%), 22/326 (6,75%) in codons 12, 13, 59, 61, 117, 146 respectively. Additional Nras mutation testing was performed for 400 patients which were found to be wild-type for Kras mutations. 31/400 (7,75%) patients were found to carry Nras mutations while 369 (92,25%) of them were wild-type for Nras mutations. 1 of 31 (3,23%) patients carried two mutations which made totally 32 Nras mutations. Mutation distribution was 10/32 (31,25%), 4/32 (12,50%), 4/32 (12,50%), 11/32 (34,38%), 2/32 (6,25%), 1/32 (3,13%) in codons 12, 13, 59, 61, 117, 146 respectively. Conclusions', ' High rate (349/718, 48,61%) of mutation finding in Kras and Nras testing makes mutation profiling in Kras and Nras genes an effective approach to select patients who are more likely to respond to anti-EGFR immunotherapy or rule out this treatment for those who are not likely to respond, and predict patient outcomes using minisequencing reaction which is a highly sensitive and cost effective method.']",
        "Doc_id":"ASCO_169851-176",
        "Doc_title":" Molecular analysis of Kras and Nras mutations in a series of 720 patients for guiding the treatment of metastatic colorectal cancer in Turkey.",
        "_version_":1606189012618313728},
      {
        "Meeting_name":" Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer",
        "Background":"['Background', '  Tumor genome sequencing is being used widely in clinical settings but its value to individual patients has not been well-studied. A prospective cohort study of outpatient genomic testing to identify prevalence of actionable alterations and their impact on management decisions was conducted.  Methods', '  Eligibility requirements included pathologic diagnosis of select solid tumor malignancies without a known curative option, age 18 years, and an ECOG PS of 0-2. Data for the colorectal cancer (CRC) subgroup are presented here. Tumor samples were sequenced for up to 315 candidate genes using FoundationOne (Cambridge, MA). Results were discussed at the Cleveland Clinic Genomics Tumor Board that made therapeutic recommendations to treating physicians.  Results', '  From Aug 2013 to Aug 2014, samples from 45 patients with CRC were analyzed. Median age was 60 years; 23 (51%) were female; 38 (84%) were white. Median time from consent to result was 25 (range, 7-75) days. One (2%) sample had inadequate tissue. A median of 5 (range, 2-19) mutations were detected per sample; APC (89%), TP53 (73%) and KRAS (66%) were most common. A therapy targeting an actionable alteration was recommended in 22 (51%) patients; 88% of these recommendations were for clinical trials. To date, 6 (33%) of 18 patients who switched management after test results received genomics-driven therapies (Table). Previously unknown RAS (KRAS Q61H, NRAS) mutations were detected in an additional 3 patients, influencing EGFR antibody use decisions. The commonest reason for non-receipt of therapy based on the test result was non-availability of clinical trials.  Conclusions', '  Routine tumor genome profiling in CRC patients is feasible and influenced treatment decisions in a third of patients. A genomics tumor board for the interpretation of rapidly evolving information, and improved access to clinical trials of targeted agents are critical to the success of precision oncology. TargetTherapyNClinical TrialsFLT3Dovitinib2PTCH1SMO inhibitor1Off-label usePIK3R1Everolimus1FLT3Sunitinib1HER2Trastuzumab1Non-genomics-based-Standard systemic therapy6-Standard local therapy4-Hospice2']",
        "Doc_id":"ASCO_140479-158",
        "Doc_title":" Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer",
        "_version_":1606188988145598464},
      {
        "Meeting_name":" DUSPs as markers of MEK/Erk activation in primary colorectal cancer.",
        "Background":"['Background', ' DUSPs dephosphorylate P-MAPK and are activated as a negative feedback loop upon RTK signaling. Higher expression of DUSP 4 & 6 is also found in cells with constitutive Erk activation like KRAS mutant (MUT) cells (Bild et al. Nature 2005). We correlated DUSP1, 4, 6 (isoforms a & b) & 8 mRNA expression level in FFPE primary colorectal cancer (CRC) of 186 chemorefractory patients treated with cetuximab (CTX) with KRAS MUT state and progression-free survival (PFS) and overall survival (OS). Methods', ' KRAS codon 12,13, 61&146, BRAF V600E and NRAS codon 12&13 MUT were analyzed with the Sequenom MALDI TOF MassArray system. The DUSPs and 3 housekeeping genes were quantified by qRT-PCR. TwoStep cluster analysis was performed. PFS and OS were estimated by the Kaplan-Meier method. Results', ' KRAS MUT was associated with increased DUSP4 (MWU;p=.0006) & 6a (p=.0067). DUSP6a dephosphorylates P-Erk, DUSP4 also dephosphorylates P-JNK & P-p38. DUSP1 & 8 primarily dephosphorylate P-JNK & P-p38 and were not associated with KRAS MUT. KRAS MUT clustered into 3 groups according to DUSP4 expression', ' 32 high, 38 median & 13 low (t- test;p<.0001). The low MUT expression was comparable to wild-type (WT) expression. KRAS WT clustered into 2 groups', ' 69 low & 24 high DUSP4 (ANOVA;p<.0001). 7/24 of high expressors were found to have a BRAF or NRAS MUT. The 32 MUT high expressors had a longer median PFS (log-rank;p=.015) and OS (p=.065) after CTX. The 17 KRAS/BRAF/NRAS WT high expressors had a shorter median OS (p=.026), but not PFS (p=.745). Conclusions', ' There is a significantly higher DUSP4 & 6a mRNA expression in the KRAS MUT compared to WT primary CRC. However, this is not a black and white observation. In the KRAS MUT there are 3 distinct clusters of DUSP4 expression. The high expressors (= supposed attenuated Erk signaling) have a longer PFS and OS after CTX. Adaptation to constitutive KRAS signaling with differential levels of MEK/Erk activation needs to be further investigated and will be of help in selecting patients for therapy with MEK inhibitors. It suggests not all KRAS MUT will be good candidates for MEK inhibitors. In the cluster of high DUSP4 expressing KRAS WT 30% are BRAF or NRAS MUT. This suggests DUSP expression of FFPE samples could be a more sensitive marker of MEK/Erk activation and resistance to EGFR inhibitors than KRAS MUT analysis alone.']",
        "Doc_id":"ASCO_33836-65",
        "Doc_title":" DUSPs as markers of MEK/Erk activation in primary colorectal cancer.",
        "_version_":1606188999358021632},
      {
        "Meeting_name":" HDAC inhibitors and the mechanism of resistance in colorectal cancer",
        "Background":"['Although histone deacetylase inhibitors (HDACi) are considered a promising novel therapeutic approach in the light of their potent tumour-selective effects, the use of these inhibitors for treatment of colorectal cancer (CRC) have thus far demonstrated limited success as a monotherapy. What this eventually boils down to is our incomplete understanding of the molecular mechanisms, the impact of oncogenes, and thus the key pathways through which HDACi affect tumour cell growth. To shed further light on this, the involvement of oncogenic RAS - a key driver of CRC, in determining the responsiveness to HDACi has been explored. By using cell line model systems harbouring conditional oncogenic NRAS, KRAS and HRAS, we uncovered an oncogenic RAS-dependent safeguard mechanism imposed in order to evade the cytotoxic effect of HDACi and therefore apoptosis. Characteristically, cells harbouring oncogenic RAS were observed to undergo a reversible senescence-like growth arrest in G2, allowing for re-entry into cell cycle following the withdrawal of HDACi. This mechanism is implemented as a consequence of the direct targeting of RAS by HDAC inhibition, which resulted in a further amplified GTP-binding activity and subsequent signalling through the MAPK pathway. The observed outcome was an increase in the priming of MYC for ubiquitin-mediated proteasomal degradation, thereby enabling the cells to exit the cell cycle and enter the protective state of G2 arrest. This process was functionally reversed with a conditional non-degradable MYC (T58A/S62A), which in turn rendered the cells more susceptible to undergo apoptosis. Conclusively, in the context of a constitutively activating RAS mutation, the prospect of HDACi treatment was effectively improved using current MAPK-targeted therapy by preventing the observed pro-oncogenic effect of the HDACi treatment alone.']",
        "Doc_id":"AACR_2017-5170",
        "Doc_title":" HDAC inhibitors and the mechanism of resistance in colorectal cancer",
        "_version_":1606189041901895681},
      {
        "Meeting_name":" Modeling the rise of intratumoral heterogeneity in growing, static, and regressing human colorectal polyps",
        "Background":"[\"Benign adenomatous colon polyps are thought to be transformed into cancers through the stepwise accumulation of mutations. However, not all polyps progress. A significant number remain static in size, regress, or resolve completely. The mechanisms underlying these differential fates are unknown, and currently there are no biological characteristics that can reliably predict which polyps will grow or progress into invasive cancer. To determine the mutational landscape, targeted next generation sequencing was performed on a unique collection of small (6-9mm) colorectal polyps with known growth rates based on interval imaging with CT colonography. To determine spatial location of identified mutations within a polyp, micro-dissection was performed followed by quantitative PCR to validate low frequency mutations. The mutational landscape of small polyps is varied both within and among individual polyps. Polyps carried 0-3 pathogenic mutations with the most frequent being in APC (67%, 32/48), KRAS/NRAS (17%, 8/48), BRAF (17%, 8/48), FBXW7 (10%, 5/48), and TP53 (8%, 4/48). Additionally, 13% (6/48) contained driver mutations at varied mutant allele frequencies, indicating the presence of subclonal populations. In silico modeling of tumor growth was used to determine the likely size at which additional driver mutations arose in order to observe those varied frequencies. This model of colon tumor growth was adapted so that mutations occur with a given probability of 105, which may change the fitness positively or negatively, and the lineage from these mutant subpopulations was tracked during tumor growth. In silico polyps were sectioned and mutant allele frequency was recorded and compared to the frequencies observed from the targeted sequencing of human polyps. Contrary to the slow step-wise accumulation of mutations theory, these data indicate small colonic polyps can have multiple pathogenic mutations in crucial driver genes that arise early in a tumor's existence. Understanding the molecular pathway of tumorigenesis and clonal evolution in polyps that are at risk for progressing to invasive cancers will allow us to begin to better predict which polyps may be more likely to progress into adenocarcinomas and which patients are predisposed to developing advanced disease.\"]",
        "Doc_id":"AACR_2016-151",
        "Doc_title":" Modeling the rise of intratumoral heterogeneity in growing, static, and regressing human colorectal polyps",
        "_version_":1606189033976758272},
      {
        "Meeting_name":" Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status.",
        "Background":"['Background', '  KRAS, BRAF, NRAS and exon 20 PIK3CA quadruple wild-type CRC is associated with 41.2% response rate to anti-EGFR treatments. Even in molecular characterized patients, there is still a subset of non responders. The identification of additional predictive biomarkers is an unmet clinical need for treatment personalization. Alterations of ALK oncoprotein may interfere with the biological activity of EGFR through cross-talk of downstream signalling pathways.  Methods', '  This retrospective analysis aimed to investigate the correlation between ALK gene copy number (GCN), assessed by fluorescence in situ hybridization (FISH), and clinical outcome in KRAS/NRAS/BRAF/PI3KCA wild-type chemorefractory advanced CRC patients receiving cetuximab or panitumumab. FISH was perfomed with break-apart ALK (2p23) probes and gain of ALK GCN was defined as a mean of 3 to 5 signals in 10% of cells and amplification as 6 signals. Association of ALK status with RECIST response was performed by Fishers exact test.  Results', '  Forty-one patients were identified, of whom 17 (41%) were ALK GCN positive, whereas the remaining 24 cases (59%) were ALK GCN negative. No ALK translocations were detected. Overall response rate was 19/41 (46%). We observed a partial response in 3/17 patients with ALK GCN positive versus 16/24 patients with ALK GCN negative (18% versus 67%, respectively; P=0.0036). Kaplan-meier curves for comparison of median progression-free and overall survival, as well as correlation with ALK expression by immunohistochemistry, will be presented at the Meeting exploring the whole National Cancer Institute data-set.  Conclusions', '  In this study population with KRAS/NRAS/BRAF/PI3KCA wild-type tumors, the response rate greater than 40% is in line with literature data. ALK GCN may be a biomarker for clinical outcome prediction in advanced chemorefractory CRC patients treated with cetuximab or panitumumab.']",
        "Doc_id":"ASCO_117318-132",
        "Doc_title":" Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status.",
        "_version_":1606189020752117760},
      {
        "Meeting_name":" DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC)",
        "Background":"['Background', '  The small intestine is in continuity with the stomach and colon/rectum. However mGC and mCC/mRC differ in oncogene profiles. No study has evaluated the oncogene profile of mSBA on the continuum of mGC and mCC/mRC. This may give insight into biology and have implications for treatment.  Methods', '  Respective analysis was performed on GI cancer patients who underwent tumor mutational profiling since 2010. Genotyping was performed on formalin-fixed and paraffin-embedded tumor tissue using a multiplexed mutational profiling platform. Here we report results for APC, BRAF, EGFR, IDH1, KRAS, NRAS, PI3K, PTEN, and TP53.  Results', '  We identified 12 patients with mSBA (11/12 with clinical data, 11/12 with genotype data). Median age at stage IV diagnosis was 61.1y (49.3-71.5y). Four patients had duodenal, 3 jejeunal, 2 ileal, and 2 multiple/unknown primary sites. All patients received 5FU and ox, while 8/11 received irino, 5/11 bev, 3/11 cetux, 1/11 regorafenib and 1/11 capecitabine. Two patients had adjuvant RT (both duodenal) while 4/11 received palliative RT. Survival was calculated from the date of stage IV diagnosis until death, with data censored on 2/1/2013. Median survival was 24.0 months (95% CI 6.4  60.0 mo). We compared genotype frequencies of mSBA patients (11) with mGC (41), mCC (161), and mRC (64) using Fishers exact test for pairwise comparisons. Conclusions', '  While the small bowel sample size was small, a significant difference in KRAS mutation frequency was found when compared to gastric cancer. No significant differences in mutation frequencies were found when compared with colon or rectal cancer.']",
        "Doc_id":"ASCO_117218-132",
        "Doc_title":" DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC)",
        "_version_":1606188994907865088},
      {
        "Meeting_name":" Efficiency of biomarker screening for enriched metastatic colorectal cancer trials",
        "Background":"['Background', '  Incorporation of multiple enrichment biomarkers into prospective clinical trials for metastatic colorectal cancer (mCRC) has been proposed or initiated by NSABP, EORTC, NCI Colon Task Force, and UK MRC. The feasibility of large scale screening efforts in mCRC has not been previously assessed.  Methods', '  Patients (pts) with 5-FU refractory mCRC at MD Anderson Cancer Center were offered screening in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program to identify eligibility for companion clinical trials with a therapy targeted to an aberration detected in the patient.  Results', '  Between 8/2010 and 8/2013, 400 heavily pretreated mCRC pts were enrolled onto ATTACC for screening and allocation onto 10 separate Phase I or II companion trials based on banked FFPE tumor testing by IHC, gene sequencing, and CpG island methylation phenotype (CIMP) assay.  Outside tissue was obtained with a median of 6 calendar days (8% had insufficient tumor).  IHC, sequencing, and CIMP results required a median of 11, 12, and 20 days, respectively.  In this population, 53% tumors had KRAS mutations, with BRAF, NRAS, and PI3KCA mutations, and complete PTEN loss present in 8.1%, 8.6%, 21%, and 12%, respectively. CIMP-high status (2 markers) was noted in 38% of pts.  Given molecular results, trial-specific eligibility, and intermittent study openings, fewer than 25% of screened pts were eligible for enrollment onto a companion protocol. Of these eligible patients, approximately half (13%) enrolled onto a companion trial. Within the entire cohort, 19% enrolled in unenriched trials, and 51% received standard-of-care therapies. ATTACC screening, with an expanding biomarker panel, remains ongoing at a rate of 25-30 patients per month.  Conclusions', '  Universal screening programs such as ATTACC represent an optimal strategy for enrolling patients in multiple biomarker enrichment studies.   Even in the setting of multiple companion treatment studies, motivated patients/physicians, and a dedicated screening infrastructure, a majority of patients did not ultimately participate on a companion trial, emphasizing the lack of drugs targeting a number of common aberrations.']",
        "Doc_id":"ASCO_123359-143",
        "Doc_title":" Efficiency of biomarker screening for enriched metastatic colorectal cancer trials",
        "_version_":1606188993142063104},
      {
        "Meeting_name":" A rapid, multiplexed, and highly accurate next-generation sequencing RAS Panel for FFPE colorectal samples reporting on the absence or presence of low frequency somatic variants",
        "Background":"['Introduction', ' Next generation sequencing (NGS) is a highly sensitive method for detecting somatic mutations. Mutations in NRAS and KRAS may affect up to 50% of patients with colorectal cancer (CRC). Recent data suggest the clinical benefit of panitumumab is restricted to patients who have no tumor mutations in RAS, defined as codons 12, 13, 59, 61, 117 and 146 of KRAS and NRAS genes. An Extended RAS panel* targets these codons as a single multiplex assay. A dual strand approach distinguishes true mutations from artifacts commonly found in DNA from Formalin Fixed Paraffin Embedded (FFPE) tissue. Analytical performance of this panel was characterized.Methods', ' FFPE tissue was examined for tumor content and area. DNA was extracted from FFPE tissue, cell lines and plasmids. The DNA quality and quantity were simultaneously determined through a quantitative PCR measurement of amplifiability. TruSeq Custom Amplicon technology targeting each strand of DNA was used to construct NGS libraries. Sequencing was performed on the MiSeqDx, and the Illumina Somatic Variant Caller was used to call somatic variants.Results', ' The dual-strand amplicon approach results in high accuracy by eliminating false positives observed on one strand of DNA typical of an FFPE artifact, by requiring every variant to be detected on both strands. We evaluated performance on 500 FFPE CRC samples processed with the Extended RAS panel. Concordance against Qiagen TheraScreen and Sanger Sequencing results was evaluated. The somatic variant caller yields a specificity of 0.98 and sensitivity of 0.72 for variants in the 5%-10% range, and a specificity of 0.96 and sensitivity of 0.98, overall, where we take the alternate methods as truth. Cumulative FFPE tissue area influences performance of the RAS panel. FFPE of a range of tissue area were tested using 1, 3, 5, and 8 sections per sample. 80mm2 minimum (240mm2 recommended) cumulative tissue area using 5uM slices was optimal for performance and accuracy. DNA quantity and quality also influence test accuracy and sensitivity. A study with 40 FFPE specimens assayed over multiple operators and sequencers produced average coverage of 32,000 reads per target per sample, and over 93% alignable reads per sample. Reproducibility of mutations detected over multiple operators and instruments was 100%. The Extended RAS Panel demonstrates robust performance across many sources of variation, including FFPE DNA extraction method, DNA storage time, recommended DNA input range, qPCR/PCR thermocyclers with little to no impact on sample pass rate and agreement with Sanger sequencing. We also demonstrate detection of 56 distinct mutations in a single run.Conclusion', ' This multiplex assay achieves high accuracy for detection of somatic mutations from DNA extracted from FFPE colorectal tissue samples.*In development For Research Use Only. Not for use in diagnostic procedures.']",
        "Doc_id":"AACR_2016-3638",
        "Doc_title":" A rapid, multiplexed, and highly accurate next-generation sequencing RAS Panel for FFPE colorectal samples reporting on the absence or presence of low frequency somatic variants",
        "_version_":1606189011639992321},
      {
        "Meeting_name":" DNA repair defect and RAS mutation in Schistosoma mansoni-associated colorectal cancer patients",
        "Background":"['Background', ' Data on Schistosoma mansoni-associated colon cancer is scarce. Infestion induces inflammation which may trigger genetic mutations. We report two pts and potentially implicated carcinogenesis. Methods', ' KRAS/NRAS exons 2, 3 and 4 were amplified by PCR and second-generation sequencing by Illumina MiSeq. Pts were tested for MSI using immunohistochemistry antibodies MLH1, MSH2, MSH6, and PMS2. Results', ' 1) 45 year-old female, abdominal pain, weight loss and diarrhea. Colonoscopy Oct 2014, 3 cm tumor in cecum. Right colectomy in Jan 2015. Well differentiated mucinous adenocarcinoma. 2.5 x 1.5 x 1.5 cm invasion into muscularis propria. No perineural or lymphovascular invasion. Mild tumor inflammatory infiltrate. Free margins, metastasis to 1 of 24 lymph nodes. Ileal schistosomiasis found. MSI confirmed (loss of MLH1 and PMS2). All-RAS mutation negative. Six-month adj CAPOX. Last visit Dec 2015. 2) 47 year-old male, hepatosplenic form. Right hemicolectomy in 2012 due to complications of appendicitis. Mar 2014, splenectomy and esophageal varices clamp due to GI hemorrhage. He presented diarrhea and in Nov 2014, colonoscopy showed 2 cm tumor next to ileum-transverse colon anastomosis. Mar 2015, segmental colectomy. Ileum', ' granulomatous reaction in response to Schistosoma eggs; Merkel diverticula; 3.5 x 1.8 cm mucinous moderately differentiated adenocarcinoma infiltrating subserosa, free margins, lymphovascular invasion present, perineural infiltration absent. Mild tumor lymphocytic infiltrate. No lymph nodes were identified in the specimen. Other findings', ' diffuse granulomatous reaction in response to Schistosoma eggs in ileum and colonic mucosa. MSI negative. Exon 2 KRAS mutation (c.38G > A', 'p.G13D) was identified. No adj chemo. Last visit Dec 2015. Conclusions', ' age of patients and mucinous subtype were in accordance with literature. RAS mutation, along with the presence of MSI, may be implicated in the carcinogenesis of Schistosoma mansoni-associated colorectal cancer or represent coincidental events. If the first is right, it would determine screeeing, treatment and prognosis implications among Schistosoma mansoni infested patients.']",
        "Doc_id":"ASCO_162961-176",
        "Doc_title":" DNA repair defect and RAS mutation in Schistosoma mansoni-associated colorectal cancer patients",
        "_version_":1606188978143232000},
      {
        "Meeting_name":" Broad, hybrid capture-based next generation sequencing guided personalized therapy in metastatic colorectal cancer.",
        "Background":"['Background', ' Patients with metastatic colorectal cancer are now recommended to profile for RAS and BRAF mutations before receiving cetuximab or panitumumab. However, lots of patients with both RAS and BRAF wild-type tumors determined by non-NGS testing might still not respond due to the presence of additional gene mutation such as PIK3CA or PTEN. Therefore, its necessary to screen mutations in genes other than RAS and BRAF on the efficacy of anti-EGFR therapy. Besides, new available agents could potentially be used based on the other targetable alterations discovered. In this study, a broad, hybrid capture-based next generation sequencing (NGS) assay was used to identify RAS, BRAF and additionally targetable genetic alterations from colorectal cancer tissue. Methods', ' 72 cases of colorectal cancers were enrolled and all the patients signed the informed consent before assay. 7708 exons of 508 tumor related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, indels, copy number alterations, and gene fusions. The average median sequencing depth was 450. Results', ' 50.4% (37/72) of the tumors harbored a KRAS mutation, 4.2% (3/72) harbored a NRAS mutation and 4.2% (3/72) harbored a BRAF mutation. More specifically, 82.5% (33/40) of RAS mutation was located in exon 2. Except for RAS and RAF, 4.2% (3/72) anti-EGFR therapy response genetic mutations were found in PTEN (n = 3). Its also worth noting that actionable alterations were found in HER2 (n = 5, including 4 amplification and 1 activating mutation), FBXW7 (n = 3) and others (n = 5). Conclusions', ' Our results implied that 63.9% (46/72) metastatic colorectal cancers with genetic mutations including KRAS, NRAS, BRAF and PTEN might not benefit from anti-EGFR therapy. 26.4% (19/72) of samples harbored at least one actionable genetic alteration rather than RAS identified by NGS testing. Significantly, HER2 defined a unique subpopulation of 6.9% (5/72) of metastatic colorectal cancer and might be a promising driven-gene. These findings suggest that high throughput NGS testing in colorectal cancer tissue was a comprehensive and efficient genomic profiling assay to guide personalized therapy.']",
        "Doc_id":"ASCO_164103-176",
        "Doc_title":" Broad, hybrid capture-based next generation sequencing guided personalized therapy in metastatic colorectal cancer.",
        "_version_":1606189033249046528},
      {
        "Meeting_name":" Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome.",
        "Background":"['Background', '  The incidence of colorectal cancer (CRC) among young individuals is rising.  The effect of an individuals age on their tumor molecular profile is unknown.  Methods', '  Molecular profiles of 4,821 tumors obtained from younger and older CRC patients (pts) were reviewed and correlated with pt outcome. Protein expression (IHC), gene amplification (ISH), sequencing (NGS and Sanger), and fragment analysis were performed. T and Fishers exact tests determined differences between age groups; Kaplan-Meier methodology estimated survival.  Results', '  Tumors from 1,277 younger (median age 40; range 15-45 yr) and 3,544 older (72; 65-98) pts were studied. Most frequently mutated genes included TP53, APC, KRAS, PIK3CA, SMAD4, and BRCA1/2. Mutation rates for BRAF (14.4% vs. 4.8%, p < 0.001), APC (62% vs. 54%, p = 0.0034), FBXW7 (9.6% vs. 5.5%, p = 0.01), and KRAS (45% vs. 41%, p = 0.02) were higher in older pts; NRAS mutation rates (4.5% vs. 3.9%) were similar in both groups.  Younger pts had higher overexpression rates of HER-2/neu (3.2% vs. 1.8%, p = 0.017) and MGMT (64% vs. 58%, p = 0.001). Microsatellite instability (MSI), determined by IHC (MLH1, MSH2, MLH6 and PMS2) and fragment analysis, was similar between cohorts (10.3% vs. 8.1%), but somatic MSI high (determined by concurrent BRAF mutation) was higher in older pts (6% vs. 0%, p < 0.0001). There was no difference in TS (37% vs. 34%), ERCC1 (25% vs. 26%) or TOPO1 (49% vs. 46%) expression between age groups.  Older pts showed a trend toward higher PD-L1 expression (2.9% vs. 0.7%, p = 0.0512) but there was no difference in the frequency of PD-1 expression on tumor-infiltrating lymphocytes (39% vs. 43%).    Outcome was evaluable for 82 pts (younger, 47; older, 35). Most pts received FOLFOX + Bev as first line Rx.  Median OS was worse in younger pts (p = 0.03). Low ERCC1 expression was associated with prolonged survival in older (p < 0.01) but not in younger (p = 0.3) pts.  There was no association between TOPO1 expression and OS (p = 0.8). Pts with low TS expression showed a trend toward longer OS (p = 0.08).  Conclusions', '  Young pts with CRC may carry genetic alterations that are distinct from older pts.  A better understanding of disease biology may help to identify therapeutic targets for younger pts.']",
        "Doc_id":"ASCO_158533-173",
        "Doc_title":" Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome.",
        "_version_":1606188984262721536},
      {
        "Meeting_name":" PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.",
        "Background":"['Background', '  Double somatic mutations in mismatch repair (MMR) genes have recently been described in a high proportion of colorectal and endometrial cancers with microsatellite instability (MSI) not attributable to MLH1 hypermethylation or germline mutation. We sought to define the molecular phenotype of this new tumor subtype.  Methods', '  We identified patients with double somatic colorectal and endometrial tumors from two Ohio-based prospective Lynch syndrome screening studies who had abnormal tumor testing (MSI and/or by immunohistochemistry (IHC) without coexistent MLH1 methylation), but normal germline MMR testing. We determined the frequency of PIK3CA, BRAF, KRAS, NRAS, and PTEN mutations in double somatic tumors by targeted next-generation sequencing and compared the mutation frequencies to tumors of other MSI sub-groups', ' Lynch syndrome, MLH1 hypermethylation, and microsatellite stable (MSS) tumors. The frequencies were compared among groups with a logistic regression model.  Results', '  We found that 28/35 (80%) of double somatic tumors had PIK3CA mutations compared to 6/21 (29%) in Lynch syndrome tumors, 4/13 (31%) in MLH1 hypermethylated tumors, and 17/90 (19%) in MSS tumors, p < 0.0001. Among double somatic cases, a PIK3CA mutation was observed in 100% (13/13) of endometrial tumors and 68% (15/22) of colorectal tumors. These frequencies were significantly higher than all other case groups when analyzing by tumor type (colorectal p < 0.0001, endometrial p = 0.02). As expected, BRAF V600 mutations were frequent in MLH1 hypermethylated tumors (8/13) and not detected in any double somatic or Lynch tumors (p < 0.0001). No substantive differences were observed for KRAS, NRAS, or PTEN.  Conclusions', ' PIK3CA mutations are present in the majority of double somatic colorectal and endometrial cancers at frequencies significantly higher than those observed in other MSI sub-groups. PIK3CA mutation status may improve identification of Lynch syndrome by tumor-based screening and better define an emerging molecular entity in colorectal and endometrial cancers.']",
        "Doc_id":"ASCO_146200-156",
        "Doc_title":" PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.",
        "_version_":1606189027810082816},
      {
        "Meeting_name":" Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease",
        "Background":"['Background', ' Downsizing with chemotherapy (CT) unresectable liver-limited disease (LLD) can permit resection and prolonged survival in patients (pts) with colorectal cancer (CRC). We assessed the value of adding panitumumab (P) to standard CT in this setting.  Methods', ' This was a phase II, open-label, randomized, multicenter study which included pts18 years with wild-type (WT) KRAS exon 2 metastatic CRC and LLD fulfilling one of the following criteria', ' 4 metastases; at least 1 metastasis>10 cm in diameter; or technically not resectable. Pts were randomized 1', '1 to receive P-FOLFOX4 or P-FOLFIRI every two weeks. The primary endpoint was the objective response rate.  Results', '  There were77 pts analyzed (38 received P-FOLFOX4 and 39 P-FOLFIRI). Not confirmed response was noted in 70.1% pts (73.7% with P-FOLFOX4 and 66.7% with P-FOLFIRI). After a median of 8 P infusions in both groups, 51.9% underwent surgical resection of liver metastases (44.7% and 59.0%, respectively). The resection rate (R0+R1) was 77.5% (76.5% and 78.3%). Median progression-free survival was 12.5 months with P-FOLFOX4 and 12.6 months with P-FOLFIRI (p=0.943). Preliminary median overall survival was 32.5 and 42.4 months. Median pre-surgery relative dose-intensity (RDI) for panitumumab was 79.8% with P-FOLFOX4 and 87.5% with P-FOLFIRI, and RDI for CT was 83.0% and 88.7%. Peri-operative safety was similar between groups (22.2% and 18.5% of pts with any adverse event). Neutropenia grade 3/4 (P-FOLFOX4 39.5% vs P-FOLFIRI 10.3%; p=0.0029) and neuropathy (P-FOLFOX4 13.2% vs P-FOLFIRI 0%;p=0.025), were the only statistically significant differences in grade 3/4 adverse events. It was possible to determine the RAS status (exon 2,3,4 of KRAS/NRAS) in 83.1% of the pts. In the subset of pts with RAS WT the response rate increases to 75.5% pts (77.8% with P-FOLFOX4 and 73.1% with P-FOLFIRI).  Conclusions', '  In this selected population with WT KRAS CRC and LLD, panitumumab plus CT offers the possibility of rapid tumour shrinkage and potentially curative hepatic resection. Similar efficacy and safety results were obtained with either P-FOLFOX4 or P-FOLFIRI schema. Clinical trial information', ' NCT00885885.']",
        "Doc_id":"ASCO_128867-144",
        "Doc_title":" Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease",
        "_version_":1606189028163452928},
      {
        "Meeting_name":" Detecting KRAS and NRAS resistance mutations in plasma of lung cancer patients.",
        "Background":"['Background', ' Mutations in KRAS and NRAS have been found in a number of malignancies, particularly metastatic colorectal cancer, lung adenocarcinoma, and thyroid cancer. Several studies have shown that specific mutations in KRAS and NRAS are less likely to respond to anti-EGFR therapies. Several diagnostics have been developed to identify such mutations. However, in a large number of cancer patients, tumor biopsy poses a significant health risk thereby limiting the tissue available for current molecular diagnostics. Non-invasive liquid biopsy diagnostics are revolutionizing cancer treatment selection, patient prognosis, and monitoring. Low abundance circulating tumor DNA (ctDNA) is purified from patient plasma and used as an alternative source of genomic material for detecting tumor mutations. Currently available qPCR kits for detecting RAS mutations have a limited sensitivity and coverage since they are not optimized for liquid biopsy purposes. Methods', ' We have developed a two-step PCR to qPCR method to identify down to single mutant copies of KRAS or NRAS in ctDNA isolated from plasma. The mutant copies are first enriched by a novel multiplexed formula of primers and wildtype (WT) allele blockers. The mutations are then identified by EntroGens RAS Mutation Screening Panel or next generation sequencing (NGS). Synthetic mutant DNA was spiked in a background of WT DNA purified from plasma to yield a range of mutant allelic burden over WT background. The dilutions were analyzed to determine the methods sensitivity. We subsequently used the method to screen 53 non-small cell lung cancer (NSCLC) patient samples. Results', ' Our two-step method detects single digit mutant copies of 35 clinically significant KRAS and NRAS mutations. Furthermore, NGS experiments demonstrated the two-step method can enrich mutations more than 52-fold. KRAS 12/13 mutations were identified in 6 out of 53 (11%) NSCLC patients. Conclusions', ' ctDNA-based liquid biopsy tests have been employed by few laboratories but are generally available only as a service. EntroGens platform agnostic liquid biopsy RAS assay provides clinicians the tools necessary to determine cancer treatment and monitor patients using most PCR and qPCR instruments.']",
        "Doc_id":"ASCO_187020-199",
        "Doc_title":" Detecting KRAS and NRAS resistance mutations in plasma of lung cancer patients.",
        "_version_":1606189037984415744},
      {
        "Meeting_name":" Prognostic factors of recurrence and survival of gastrointestinal stromal tumors",
        "Background":"['Background', ' Gastrointestinal stromal tumors are mesenchymal lesions arising from the interstitial cells of Cajal. In GIST the location, size, number of mitosis and risk group are accepted as prognostic factors; some factors in which there are still controversies about their value as prognostic factors include male gender, tumor cellularity, the margins of resection, the presence or absence of p16 or intraperitoneal tumor breakdown. Methods', ' Observational, retrospective and longitudinal study. Patients admitted to the Oncology Hospital, CMN Siglo XXI of January 1, 1991 to April 30, 2012. Results', ' We identified 384 patients, the mean follow-up time was 55.86 months, the mean age was 58 years, 80.3% had symptoms and only 4.54% the finding was incidental. The most common site was the stomach (66.6%), followed by small intestine (28.7%) and colon (1.54%). The 7.57% had metastases at diagnosis, 4.54% in liver and 3.03% in the peritoneum. Were expressed by abdominal pain (39.39%) and gastrointestinal bleeding (30.30%), intestinal obstruction in 1.5%. The most common site was the stomach (66.6%), followed by small intestine (28.7%) and colon (1.54%). The 7.57% had metastases at diagnosis. The average tumor size was 10.84 cm (2.2 to 38 cm). Immunohistochemical markers were studied', ' 94.28% positive for CD117, CD34 74.28%, 11.42% S100 protein, desmin 5.71% and 51.72% for smooth muscle actin (AML). Overall rate at 5 years and 82% rate of recurrence-free survival at 5 years and 61% survival. The location of the tumor (p = 0.0002), size (p = 0.03145), the number of mitosis (p = 0.008), risk group (p = 0.020) and adjuvant treatment with Imatinib showed a statistically significant difference for Survival Recurrence-free. For overall survival, lesion location was the only factor that showed statistical significance with p = 0.0054. Conclusions', ' The tumor location, size, number of mitosis, the risk group and adjuvant treatment with Imatinib were statistically significant prognostic factors for disease recurrence. The location of the lesion was the only factor that showed statistical significance as a predictor of overall survival.']",
        "Doc_id":"ASCO_194793-199",
        "Doc_title":" Prognostic factors of recurrence and survival of gastrointestinal stromal tumors",
        "_version_":1606189026236170240},
      {
        "Meeting_name":" KEYNOTE-164",
        "Background":"['Background', '   A subset of advanced colorectal cancers (CRC) is characterized by mismatch repair (MMR) deficiency leading to a microsatellite instability-high (MSI-H) phenotype, which is characterized by a high mutational burden and lymphocytic infiltrates. Pembrolizumab is a monoclonal antiPD-1 antibody designed to block the interaction between PD-1 and its ligands PD-L1 and PD-L2. In the phase II KEYNOTE-016 study, pembrolizumab provided an ORR of 62% in patients (pts) with progressive MMR-deficient metastatic CRC vs 0% in pts with MMR-proficient CRC. The multicenter, phase II KEYNOTE-164 trial (NCT02460198) will evaluate the efficacy and safety of pembrolizumab in pts with previously treated, advanced MSI-H CRC. Methods', '   Key eligibility criteria include age  18 y; advanced CRC; MSI-H phenotype evidenced by  2 allelic shifts using a PCR-based assay or lack of expression of  1 MMR protein (MLH1, MSH2, MSH6, PMS2) by IHC; prior treatment with a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS and NRAS wild type, cetuximab or panitumumab; ECOG PS 0-1; no active autoimmune disease or brain metastases; and no prior anticancer therapy within 2 wk of study treatment. Pembrolizumab 200 mg Q3W will be administered for 35 cycles or until disease progression, unacceptable toxicity, pt withdrawal, or investigator decision. Clinically stable pts with RECIST-defined progression may continue pembrolizumab until a scan performed  4 wk later confirms progression. Pts who complete all 35 cycles or who discontinue pembrolizumab following a complete response and experience progression may be eligible for 1 y of pembrolizumab retreatment. Response will be evaluated every 9 wk per RECIST v1.1 by central review and per RECIST adapted for immunotherapy response patterns. AEs will be assessed throughout treatment and for 30 d thereafter (up to 90 d for serious AEs) and graded per NCI CTCAE v4.0. Pts will be followed for survival every 2 mo. ORR per RECIST v1.1 by central review is the primary end point; secondary end points include PFS, OS, disease control rate, and duration of response. Enrollment is ongoing and will continue until ~60 pts have enrolled. Clinical trial information', ' NCT02460198']",
        "Doc_id":"ASCO_160143-173",
        "Doc_title":" KEYNOTE-164",
        "_version_":1606189040091004929},
      {
        "Meeting_name":" Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients",
        "Background":"['Introduction There are numerous causes triggering CRC. 25-80% of CRC shown a deregulation in Epidermal Growth Factor Receptor (EGFR) pathway. Two signaling pathways downstream of the EGFR are dysregulated in CRC the mitogen-activated protein kinase (MAPK) and the phosphoinositide-3-kinase (PI3K) pathway. Activating mutations in KRAS and BRAF (MAPK pathway) and PIK3CA affect prognosis and/or response to anti-EGFR MoAb. PTEN is a downstream effector of EGFR pathway and is involved in PI3K pathway. Loss of PTEN protein expression can occur through epigenetic silencing and mutation or allelic loss. Immunohistochemistry (IHC) is the most effective way to assay for loss of PTEN expression. IHC lack of reproducibility and this has lead to discordant results regarding the concordant in paired CRC metastases and primary tumors.The aim of the work was to asses the feasibility of PTEN gene expression analysis from FFPE tissue in CRC samples.Materials and methods We selected a series of 33 patients, already tested for KRAS mutational status and resulted wild-type. At the time of the study mutational status of NRAS gene has not a role as predictive marker, so was not performed. A retrospective analysis on CRC FFPE tissue was performed. As control samples we have selected specimen of colorectal surgery not tumor-associated (diverticulitis). On these samples BRAF mutational analysis and PTEN gene expression was performed. For BRAF analysis, DNA was extracted by means of QIAamp DNA FFPE tissue kit (Qiagen, USA). BRAF mutational status was assed through direct automated sequencing (3100 Genetic Analyzer, Applied Biosystems) and TaqMan mutation detection assay (ABI PRIM 7900HT, Applied Biosystems). For PTEN gene expression, total RNA was obtained through the miRNeasy FFPE tissue kit (Qiagen, USA), according to manufacturer instructions, and reverse transcribed. PTEN expression was assessed by means of TaqMan probes.Results According to BRAF mutational status we have found 10/33 (30%) mutated samples. PTEN expression levels were evaluated by the comparison of tumor samples vs diverticula samples, the data obtained were then integrated with those from BRAF mutational analysis. Interestingly we found that all the BRAF mutated samples present also a down-regulation of PTEN. Statistical analyses were conducted through the X2 test with the Yatesha correction (p=0.00023). The p-value was also calculated Exact Fisher Test (p= 0.00021) to confirm the results.Conclusion The determination of PTEN gene expression level is feasible with real-time PCR using TaqMan probe technology. BRAF analysis might be used as prognostic and/or predictive marker in CRC patients treatment. The identification of a validated method for PTEN analysis would establish it as a molecular marker meriting further investigation in large numbers of available primary tumors from patients with CRC. Further analyses are requested to confirm these data.']",
        "Doc_id":"AACR_2014-448",
        "Doc_title":" Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients",
        "_version_":1606189038417477632},
      {
        "Meeting_name":" Clinical support with integrated multimodality molecular profiling for colorectal tumors.",
        "Background":"['Background', ' Current recommendations for colorectal cancer testing include KRAS and NRAS for anti-EGFR therapy, and BRAF mutational analysis with microsatellite instability (MSI) testing for prognostic stratification and Lynch syndrome. We developed a multi-modality colorectal cancer profile useful for clinical management. Methods', ' 133 Colorectal cancer samples were profiled with our platform, which includes 1) 21 gene mutation analysis using deep sequencing (ca. 15K reads), 2) MSI status, 3) MLH1 Promoter Methylation, 4) MET amplification and PTEN deletion by FISH, and 5) PD-L1 expression (30% of samples) by IHC. Results', ' 99% of tumors contained at least 1 mutation found by NGS. The most commonly observed mutations were TP53(85%), KRAS (49%), PIK3CA(26%), BRAF(19%), EGFR(16.5%), NRAS(8%), FGFR3(6%), HRAS(5%), KIT (5%), SMO(5%), JAK3(5%), and ERBB2(5%). 39 patients had a TP53 mutation allele frequency consistent with germline mutations, raising the possibility of a LiFraumeni syndrome. Most tumors (51%) also had at least 1 abnormal non-sequencing result. The most common findings were PTEN deletion (25%), MLH1(17%) methylation, MSI(11%), PDL1 (17.5%) overexpression. PTEN/MET/PDL1 was anticorrelated to MSH/MLH status. (p < 0.05). Our integrated profile (NGS, FISH, MSI, MLH) robustly recapitulated hypermutation profiles that were associated with BRAF+/MLH+/MSH+ profiles using comprehensive WGS in a recent TCGA study. In addition, 25%(10) were KRAS-/MLH-/MSH-/BRAF- of unknown prognosis without PTEN deletion status. The integrated profile also identified ~2 percent (3/131) of patients as candidates for Lynch Syndrome testing (MSH+/MLH-/BRAF- and < 50 years). Conclusions', ' Multimodality Colorectal Cancer profiling identified patients with potential new targeted therapy. Specifically, we identified a significant number of cases that were PTEN, PI3KCA, HRAS, FGFR3, MET, KIT, ERBB2, and PDL1 positive that change treatment options. In addition, to identifying patients with prognostic status (e.g.BRAF+, MSI+/MLH+), we identified important candidates for Lynch syndrome testing or possibly Li-Fraumeni Syndrome who would benefit from alternative treatments and different management.']",
        "Doc_id":"ASCO_168194-176",
        "Doc_title":" Clinical support with integrated multimodality molecular profiling for colorectal tumors.",
        "_version_":1606189016103780352},
      {
        "Meeting_name":" Performance study of an amplification-based NGS test on clinical FFPE specimens in Chinas first multi-center study.",
        "Background":"['Background', ' Next Generation Sequencing (NGS) assays provide a comprehensive view of clinically actionable variations in patients. The increasing application of NGS holds new promise towards accurate diagnosis, personalized treatment and precision medicine. Formalin-fixed Paraffin-embedded (FFPE) treatment remains to be the most popular format of tissue preservation. To further standardize the whole process of the application of NGS assays on FFPE tissues, the Chinese Medical Association Pathology Division organized a multi-center performance study of a NGS assay on more than 1,000 clinical FFPE specimens by inviting top pathology departments in the country. Methods', ' OncoAim Tumor Mutation and PharmGx Detection Kit (Singlera Genomics, Shanghai) was used for this study. Reference samples with known mutations and allele frequencies together with 1045 clinical FFPE specimens from 11 participating hospitals were tested. Among them, 615 Colorectal Cancer (CRC) and 430 Non-Small Cell Lung Cancer (NSCLC) FFPE samples were processed and sequenced on Illumina Miseq platform and Thermo ion torrent PGM platform, respectively. Results', ' The results on reference materials show 100% (Confidence interval = 100%) analytical sensitivity for mutations with MAF  10% when median coverage is  500X.Positive predictive value of > 99% was observed for mutations with MAF at 5% (data not shown). The median depth for CRC and NSCLC samples were 977Xand 828X, respectively. Among all CRC samples, 564 (91.7%) samples were found containing at least 1 clinical hotspot alteration. The top mutated genes were TP53, KRAS, APC, PIK3CA, SMAD4, BRAF, FBXW7, NRAS, PTEN, and ERBB2. For all the NSCLC samples, 304 (70.69%) were detected containing at least 1 clinical hotspot mutation. The top 10 mutated genes were EGFR, TP53, KRAS, PIK3CA PTEN, VHL, ERBB2, SMAD4, NFE2L2 and CTNNB1. Conclusions', ' In this study, we showed that the amplification-based NGS assay can achieve very high sensitivity and specificity for samples with median depth over 500X. The samples containing at least 1 clinical hotspot mutation were about 83% on average, suggesting NGS could be of great use for further characterization of the tissues.']",
        "Doc_id":"ASCO_194442-199",
        "Doc_title":" Performance study of an amplification-based NGS test on clinical FFPE specimens in Chinas first multi-center study.",
        "_version_":1606189004077662208},
      {
        "Meeting_name":" Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.",
        "Background":"['Background', '  Recently, anti-programmed death 1 (PD-1) antibody has shown promising efficacy in a phase II trial for patients with microsatellite instability-high (MSI-H) tumors, especially in those with metastatic colorectal cancer (mCRC). Currently, several clinical trials of anti-PD-1 antibody for patients with MSI-H mCRC are ongoing. However, little is known about the frequencies and clinicopathological features of MSI-H mCRC in Japanese patients.  Methods', '  Patients with histologically confirmed adenocarcinoma of mCRC were eligible for this observational study. MSI status was analyzed in tumors using the MSI Analysis System (Promega) composed of 5 mononucleotide markers. KRAS, NRAS, BRAF and PIK3CA mutations were also evaluated using the multiplex kit.  Results', '   A total of 232 patients were enrolled until August 31, 2015, of which MSI-H was detected in 5 patients (2.1%). Among five patients with MSI-H mCRC, median age was 45 years (28-75), four had tumors on right-sided colon, five had moderately differentiated adenocarcinoma, one had poorly differentiated adenocarcinoma, and three had stage IV disease at presentation. Overall survival for patients with MSI-H mCRC from the start of first-line systemic chemotherapy ranged from 8.1 to 62.0 month. All five patients with MSI-H mCRC had RAS wild-type tumors and two had BRAF V600E mutation. One patient with MSI-H mCRC was enrolled in a phase II trial of anti-PD-1 antibody.  Conclusions', '   MSI-H mCRC is rare in Japanese patients. A large scale nationwide cancer genome screening project together with MSI status is required to evaluate more detailed clinicopathological features and facilitate the enrollment of patients with MSI-H mCRC for clinical trials with anti-PD-1 antibody.']",
        "Doc_id":"ASCO_159353-173",
        "Doc_title":" Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.",
        "_version_":1606189006875262976},
      {
        "Meeting_name":" Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).",
        "Background":"['Background', '  IMPACT is an institution-wide screening program to identify patients (pts) treated at PMCC with somatic alterations that can be matched to targeted therapies.  Methods', '  Pts with advanced breast, colorectal (CRC), non-small cell lung (NSCLC), ovarian cancers and selected other solid tumors treated at PMCC were eligible. Tumor DNA was isolated from a FFPE archived sample and genotyped using a customized Sequenom panel (23 genes, 280 mutations) in a CLIA-certified laboratory. Verified mutations were reported in pts electronic health records. Selected FFPE samples were further characterized by NGS with the Illumina MiSeq TruSeq Amplicon Cancer Panel (48 genes, 212 amplicons, 500x coverage) for platform validation.  Results', '  From Mar 1/12-Jan 10/13, 485 pts were enrolled with median 1 prior treatment for advanced disease (range 0-6). Of 33 (7%) screen failures, 5% were for insufficient tissue and 2% for clinical deterioration. Median DNA quantity from FFPE = 4250ng (range 15-32550ng). The median time from tissue receipt to reporting was 5 weeks (range 1-23).  Mutations were identified by Sequenom in 137/349 (39%) pts, including 24/79 (30%) breast, 40/80 (50%) CRC, 54/88 (61%) NSCLC, 17/78 (22%) ovarian, and 2/24 (8%) other cancers. Mutations detected were', ' 76 KRAS, 35 PIK3CA, 22 EGFR, 5 NRAS, 5 ERBB2, 5 CTNNB1, 4 BRAF, and 1 AKT1. MiSeq was concordant with Sequenom in 112/113 (99%) pts, with mutations identified in 94/114 (82%). The average number of mutations detected by MiSeq was 1.72/pt (range 0-7) compared with 0.49/pt by Sequenom (range 0-2). After a median follow up of 5.0 months, 31/137 (23%) pts with mutations have been matched to targeted therapies, including 14 pts enrolled in clinical trials (15 trials) matched to their genotype. Of the 10 trial pts with at least one response assessment, 3 PR (1 confirmed) and 2 SD  24 weeks have been observed.  Conclusions', '  Molecular profiling can be integrated into the routine care of advanced cancer pts. Genotyping and targeted NGS are feasible in a clinical laboratory using stored archival FFPE tumor samples. NGS identifies additional actionable mutations to inform clinical-decision making. Clinical trial information', ' NCT01505400.']",
        "Doc_id":"ASCO_110989-132",
        "Doc_title":" Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).",
        "_version_":1606189004227608576},
      {
        "Meeting_name":" Occurrence of PIK3CA mutations simultaneously with RAS and RAF mutations in patients with advanced cancers.",
        "Background":"['Background', ' Oncogenic mutations in PIK3CA, RAS, and RAF have been indentified in various malignancies. Preclinical data suggest that PIK3CA mutations may predict for response to PI3K/AKT/mTOR inhibitors, but that concomitant RAS or RAF mutations may mediate resistance. Methods', ' Tumor tissues from patients with diverse cancers referred to the Phase I Program for targeted therapy from 10/08 to 05/10 were analyzed for PIK3CA, RAS (KRAS, NRAS), and RAF (BRAF) mutations using PCR-based DNA sequencing. Results', ' Overall, tumor tissues from 504 patients were analyzed', ' colorectal, n=103; ovarian, n=60; melanoma, n=55; head and neck, n=48; breast, n=29; endometrial, n=29; cervical, n=22; lung, n=22, soft-tissue sarcoma, n=17; thyroid, n=16; pancreatic cancer, n=11; and others, n=92. PIK3CA mutations were found in 54 (11%) of 504 patients tested. KRAS mutations were identified in 71 (19%) of 368 patients tested, NRAS mutations in 19 (9%) of 220 patients tested, and BRAF mutations in 32 (9%) of 362 patients tested. PIK3CA mutations were most frequent in squamous cells cervical (5/14, 36%), endometrial (7/29, 24%), breast (6/29, 21%), and colorectal cancers (17/103, 17%). KRAS mutations were most frequent in pancreatic (5/9, 56%), colorectal (47/95, 49%), and endometrial cancers (4/21, 19%). NRAS mutations were most frequent in melanomas (12/40, 30%), and endometrial cancers (2/8, 25%). BRAF mutations were most frequent in melanomas (23/52, 44%), and colorectal cancers (5/88, 6%). Irrespective of histology, PIK3CA mutations in comparison to wild-type PIK3CA were more frequently associated with simultaneous KRAS mutations (38% vs. 16% respectively; p=0.001) and simultaneous RAS/RAF (KRAS, NRAS, BRAF) mutations (49% vs. 27% respectively; p=0.002). RAS and RAF mutations were usually mutually exclusive; however, there was an endometrial cancer patient with simultaneous KRAS and BRAF mutations and a patient with melanoma with simultaneous NRAS and BRAF mutations. Conclusions', ' PIK3CA, RAS, and RAF mutations are frequent in diverse tumors. PIK3CA mutations often coexist with RAS and RAF mutations.']",
        "Doc_id":"ASCO_61025-101",
        "Doc_title":" Occurrence of PIK3CA mutations simultaneously with RAS and RAF mutations in patients with advanced cancers.",
        "_version_":1606189039741829120},
      {
        "Meeting_name":" ICE CREAM",
        "Background":"['Background', '  Patients with metastatic colorectal cancer (mCRC) whose disease has progressed despite oxaliplatin and irinotecan containing regimens may benefit from the use of EGFR-inhibiting monoclonal antibodies if the tumor contains no mutations in the KRASgene (i.e. WT).  However, it is unknown whether antibodies used in this setting, such as cetuximab, are more efficacious alone or in combination with irinotecan, as suggested by the BOND study which did not select for KRASstatus.  This international trial will also evaluate prospectively the activity of cetuximab in the subgroup of patients with mCRC with a specific KRASmutation in codon G13D. In selected retrospective analyses, tumors bearing this mutation appear to derive similar response from cetuximab as WT.  Trials involving small molecular subsets (in this case approx. 5% of patients with mCRC, or 18% of patients with KRAS mutations) will provide framework for future collaborations.  Methods', '  This randomised phase II study of cetuximab +/- irinotecan will recruit patients with metastatic colorectal cancer (mCRC) with either KRAS WT (n=50) or G13D mutation (n=50) over 2 years from sites in Australia (12), and three international sites (G13D mutations only)', ' Spain (1), England (1), and Italy (1). The trial will prospectively select the KRAS WT arm for the quadruple WT\" genotype (no mutations also in BRAF, NRAS, PIK3CA exon20).     Primary objective is 6 month progression free survival. Secondary objectives are response rate, overall survival, quality of life, and translational research including markers that may predict response such as amphiregulin and epiregulin determined  by immunohistochemistry.  Eligibility', '  Patients with histologically confirmed CRC with either quadruple WT\" genotype or KRAS G13D mutation; unresectable metastatic disease; measurable or evaluable disease; ECOG 0-2; life expectancy at least 12 weeks, and disease progression, or intolerance of thymidylate synthase inhibitor and  irinotecan and oxaliplatin containing regimens.  Status', '  Opened to accrual November 2012, at 31 Jan 2013 3/100 patients have been enrolled, all with G13D mutations. Clinical trial information', ' ACTRN12612000901808.']",
        "Doc_id":"ASCO_117869-132",
        "Doc_title":" ICE CREAM",
        "_version_":1606189015724195840},
      {
        "Meeting_name":" MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status.",
        "Background":"['Background. Activation of the Ras/Raf/MEK/MAP kinase pathway is implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in colon, pancreatic, and lung cancers; BRAF mutations have been identified in more than 60% of malignant melanomas and from 40-60% of papillary thyroid cancers. MEK, a dual specific kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. MEK162 (ARRY 438162) is a novel small molecule ATP-uncompetitive inhibitor of the kinases MEK1 and MEK2. MEK162 showed promising data in an ongoing Phase 2 Clinical Trial in patients with BRAF and NRAS mutated advanced melanoma. This is the first targeted therapy to show activity in patients with NRAS mutated melanoma. Methods and Results. The melanoma cell line panel was the most sensitive after investigating the growth inhibitory effect of MEK162 on 328 cancer cell lines from diverse histologies including melanoma, head and neck, colon, pancreas, lung, ovarian, liver, kidney, breast and endometrial. When a cutoff of IC50 <500nM or >70% Inhibition at 1uM after 6 days of culture was used 83% out of 47 melanoma cell lines were sensitive to the treatment with the MEK inhibitor. Sensitivity to MEK162 was independent of BRAFV600E andNRASQ61mutation status in this cell line panel. Cell cycle arrest and apoptosis was assessed upon exposure to MEK162 using flow cytometry. MEK162 led to a G1 arrest and marked increase in apoptotic cells in the majority of the sensitive melanoma cell lines regardless of their origin and oncogenic driver mutations. Western blots were used to characterize the changes induced by exposure to MEK162 in the MAPK and PI3K/mTOR pathways. MEK1/2 inhibition resulted in a decrease in pERK in all the cell lines tested regardless of their mutational status and the in vitro sensitivity. We observed an increase in pMEK more prominently in NRASQ61L mutant and wild type for NRAS and BRAF mutations cell lines than in BRAFV600Emutant cell lines. We found pAKT and pS6 decreased in the NRAS and BRAF mutant cell lines after treatment, suggesting that the inhibition of the mTOR pathway by MEK162 may be crucial for the sensitivity to the drug. Conclusion. These data provide evidence for supporting the use of MEK162 in the treatment of patients with melanoma.']",
        "Doc_id":"AACR_2013-2437",
        "Doc_title":" MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status.",
        "_version_":1606189039669477376},
      {
        "Meeting_name":" Colorectal cancer with mucinous component compared to clinicopathological and molecular features as mucinous adenocarcinoma.",
        "Background":"['Background', ' CRC can be divided into 3 groups', ' regular adenocarcinoma (RA), mucinous adenocarcinoma (MA), and adenocarcinoma with mucinous component (MC, mucin formation <50 % ). MA is distinct from RA, however, little is known about MC. We aimed to compare the clinicopathological and genetic features of 3 groups. Methods', ' A retrospective chort of consecutive CRC patients with available gene status was enrolled. KRAS,NRAS,BRAF,PIK3CA gene, MSI(IHC method) status were analyzed. Results', ' A total of 1454 patients were enrolled, including 1179 RA, 106 MA and 169 MC. Similar to MA, MC patients were younger, tended in proximal colon, had more advanced T stage ,higher nodal and peritoneal metastasis compared to RA. MSI-H were more occurred in MA and MC than RA (18.9%, 15.1% vs.3.9%). MC and MA had identical mutation frequency.They had higher KRAS (62.1%,62.3% vs.41.4%), BRAF(10.1%,9.4% vs.1.9%) and PIK3CA(21.3%,21.7% vs.9.4%) mutation than RA. Among MA or MC patients, almost 80% had at least one mutation, 17% had double mutation,and the mutation rates between left and right colon was similar, which is distinguish from RA. Conclusions', ' MC has comparable patholgical and molecular features as MA, which is distinct from RA. We should consider mucinous histology and the genetic features into future clinical practice. CharacteristicsMCMARAn=169(%)n=106 (%)n=1179 (%)Age,years#< 65122(72.2)79(74.5)771(65.4) 6547(27.8)27(25.5)408(34.6)Location*Right colon69(40.8)47(44.3)192(16.3)Left colon34(20.1)30(28.3)403(34.2)Rectum66(39.1)29(27.4)584(32.5)pT#T1-224(14.2)10(9.5)245(20.8)T3-4145(85.8)96(90.5)934(79.2)pN*N072(42.6)53(50.0)719(61.0)N1-297(57.4)53(50.0)460(39.0)Distant metastasis#M0145(74.0)73(68.7)967(82.1)M124(26.0)33(31.3)212(17.9)Peritnoneal metastasis*no146(86.4)88(83.0)1142(96.9)yes23(13.6)18(17.0)37(3.1)Microsatellite Status*MSI32(18.9)16(15.1)46(3.9)MSS137(81.1)90(84.9)1133(96.1)Gene statusKRAS-MT*105(62.1)66(62.3)488(41.4)NRAS-MT3(1.8)2(1.9)34(2.9)BRAF-MT*17(10.1)10(9.4)22(1.9)PIK3CA-MT*36(21.3)23(21.7)111(9.4)Double mutation*30(17.8)18(17.0)74(6.3)# p<0.05, * p<0.001']",
        "Doc_id":"ASCO_187625-199",
        "Doc_title":" Colorectal cancer with mucinous component compared to clinicopathological and molecular features as mucinous adenocarcinoma.",
        "_version_":1606188976032448512},
      {
        "Meeting_name":" Anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients",
        "Background":"['Background', ' Initially unresectable colorectal liver metastases can become resectable after chemotherapy. Chemotherapy combined with EGF-receptor antibodies has shown consistent high response rates in patients with RAS wildtype tumors. However, the influence of RAS mutations other than exon 2 mutations in the context of a conversion strategy has not been systematically studied yet. Methods', ' Out of a cohort of 424 patients with mCRC, we identified 30 patients with initially unresectable KRAS exon 2 wildtype colorectal liver metastases who received neoadjuvant chemotherapy including cetuximab or panitumumab between January 2008 and February 2014. In all patients extended RAS analysis (KRAS and NRAS exon 3 codon 59 and 61 and exon 4 codon 117 and 146) was carried out. Resection status (R0, R1 or R2), PFS and OS were recorded in all patients and maximum tumor shrinkage was calculated. Results', ' RAS mutation analysis identified further KRAS mutations in 4/30 patients (13.3%). No NRAS mutations were found. In none of these four patients a R0 resection could be achieved. In contrast, 15/26 (57.7%) RAS wildtype patients could be R0 resected. Median survival of patients with a RAS wildtype tumor was 64.0 [range', ' 7.4-98.6] months vs. 28.0 [range', ' 16.4- 40.6] months in those with a RAS mutation (hazard ratio, HR, 0.53; 95% confidence interval, CI', ' 0.15-1.81, p = 0.3). Median PFS in patients with a RAS mutation was 8 [range', ' 6-28.8] months compared to 10.4 [range, 1.7-15.2] months in patients with a RAS wildtype cancer. Median overall survival was > 63.3 months in R0-resected patients vs. 30.0 months in those with a R1 or R2 resection (HR 0.23; [95% CI 0.10- 0.75; p = 0.008). Conclusions', ' Our data suggest that a RAS wildtype status and a R0 resection are the strongest predictors for overall survival. The extended RAS analysis allows a better patient selection for anti-EGFRbased conversion chemotherapy before secondary resection of colorectal liver metastases.']",
        "Doc_id":"ASCO_188077-199",
        "Doc_title":" Anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients",
        "_version_":1606189008476438528},
      {
        "Meeting_name":" Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases",
        "Background":"['Background', ' Tumour heterogeneity may limit the efficacy of targeted therapies. Pulmonary metastases (PM) occur in 10-20% of patients (pts) with colorectal cancer, but little is currently known about the genetic characteristics of colorectal PM and whether they differ from the primary tumour. Methods', ' Clinical data and archival formalin fixed paraffin embedded tissue samples were retrospectively collected from pts who underwent  1 pulmonary metastastectomies for colorectal cancer between 1997  2012. Primary tumour and metastatic samples were analysed using a targeted capture sequencing panel of 45 cancer-associated genes (median depth 806x, median coverage 96.6%). Results', ' Clinical data were collected from 81 pts. The median progression-free survival (PFS) and overall survival (OS) were 24 months (95% CI 19  38) and 91 months (95% CI 72  130) respectively, and the 5-year PFS and OS rates were 32% and 77%. No clinicopathological factors were prognostic for PFS or OS by multivariate analysis. Fifty-four pts had samples available from  1 PM, and sequencing data was successfully obtained from 33 PM samples from 24 pts. The most frequently altered genes were APC (76%), KRAS (67%) and TP53 (48%). Mutations were also detected in a number of other genes ( < 20% frequency), including FBXW7, PIK3CA and ATM. Results were available from matched primary and PM samples for 15 pts, and 11 of these pts (73%) had concordant genetic profiles. The allele frequencies of key cancer mutations were slightly lower in the first PM in contrast to the primary tumour. Six of the 7 pts with results from  2 PM (86%) had concordant results. The overall concordance for all matched samples was 95% and 100% for KRAS and NRAS. Conclusions', ' Pts treated at our institutions for resectable colorectal PM had a favourable prognosis. In keeping with previously published data, KRAS mutations occurred at a higher frequency in pts with colorectal PM. Mutation status, and RAS status in particular, was highly concordant between the primary cancer and PM from the same individual. When PM develop, it may not be necessary to undertake repeat biopsies to determine pts suitability for anti-EGFR therapy.']",
        "Doc_id":"ASCO_169784-176",
        "Doc_title":" Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases",
        "_version_":1606189002121019392},
      {
        "Meeting_name":" Inactivation/loss of PTPRS promotes ERK activation that sensitizes colorectal cancer cells to ERK inhibitors.",
        "Background":"['The RAS pathway is a driver of many cancers, and has been targeted for the development of a variety of therapeutic inhibitors of BRAF, MEK, and more recently ERK. One of challenging issues is to predict response to targeted therapies. Here we report identification of PTPRS, a receptor-type protein tyrosine phosphatase, as a regulator/biomarker of ERK activation and inhibitor response in colorectal cancer. To identify the genes with high frequency mutations that might be predictive of RAS pathway dependence (addiction), we used a gene expression signature score to stratify 468 colorectal cancer tumors that also underwent targeted exome sequencing for 1321 cancer-associated genes. We found that, when the masking effects caused by mutant KRAS, BRAF and NRAS was iteratively removed, mutant PTPRS was strongly correlated with RAS pathway activation, with a mutation rate of 10.4% (22 out of 211 remaining tumors). This led us to inactivate PTPRS in vitro using a specific peptide inhibitor, siRNA or CRISPR approaches in various colorectal cancer cell lines. Inhibition/loss of PTPRS significantly elevated phosphorylation of ERK and AKT and substantially sensitized cancer cells to the treatment of ERK inhibitors, which was enhanced by an AKT inhibitor. Surprisingly, PTPRS did not modulate the activity of EGFR and the ERK kinase, MEK. Our data indicate that PTPRS negatively regulates ERK signaling downstream of the EGFR/RAS/RAF/MEK pathway in a mechanism independent of AKT and DUSP6. As a result, inactivation/loss of PTPRS promotes ERK activation and addiction, thereby contributing to increased sensitivity to ERK inhibitors.']",
        "Doc_id":"AACR_2017-4135",
        "Doc_title":" Inactivation/loss of PTPRS promotes ERK activation that sensitizes colorectal cancer cells to ERK inhibitors.",
        "_version_":1606189031651016704},
      {
        "Meeting_name":" Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers",
        "Background":"['Background', ' Detection of circulation tumor DNA (ctDNA) in plasma has become a viable option for non-invasive monitoring of patients. Also termed liquid biopsy the approach is applicable for pre-diction of response and prediction of resistance to biological therapy (1, 2). Various techniques have been used for ctDNA detection, frequently employing clonal amplification on a digital PCR format (3) with limits of detection (LOD) below 0.01% of mutant alleles. However, these techniques suffer from high complexity, expensive instrumentation, and a considerable cost per sample. We hereby present a simple low-cost alternative that is implementable to routine ctDNA testing.Methods', ' A panel of PCR amplicons (106 - 174bp) was resolved by denaturing capillary electrophoresis (DCE) revealing minute presence of mutation specific hetero-duplexes. The final panel consisted of clinically relevant oncogenic mutations KRAS, NRAS, BRAF, PIK3CA and EGFR as well as cancer-related mutations in tumor suppressors TP53, APC and CTNNB1. A total of 299 patients was subsequently examined for presence of ctDNA in plasma including 194 with colorectal cancer (CRC), 26 with NSCLC and 79 with pancreatic cancer (PanC). CtDNA status was correlated to TNM stage and tumor markers (CEA and Ca19-9). In a subset of CRC patients (n = 20) the ctDNA was monitored in 2 - 6 month intervals and correlated to the therapy response.Results', ' The experimental LOD value was in the range between 0.03 - 1% for all tested mutations within the panel. A minimum input amount of DNA was 5 pg (0,005 ng).. The overall rate of ctDNA detection was 32% for CRC (stages I - IV), 31% for NSCLC (stages III - IV) and 27% for PanC (stages II - IV). The highest detection rate, 69%, was observed in Stage IV CRC patients. Comparison with tumor markers (TM) revealed 62% of cases positive for both TM and ctDNA and 13% TM-negative cases with ctDNA positivity. Post-operative absence or persistence of ctDNA was related to the radicality of the surgical treatment and the ctDNA levels were concordant with the response to adjuvant chemotherapy. In several patients a disease progression was signalized based on ctDNA even prior to actual clinical detection by CT imaging.Conclusion', ' DCE is a simple technique applicable for detection of ctDNA in cancer patients without a need for costly hardware/software equipment. The detection rates are 10 - 15% lower compared to the dedicated dPCR techniques, however, the method requires ca 100x less input DNA, the cost per patient is about 10-fold lower and the turnaround time per test is under 5 hours.Supported by the Czech Ministry of Health Grant 14383.Literature1. Bettegowda C et al. Sci Transl Med. 2014,6(224)', '224ra242. Douillard JY et al. J Thorac Oncol. 2014, 9(9)', '1345-1353.3. Benesova L et al. Anal Biochem 2013,433(2)', '227-234.']",
        "Doc_id":"AACR_2015-2406",
        "Doc_title":" Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers",
        "_version_":1606189025286160384},
      {
        "Meeting_name":" Evaluation of a fully automated extended RAS-BRAF test on prospectively collected plasma samples from patients with metastatic colorectal cancer.",
        "Background":"['Background', ' Extended analysis of RAS genes in metastatic colorectal cancer (mCRC) is not available in many settings and the need for an easy plasma test is high. Methods', ' Pre-treatment plasma samples from 198 mCRC patients enrolled in the prospective multicenter RASANC study (NCT02502656) were retrospectively assessed for the presence of ctDNA mutations in KRAS, NRAS and BRAF by the fully automated Idylla platform.Proper informed consent and statistical analysis were included. The study is ongoing. We used Idylla platform which allows analysis of 21 KRAS, 18 NRAS and 4 BRAF ctDNA mutations from mCRC using 2 ml of plasma. The tests were performed using prototype versions of the Idylla ctKRAS and ctNRAS-BRAF-EGFR S492R Mutation Assays (RUO), which contain all reagents for integrated sample preparation and multiplex real time PCR detection. The tests each require 1 ml of plasma, less than 1 minute hands-on time, and have a turnaround time of less than 130 minutes.As a comparator test, NGS analysis with a sensitivity of 0.2% was performed on extracted plasma ctDNA according to Pcuchet et al. (2016). Results', ' The Idylla ctDNA assays identified 84 KRAS mutated (42.4%), 6 NRAS mutated (3%) and 13 BRAF mutated (6.6%) cases. The Idylla assays detected 62 KRAS codon 12 (31%), 16 codon 13 (6.5%), 3 codon 61 (1.5%), and 8 codon 146 (4%), and 1 NRAS codon 13 (0.5%) and 5 (2.5%) codon 61 mutated samples. All BRAF mutations detected were V600E. Overall agreement between Idylla and NGS for KRAS, NRAS, and BRAF was 96%, 100%, and 99.5% respectively. Overall RASconcordance with the NGS reference method was 96.5% with a positive agreement of 98% and a negative agreement of 95% (Table 1). Discordancy analysis by means of ddPCR on plasma and/or tissue will be presented. Conclusions', ' Plasma-based analysis of 41 extended RAS and BRAF mutations in ctDNA on the Idylla platform enables rapid and reliable genotyping in patients with advanced colorectal cancers. Clinical trial information', ' NCT02502656Agreement between Idylla and NGS plasma analysis.NGS Plasma RAS StatusWildtypeMutantTotalIdylla Plasma RAS StatusWildtype1012103Mutant59095Total10692198Overall agreement96.5%Negative agreement95%Positive agreement98%']",
        "Doc_id":"ASCO_191667-199",
        "Doc_title":" Evaluation of a fully automated extended RAS-BRAF test on prospectively collected plasma samples from patients with metastatic colorectal cancer.",
        "_version_":1606189016378507264},
      {
        "Meeting_name":" PTEN null expression is concordant in colorectal cancer primaries and metastases and associates with poor survival.",
        "Background":"['Background', ' Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a negative regulator of the phosphoinositide-3-kinase (PI3K) survival pathway. In colorectal cancer, the method of detection is relevant in determining the frequency of loss of PTEN and the association of PTEN status with outcome. Earlier studies reported discordant PTEN expression in an average of 1 in 3 matched colorectal primaries and metastases. Ours is the first investigation of PTEN concordance using a standardized immunohistochemistry assay.Objectives', ' Our primary aim was to determine the level of concordant PTEN expression in matched human colorectal primaries and liver metastases using a robust assay. Secondary aims were to relate PTEN status to oncogenic mutations in the RAS and PI3K pathways, and to overall survival.Experimental Design', ' We used a standardized immunohistochemistry assay and a reproducible method of interpretation to characterize PTEN expression in paired colorectal primaries and liver metastases collected from 70 patients. Mutational hotspots in KRAS, NRAS, BRAF and PIK3CA were sequenced.Results', ' 7 patients were excluded due to insufficient primary tumor. PTEN null expression was found in 7 of 62 assessable colorectal primaries (12.3%) and 6 of 58 assessable liver metastases (10.3%). PTEN expression (positive or null) was concordant in 98% of matched primaries and liver metastases. There was no significant association between PTEN status and RAS family or PIK3CA mutations. The median overall survival of patients with PTEN null tumors was 9 months, compared to 49 months with PTEN expressing tumors (HR=6.25, 95% CI (1.98, 15.42), p = 0.0017). The association of increased risk of death with PTEN null expression remained significant in multivariate analysis (HR=6.31, 95% CI (2.03, 17.93), p = 0.0023).Conclusion', ' PTEN status was highly concordant in matched colorectal primaries and liver metastases. Loss of PTEN expression predicted poor overall survival.']",
        "Doc_id":"AACR_2013-1201",
        "Doc_title":" PTEN null expression is concordant in colorectal cancer primaries and metastases and associates with poor survival.",
        "_version_":1606188972479873024},
      {
        "Meeting_name":" Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFR therapy.",
        "Background":"['Background', ' Tumor tissue is currently used for RAS testing in metastatic colorectal cancer (mCRC) patients, but the detection of circulating tumor DNA (ctDNA) is being actively investigated as a new method for the detection and longitudinal monitoring of actionable mutations in plasma samples. Methods', ' Retrospective analysis to evaluate the concordance of tissue and plasma RAS determination for assessing eligibility for anti-EGFR therapy in mCRC patients. RAS mutations were also analyzed in serial plasma samples in selected patients. Plasma mutations were determined with Sysmex Inostics BEAMing34 RAS mutation panel and compared to standard-of-care (SOC) RAS testing in tissue samples. Detectable mutation cutoff for BEAMing was standardized for each codon and was 2% for SOC. In cases with discordant tissue-plasma results tissue samples were re-examined by BEAMing. Results', ' 38 treatment nave mCRC patients with known RAS status in tissue sample were analyzed. Results showed a concordance of 89.5% (34/38 patients) (table). Among two patients in which a RAS mutation was identified in plasma but not in tissue, one patient was treated with anti-EGFR therapy and did not respond. In the other case, the mutation was detected in tissue by BEAMing re-examination and the patient was subsequently treated with anti-VEGF achieving a partial response. In one of two cases in which a RAS mutation was detected in tissue but not in plasma the re-analysis of RAS status by BEAMing in tissue confirmed the same NRAS codon 61 mutation detected by SOC. Analysis of RAS mutations in serial plasma samples from 5 selected patients that progressed to anti-EGFR, showed emergence of RAS mutations in 2 patients (40%) at the time of relapse. Conclusions', ' The high overall concordance between tissue and plasma BEAMing extended RAS determination supports the blood-based RAS mutation testing to determinate the eligibility of CRC patients for anti-EGFR treatment. The detection of RAS mutations in plasma at progression to anti-EGFR suggests that BEAMing 34 RAS mutation panel may be used to monitor resistance and anticipate treatment options. Tissue RAS result.PositiveNegativeTotalPlasma RAS ResultPositive17219Negative21719Total191938']",
        "Doc_id":"ASCO_169979-176",
        "Doc_title":" Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFR therapy.",
        "_version_":1606188982608068608},
      {
        "Meeting_name":" Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).",
        "Background":"['Background', '  Mutations affecting RAS genes are now established predictive markers of non-response to anti-epidermal growth factor receptor (EGFR) antibodies in advanced colorectal cancer (CRC). PI3KCA (and BRAF) may also be predictive. A previous analysis restricted to KRAS exon 2 has not revealed any role for mutation status as a predictive marker for bevacizumab therapy. This analysis assessed the prognostic and predictive impact of extended RAS and PI3KCA gene mutation status in patients receiving C +/- B +/- M in the randomised phase III MAX study.  Methods', '  DNA was macrodissected from archival formalin fixed paraffin embedded tumor tissue. Mutation status was determined using pyrosequencing and confirmed with Sanger sequencing (for equivocal RAS). Mutation status (Wild type/WT v Mutated/MT) was correlated with efficacy outcomes (RR, PFS & OS). Predictive analyses were undertaken using a test for interaction involving both C vs CB + CBM  Results', '  Patient demographics and clinical outcomes were comparable between the tissue study population (n=281/60%) and the intention to treat population (n=471). MT in KRAS exons 2, 3, 4 and NRAS 2, 3, 4 as follows; 32.4%, 4.3%, 3.9%, 1.4%, 0.7% & 0. There were five patients who had more than one RAS MT (four with KRAS exon 2&4, one KRAS exon 2&3). The total proportion with any RAS MT is 40.9%. PI3K MT rate was 7.5% exon 9, and 3.6% exon 20. All RAS gene mutation status (WT v MT) had no prognostic impact for PFS, HR 0.92 (0.72-1.17) or OS HR 0.97(0.73-1.27). Using the comparison of C v CB + CBM, RAS gene mutation status was not predictive of the effectiveness of B for PFS, HR 0.56 (0.37-0.84) for RAS MT and HR 0.69 (0.49-0.97) for RAS WT, p for interaction 0.51. RR with RAS MT was higher without Bev (C 50% v CB/CBM 37.3%), but RR improved with Bev in the WT group (C 27.3% v CB/CBM 42.3%), p for interaction 0.01. PI3KCA mutation was neither predictive for bevacizumab effect nor prognostic.  Conclusions', '  An additional 12.6% of MAX study patients who were KRAS exon 2 WT had additional RAS mutations. Neither all RAS gene mutation status nor PI3KCA mutation status was prognostic for progression-free survival or overal survival, or predictive of bevacizumab outcome in patients with advanced CRC. Clinical trial information', ' NCT00294359.']",
        "Doc_id":"ASCO_125437-144",
        "Doc_title":" Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).",
        "_version_":1606189022353293312},
      {
        "Meeting_name":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "Background":"['Background', ' The requirement to establish RAS status prior to administration of an EGFR inhibitor has increased the need to understand which patients are tested for RAS and the length of time it takes for the treating oncologist to receive the RAS test result. Our objective was to evaluate factors that may influence RAS testing among metastatic colorectal cancer (mCRC) patients and the turn-around time for RAS testing among patients who are treated at community cancer centers in the United States (U.S.) Methods', ' The sample includes 1550 patients in the Oncology Services Comprehensive Electronic Records (OSCER) database who were diagnosed with mCRC between 1/1/2011 and 8/31/2015. Patient demographics and clinical characteristics were evaluated at the time of mCRC diagnosis. The median number of days and interquartile range (IQR) between the following dates was summarized', ' diagnosis for mCRC, tissue collection for biomarker testing, tissue was received by the lab for biomarker testing, and biomarker results returned to the oncologist. Results', ' The frequency of RAS testing was as follows', ' KRAS (n = 964; 62%), NRAS (n = 116; 7%), BRAF (n = 231; 15%), all three simultaneously (n = 94, 6%). There were significant differences in KRAS testing by age and type of insurance, with young (p < 0.001) and commercially-insured (p = 0.01) patients more likely to receive testing. The median number of days and IQR between specimen collection and diagnosis of mCRC was as follows', ' KRAS (0; 0 to 443), NRAS (0; -18.5 to 362), and BRAF (-3; -474 to 0). The median number of calendar days between the date the specimen was collected and the date it was received by the lab was as follows', ' KRAS (19; 1 to 303), NRAS (34.5, 8 to 518), and BRAF (29; 2 to 428). The median number of days between the date the specimen was received by the lab and the date the result was returned to the oncologist was as follows', ' KRAS (7; 5 to 13), NRAS (10; 7 to 15), and BRAF (8; 6 to 14). Conclusions', ' Many patients had a specimen collected for biomarker testing at the time of mCRC diagnosis and the results were generally returned to the treating oncologist within one week of it arriving at the lab.']",
        "Doc_id":"ASCO_170846-176",
        "Doc_title":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "_version_":1606188980977532928},
      {
        "Meeting_name":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "Background":"['Background', '    The requirement to establish RAS status prior to administration of an EGFR inhibitor has increased the need to understand which patients are tested for RAS and the length of time it takes for the treating oncologist to receive the RAS test result. Our objective was to evaluate factors that may influence RAS testing among patients with metastatic colorectal cancer (mCRC) and the turn-around time for RAS testing among patients who are treated at community cancer centers in the United States (U.S.). Methods', '    The sample includes 1550 patients in the Oncology Services Comprehensive Electronic Records (OSCER) database who were diagnosed with mCRC between 1/1/2011 and 8/31/2015. Patient demographics and clinical characteristics were evaluated at the time of mCRC diagnosis. The median number of days and interquartile range (IQR) between the following dates was summarized', ' diagnosis for mCRC, tissue collection for biomarker testing, tissue was received by the lab for biomarker testing, and biomarker results returned to the oncologist. Results', '    The frequency of RAS testing was as follows', ' KRAS (n = 964; 62%), NRAS (n = 116; 7%), BRAF (n = 231; 15%), all three simultaneously (n = 94, 6%). There were significant differences in KRAS testing by age and type of insurance, with young (p < 0.001) and commercially-insured (p = 0.01) patients more likely to receive testing. The median number of days and IQR between specimen collection and diagnosis of mCRC was as follows', ' KRAS (0; 0 to 443), NRAS (0; -18.5 to 362), and BRAF (-3; -474 to 0). The median number of calendar days between the date the specimen was collected and the date it was received by the lab was as follows', ' KRAS (19; 1 to 303), NRAS (34.5, 8 to 518), and BRAF (29; 2 to 428). The median number of days between the date the specimen was received by the lab and the date the result was returned to the oncologist was as follows', ' KRAS (7; 5 to 13), NRAS (10; 7 to 15), and BRAF (8; 6 to 14). Conclusions', '    Many patients had a specimen collected for biomarker testing at the time of mCRC diagnosis and the results were generally returned to the treating oncologist within one week of it arriving at the lab.']",
        "Doc_id":"ASCO_160157-173",
        "Doc_title":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "_version_":1606189007768649728},
      {
        "Meeting_name":" EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.",
        "Background":"['Background', ' Anti-EGFR monoclonal antibodies are used for the treatment of RAS wild type (wt) metastatic colorectal cancer. However, only a fraction of patients selected for treatment by the RAS mutation status benefit. We previously showed that EGFR gene copy number (GCN), as analyzed by immunohistochemistry (IHC)-guided in situ hybridization (ISH), predicts response to anti-EGFR therapy in KRAS exon 2 wild-type (wt) metastatic colorectal cancer. The aim of this study was to analyze the predictive role of EGFR GCN in RAS/BRAF/PIK3CA wt metastatic colorectal cancer. Methods', ' The patient material included 102 patients with KRAS exon 2 wt metastatic colorectal cancer treated with anti-EGFR antibodies. Next generation sequencing (NGS) was used for KRAS exons 2, 3 and 4, NRAS exons 2, 3 and 4, BRAF and PIK3CA gene mutation analyses from primary tumor tissue samples. EGFR GCN was analyzed by EGFR IHC guided automated silver ISH (GCN cutoff 4.0). Results', 'RAS, BRAF, and PIK3CA gene mutation analyses were successfully performed for 86.3% of the patients. Additional mutations in the RAS gene were found in 28.4% (25/88) of the KRAS exon 2 wt tumors. BRAF and PIK3CA mutations were observed in 22.7% and 15.9% of the cases, respectively. EGFR GCN was  4.0 in a majority of the RAS wt patients (40/63, 63.5%). An elevated EGFR GCN predicted a better response to anti-EGFR therapy and prolonged PFS in the RAS/BRAF/PIK3CA wt patients. In addition, most RAS wt patients with an EGFR GCN  4.0 in their primary tumors benefited of anti-EGFR therapy in terms of clinical benefit (SD, PR or CR) (Chi-Square Test, p = 0.0005), and had a longer progression free survival than those with a EGFR GCN below 4.0 (Log-Rank Test, p < 0.0001). In contrast, the response RAS/BRAF/PIK3CA wt, EGFR GCN below 4.0 patients did not differ from patients with mutant in RAS, or BRAF or PIK3CA. Conclusions', ' The study indicates that EGFR GCN serves as a predictive marker for anti-EGFR treatment efficacy in patients with RAS/BRAF/PIK3CA wtmetastatic colorectal cancer. Tumors with EGFR GCN below 4.0 appear to be as refractory to anti-EGFR treatment as tumors with mutation in any of the RAS/RAF/PIK3CA pathway genes.']",
        "Doc_id":"ASCO_165969-176",
        "Doc_title":" EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.",
        "_version_":1606189000688664576},
      {
        "Meeting_name":" Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients",
        "Background":"['Background', ' Colorectal cancer morbidity and mortality rates vary by race and ethnicity. The combined contribution of genetics and environment to response to chemotherapy, progression-free and overall survival in colorectal cancer patients is unclear, but CpG island hypermethylation (CIMP), a discrete molecular subtype of colorectal cancer, is associated with inflammation and environmental exposures. Hence our main objective is to assess correlation between various modifiable risk factors and CIMP status among metastatic colorectal cancer patients.Methods', ' We characterized CIMP methylation (MINT1, MINT2, MINT31, p14, p16, and MLH1) in 229 metastatic colorectal cancer patients using PCR amplification of bisulfite treated DNA followed by pyrosequencing. The number of methylated probes were averaged to obtain the% methylation with CIMP-High (CIMP-H) being defined as 40% of probes methylated. Associations of demographic and clinical characteristics, including BMI, diabetes, obesity, physical activity, smoking and drinking status, as well as presence or absence of other molecular alterations (BRAF, KRAS, NRAS, PIK3CA and PTEN loss) with overall survival were assessed in multivariable-adjusted Cox proportional hazards models.Results', 'When treating methylation as a continuous variable, patients with BRAF mutation had higher methylation as compared to participants with BRAF wildtype (40.6% vs 20.5%, p = 0.001). White, non-Hispanic (WNH) patients had greater degree of tumor methylation (24.8%) as compared to other racial categories (p = 0.02). When classified as a categorical variable, moderate to vigorous physical activity was associated with higher rate of having any methylated probes, as compared to sedentary patients (p = 0.02). CIMP status was not associated with OS in these patients in multivariable-adjusted Cox models. However when stratified by CIMP status. When stratified by CIMP status; among patients with 0-40% methylation, KRAS mutation was associated with poor OS(HR = 3.19, p = 0.006) and diabetes was protective (HR = .14, p = 0.025). Among patients with high methylation(41-100%) methylation, obesity was associated with poor OS (HR = 5.20, p = 0.038) and former smoking was associated with poor OS(HR = 2.92, p = 0.05). When stratified by KRAS mutation status, among patients with KRAS wildtype, obesity was associated with poor OS(HR = 2.86, p = 0.019) and among patients with KRAS mutation, diabetes was protective (HR = 0.18, p = 0.033)Conclusion and Impact', 'CpG island methylator phenotype was associated with unique clinicopathologic characteristics. Methylation, as assessed by the 6-gene CIMP panel, was not associated with worse outcomes after correcting for the KRAS mutations, a well-established genetic marker of poor prognosis. Hypermethylation did appear to modulate outcomes in obese patients with hypermethylated tumors.']",
        "Doc_id":"AACR_2015-4763",
        "Doc_title":" Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients",
        "_version_":1606189028970856448},
      {
        "Meeting_name":" Does multiple mutational analysis of the EGFR pathway have a prognostic role in advanced colorectal cancer (CRC)-",
        "Background":"['Background', '  BRAF mutation is widely recognised as a strong negative prognostic factor in advanced CRC, while the prognostic value of KRAS mutations in codons 12-13 remains controversial. Exploring mutations in other downstream components of the EGFR pathway may have an impact on survival.  Methods', '  A consecutive cohort of 201 metastatic CRC patients treated with systemic chemotherapy were analysed for KRAS (12-13-61-146), BRAF, PIK3CA and NRAS genotypes by pyrosequencing on PyroMarkTMQ96 ID instrument (Qiagen, Germany) with commercially available kits Anti-EGFR MoAb response (Diatech Pharmacogenetics, Italy). Accurate microdissection guaranteed more than 70% of cancer cells for each sample. For the purpose of the survival analysis 4 categories were created', ' (1) KRAS mutated (codons 12-13 only); (2) BRAF mutated; (3) any of KRAS codons 61-146, PIK3CA or NRAS mutations; (4) all-wild type. Log-rank and Cox proportional tests were applied for statistical analysis.  Results', '  KRAS mutations were present in 96 (47.8%) patients', ' 86 (42.8%) were in codons 12-13. BRAF mutations were found in 11 (5.5%) samples while PIK3CA and NRAS in 33 (16.4%) and 7 (3.5%), respectively. All mutations were mutually exclusive except for 24 (11.9%) patients with concomitant KRAS/PIK3CA mutations. Median survivals for different categories are shown. Patients harbouring BRAF mutation had the worst outcome (p=0.0006). Mutations of any codon of KRAS (12-13-61-146) also negatively impacted on survival (p=0.026), while the all wild-type (KRAS/BRAF/PIK3CA/NRAS) patients had the longest survival (p=0.002).  Conclusions', '  This study suggests the usefulness for early molecular profiling for advanced CRC patients. Mutational analysis of all EGFR pathway components may identify different prognostic subgroups. This information may drive treatment selection in clinical practice and stratification in clinical trials.']",
        "Doc_id":"ASCO_97829-114",
        "Doc_title":" Does multiple mutational analysis of the EGFR pathway have a prognostic role in advanced colorectal cancer (CRC)-",
        "_version_":1606188977773084672},
      {
        "Meeting_name":" Diagnostic yield of targeted next-generation sequencing for personalized cancer therapeutics.",
        "Background":"['We have implemented a clinical assay to perform next-generation sequencing (NGS) of twenty-five genes relevant to multiple cancer types. We report findings from 210 consecutive malignancies submitted to Genomics and Pathology Services at Washington University in St. Louis (GPS@WUSTL). DNA was extracted from formalin-fixed, paraffin-embedded tumor selected by histopathologic review. Up to 1 g of DNA (minimum, 0.2 g) was used for library preparation using liquid-phase cRNA capture probes targeting all exons of BRAF, CTNNB1, CHIC2, CSF1R, DNMT3A, EGFR, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MAPK1, MAP2K2, MET, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RET, RUNX1, TP53, and WT1 (302 kb). Libraries were sequenced by Illumina technology to obtain 101bp or 150bp paired-end reads. Mean coverage was 1596; 50x depth was achieved at >95% of positions. The analysis pipeline was validated for variant allele frequency >10%. Variants were called and interpreted using the Clinical Genomicist Workstation. A list of clinically actionable variants (hot spots) was curated by literature review. Of 210 cases, 94 (45%) were non-small cell lung cancer (NSCLC), 20 (9.5%) were pancreatic cancer (PCA), and 17 (8.1%) were colorectal cancer (CRC), the balance representing 38 diverse other malignancies. FFPE tissue cores yielded a median of 2.4 g DNA (interquartile range 1.0-4.9 g). Sequencing identified a mean of 5.4 non-synonymous coding and/or splice site variants per case (single-nucleotide variants and indels). Of these, a mean of 2.8/case were not known polymorphisms and likely represented somatic mutations. Somatic variants most commonly occurred in TP53 (233 variants in 107 cases), KRAS (52 variants in 51 cases), and EGFR (40 variants in 33 cases). Sequencing identified 74 clinically actionable (i.e., predictive or prognostic) mutations in 61/210 = 29% of cases. In NSCLC, actionable mutations were present in KRAS codon 12 (29/94 cases), EGFR exons 19 (5 cases), 20 (1 case) and 21 (5 cases), and the PIK3CA helical domain (4 cases). In PCA, there were no variants currently recognized as actionable, but one potentially targetable MET T1010I variant was found. In CRC, actionable mutations were present in KRAS codon 12 or 13 (6/17 cases), PIK3CA (3 cases) and KIT (1 case). Average turnaround time was 29 days. In conclusion, NGS-based diagnostics can provide clinically relevant information using readily available FFPE tissue. Actionable variants were identified in 29% of cases. The existence of targeted therapies suggests that such diagnostics have the potential to improve patient outcomes.']",
        "Doc_id":"AACR_2013-813",
        "Doc_title":" Diagnostic yield of targeted next-generation sequencing for personalized cancer therapeutics.",
        "_version_":1606188994830270464},
      {
        "Meeting_name":" Molecular profiling of patients (pts) with advanced colorectal cancer (CRC)",
        "Background":"['Background', '  The prevalence of somatic mutations other than KRAS, PIK3CA and BRAF in CRC has not been well described. This study reports molecular profiling of pts with advanced CRC in clinical practice.  Methods', '  Pts with advanced CRC are enrolled in an ongoing institution-wide screening program. Molecular profiling is performed on FFPE archival tissues using a customized Sequenom panel (23 genes, 279 mutations) or the Illumina MiSeq TruSeq Amplicon Cancer Panel (48 genes, 212 amplicons,  500x coverage) in our CLIA-certified laboratory.  PTEN negative tumor is defined by IHC with H score <1. Demographic and clinical data are collected. Data was analyzed by chi-square test.  Results', '  From March 2012 to August 2013, 132 pts were enrolled. One or more mutations were found in 50% (58/117) and 93%(14/15) of pts using Sequenom and MiSeq platforms respectively. Mutation rate was 40% for KRAS, 9% for PIK3CA, 2% for BRAF, 4% for NRAS, and 1% for each of CTNNB1, ERBB2, FGFR3, and EGFR. Mutations outside of codons 12/13 were found in 8% (4/53) of tumors with KRAS mutations. MiSeq showed additional mutations including ERBB4 (1/15), SMAD4 (1/15), FRXW7 (1/5), APC (5/15), and TP53 (12/15) in CRC. Co-mutation with KRAS was found in 58% (7/12) of pts with PIK3CA mutation and 80% (4/5) of pts with APC mutation. PTEN negative tumor was present in 20% (11/55) of pts. Presence of any mutation was significantly more common for pts with right-sided CRC (73%) compared to those with left-sided CRC (47%) and rectal CRC (38%) (p < 0.01). There was a trend toward increased proportion of KRAS mutation in right-sided CRC (p=0.06). There was no difference in age, ethnicity, gender, smoking status, stage at presentation, pathology grade, and response to first-line chemotherapy between right and left-sided CRC.  Conclusions', '  Somatic alterations are common in advanced CRC. Targeted next-generation DNA sequencing identifies additional clinically relevant alterations than multiplex genotyping. Differences in the mutation profile of right and left-sided CRC tumors should be further investigated. Updated results will be presented at the meeting.']",
        "Doc_id":"ASCO_122861-143",
        "Doc_title":" Molecular profiling of patients (pts) with advanced colorectal cancer (CRC)",
        "_version_":1606188972889866241},
      {
        "Meeting_name":" Improving access to molecularly defined clinical trials for patients with colorectal cancer",
        "Background":"['Background', '  Molecular diagnostics can identify subgroups of colorectal and other cancers that are relevant for the mode of action of new anti-cancer agents. The efficient, GCP-conform and quality assured molecular screening to identify potential study patients is one of the major challenges for targeted drug development. The EORTC has implemented a new collaborative molecular screening platform in order to facilitate these next generation trials.  Methods', '  SPECTAcolor (Screening Patients for Efficient Clinical Trial Access in advanced colorectal cancer) is a pan European network of institutions collaborating in centralized, high-throughput screening of tumor material from patients with colorectal cancer. After informed written consent, patients are screened for molecular alterations. Molecularly annotated patients can be offered so called downstream clinical trials.  Results', '  Launched in September 2013, SPECTAcolor is now initiated in 19 clinical centers in 9 countries. As of 12 September 2014, 406 patients were enrolled exceeding the expected accrual target of 300 patients in the first year. Of these 406 patients, 293 patients had their tumor block shipped to the central biobank at the Dresden University Hospital for central quality and pathological review, and core analyses. Tumor samples are being additionally analyzed using next generation sequencing for 360 key cancer alterations in cooperation with the Sanger Institute (Cambridge, UK).  In the first year, the blocks were analyzed for 5 baseline biomarkers. KRAS was wild type for exon 2, 3 and 4 in 151/284 pts (53%) and mutated 133 pts (47%; 114 pts in exon 2 (40%), 8 pts in exon 3, and 11 pts in exon 4). NRAS was tested in KRAS wild type pts only; mutations were found in 14 pts (4.9%; 6 pts in exon 2 and 8 pts in exon 3). BRAF mutations, all in exon 15, were found in 18 pts (7%). PI3K mutations occurred in 41 pts (15%; 13 in exon 20 and 28 in exon 9). IHC staining was showing deficient mismatch repair in 16 patients.  Conclusions', '  SPECTAcolor is the first pan-European and EORTC screening platform. Its successful implementation proves that a logistically complex infrastructure to run next generation trials in a multinational setting is feasible.']",
        "Doc_id":"ASCO_140182-158",
        "Doc_title":" Improving access to molecularly defined clinical trials for patients with colorectal cancer",
        "_version_":1606189024608780288},
      {
        "Meeting_name":" Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
        "Background":"['The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of tumor cells. Activation of the MAPK pathway due to mutations in BRAF, NRAS and KRAS is considered one of the causes of solid tumors (NSCLC, CRC,HCC, andthyroid cancers) and hematologic malignancies.HM95573 is a novel, highly potent RAF kinase inhibitor. Biochemically assayed for over 120 kinases, HM95573 showed the high selectivity toward BRAF mutant and CRAF kinases. The half maximal inhibition concentrations (IC50) of HM95573 against BRAFWT, BRAFV600E and CRAF kinases were 41nM, 7nM and 2nM, respectively. The strongly inhibited kinases subsequent to RAF kinases appeared to be CSF1R (44nM), DDR1 (77nM) and DDR2 (182 nM).HM95573 potently inhibited the growth of BRAFmutation CRC cell lines (e.g. IC50', ' 118nM for Colo-205) and thyroid cancer cell lines (43nM for B-CPAP); KRAS mutation NSCLC cell lines(297nM for Calu-6),CRC cell lines(65nM for HCT-116) and thyroid cancer cell lines(479nM for CAL-62); and NRAS mutation HCC cell lines(28nM for HepG2) andleukemia cell lines (39nM for HL-60). HM95573 effectively inhibited the phosphorylations of MEK and ERK, downstream kinases associated with cell proliferation in tumor cell lines mutated in BRAF, KRAS and NRAS. In addition, the phosphorylation of downstream kinases of RAF such as MEK and ERK was effectively inhibited with treatment of HM95573 in mutant KRAS NSCLC and CRC cells.HM95573 showed the excellent antitumor activity in mouse models xenografted with BRAF mutation cell line (Colo-205), KRAS mutation cell lines (Calu-6 and HCT-116)and NRAS mutation cell line (HepG2)two RAF inhibitors approved in melanoma which were effective to only BRAF mutation cell lines under conditions tested. The in vivo antitumor activity of HM95573 was potentiated with MEK inhibitors.Now, HM95573 is currently in phase I development in patients with advanced solid tumors including KRAS mutation NSCLC in Korea.']",
        "Doc_id":"AACR_2015-2607",
        "Doc_title":" Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
        "_version_":1606189039850881024},
      {
        "Meeting_name":" Relationship between tumor location and oncogenes mutations (RAS, BRAF, and PIK3CA) in colorectal cancer.",
        "Background":"['Background', ' Several studies have reported that right-sided colon cancers (RCC) and left-sided colon cancers (LCC) differ in several factors including genetic features. We investigated the difference in clinicopathological characteristics and oncogenic mutation status between patients with RCC and LCC in all stages. Methods', ' This study was a prospective, observational study. Patients were recruited from December 2014 to February 2016. Formalin-fixed paraffin-embedded tissue blocks were collected and DNA wes extracted from tissue sections from 158 cases. Mutations in KRAS, NRAS, HRAS, BRAF and PIK3CAwere detected by next-generation DNA sequencer. Tumors from cecum to transverse colon were defined as RCC, and tumors from descending colon to rectsigmoid were defined as LCC. Results', ' RCC was 66 patients and LCC was 92 patients. Poorly differentiated adenocarcinoma or mutinous adenocarcinoma were significantly more frequent in RCC compared to LCC (P = 0.047). KRAS mutations were detected in 35 patients with RCC (53.0%) and in 32 patients with LCC (34.8%). NRAS mutations were detected in 2 patients with RCC (3.0%) and in 3 patients with LCC (3.3%). There was no HRAS mutation in all patients. BRAF mutations were detected in 7 patient with RCC (10.6%) and in 2 patients with LCC (2.2%). PIK3CA mutations were detected in 8 patients with RCC (12.1%) and in 10 patients with LCC (10.9%). KRAS and BRAF mutation in RCC were significantly more frequent than in LCC (P = 0.022 and P = 0.024, respectively). These mutations were not significantly different according to tumor stage. In this study, both KRAS and BRAFmutations were exclusive. Conclusions', 'KRAS and BRAF mutation were more frequent in the patients with RCC compared to those with LCC in all stages. This study suggested that it was important to evaluate BRAF mutation in addition to KRAS in order to select more effective treatments, especially in RCC.']",
        "Doc_id":"ASCO_174561-195",
        "Doc_title":" Relationship between tumor location and oncogenes mutations (RAS, BRAF, and PIK3CA) in colorectal cancer.",
        "_version_":1606189040624730112},
      {
        "Meeting_name":" High EGFR somatic mutation frequency targeting the TK domain in colorectal cancer patients with microsatellite instability (MSI).",
        "Background":"['CRCs arise through genetic changes that impact various driver genes and in some tumors increased mutation rate in microsatellite unstable tumors. The hypermutable phenotype associated with microsatellite instability (MSI) results from loss of the mismatch repair system (MMR) activity. MSI is detected in 15% of all CRCs, and such tumors have a better prognosis and different chemotherapeutic outcome patterns, including high clinical benefit from immune checkpoint therapy or relative resistance to 5-FU as compared to microsatellite stable (MSS) tumors. The epidermal growth factor receptor (EGFR) signaling pathway plays an essential role in carcinogenesis of CRCs and is known to be overexpressed in MSI CRCs while highly mutated in Lung cancer. We analyzed the mutation frequency of deregulated pathways including EGFR and its downstream genes KRAS and BRAF in CRCs. We found a significantly elevated EGFR mutation frequency in CRC MSI-H subtype (45.5% vs. 6.5% in MSS CRCs, p<0.0000001). Although KRAS and NRAS are mutated with high frequency in both MSI-H and MSS groups, BRAF corresponding to RTK-RAS pathways is more altered in MSI-H than MSS CRCs (32.67% vs 13.10%; p=0.001), consistent with the known association between MSI-H CRCs and BRAF mutations. We hypothesized that there might be a mutation pattern in EGFR in CRC subtypes that provide a rationale for EGFR-targeted therapy for a subtype of CRC. Of 1104 profiled CRCs in the COSMIC v73 database, somatic EGFR mutations were mapped for 101 MSI-High versus 916 MSS CRCs. EGFR mutations mapped on the protein structure revealed that mutations are mainly targeting tyrosine kinase (TK) domain while the extracellular domain remained mostly wild-type with potential for targeting by anti-EGFR monoclonal antibodies. It is known that downstream genes such as KRAS as well as expression levels of EGFR ligands can affect the sensitivity of CRCs to anti-EGFR therapy. We didnt detect any difference in mRNA expression level between MSI-H and MSS group but our analysis is indicative of the presence of G12D mutations in a high proportion of KRAS-mutated MSS CRCs, therefore resistance to anti-EGFR antibodies such as cetuximab would be expected. However, EGFR tyrosine kinase inhibitors such as erlotinib and gefitinib could be considered for further testing in patients with MSI-H tumors that have a lower frequency of G12D KRAS mutations and may have mutant EGFR.']",
        "Doc_id":"AACR_2017-1412",
        "Doc_title":" High EGFR somatic mutation frequency targeting the TK domain in colorectal cancer patients with microsatellite instability (MSI).",
        "_version_":1606188975325708288}]
  }}
